Magnetic resonance imaging of colonic function by Placidi, Elisa
Placidi, Elisa (2011) Magnetic resonance imaging of 
colonic function. PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/13886/1/555501.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
MAGNETIC RESONANCE IMAGING
OF COLONIC FUNCTION
Elisa Placidi
Thesis submitted to the University of Nottingham
for the degree of Doctor of Philosophy
July 2011
Contents
Abstract vi
List of publications viii
Acknowledgments xiii
Abbreviations xiv
1 Introduction
1.1 Thesis overview
1
2
2 Nuclear Magnetic Resonance 5
2.1 Introduction ...... 5
2.2 NMR basic principles. 6
2.2.1 Atomic structure and MR active nuclei 6
2.2.2 Boltzmann statistics ....... 6
2.2.3 Precession and Larmor frequency 7
2.2.4 Resonance and MR signal 8
2.2.5 Relaxation. . 10
2.2.6 Relaxometry . 16
2.2.7 Chemical shift . 19
2.2.8 Susceptibility 19
2.2.9 Contrast agents 21
Contents ii
3 Magnetic Resonance Imaging 24
3.1 Introduction . 24
3.2 Gradients .. 24
3.3 Slice selection 26
3.4 In plane spatial encoding . 28
3.4.1 Frequency encoding . 28
3.4.2 Phase encoding 30
3.5 k-space ......... 31
3.6 Gradient echo sequence . 32
3.7 Spin echo ...... 35
3.8 Echo planar imaging 35
3.9 Fast spin echo . . . . 38
3.10 Fast imaging in the steady state 40
3.10.1 Fast field echo . . . . . . 41
3.10.2 Balanced turbo field echo 43
3.11 Image contrast 44
3.12 Artifacts .... 45
3.12.1 Image acquisition related . 45
3.12.2 Patient-related 47
3.12.3 Gradient-related 48
3.12.4 Magnetic susceptibility 48
4 Instrumentation 50
4.1 Introduction . 50
4.2 Main magnet 50
4.3 Shim coils .. 52
4.4 Gradient coils 52
4.5 RF coils ... 53
4.5.1 Body coil 53
4.5.2 Fluorine coil. 54
Contents iii
4.6 Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5 MRI of the gastrointestinal tract
5.1 The gastrointestinal tract ....
5.1.1
5.1.2
5.1.3
Anatomy and physiology of the gastrointestinal tract
Definition of colon regions .
Colonic motility and transit
59
60
60
64
65
66
67
68
68
5.1.4 Colon disorders . . . . .
5.2 Functional MRI of the GI tract
5.2.1 Measuring gastric volume
5.2.2 Measuring small bowel water content
6 Methods for measuring physiology of the colon 71
6.1 Introduction............................. 71
6.2 Colonic response to an experimental model of human diarrhoeal
disease .
6.2.1 Introduction.
6.2.2 Methods
6.2.3 Results.
6.2.4 Discussion and conclusions.
72
72
73
75
80
6.3 Measuring the Tl and T2 of the colonic contents in vitro. 84
6.3.1 Introduction.
6.3.2 Methods
6.3.3 Results.
'6.3.4 Discussion and conclusion
84
84
85
86
6.4 Defining the characteristics of the ascending colon contents 88
6.4.1 Introduction. 88
6.4.2 Methods
6.4.3 Results.
6.4.4 Discussion
88
.106
.115
Contents iv
7 MRI of pharmacological interventions in the colon 117
7.1 Introduction ....................... .117
7.2 Novel insights into the mechanisms of action of Metamucil .119
7.2.1 Introduction . .119
7.2.2 Method .119
7.2.3 Results. · 121
7.2.4 Discussion and conclusion · 122
7.3 Defining the mode of action of loperamide and loperamide plus
simethicone using an MRI model of acute diarrhoea · 128
7.3.1 Introduction .
· 128
7.3.2 Method
· 131
7.3.3 Results.
· 135
7.3.4 Discussion and conclusion
· 151
8 Using markers to measure GI transit 154
8.1 Fluorine MRI ........... · 156
8.2 Compounds for human 19F MRI · 157
8.2.1 Perfl uorocar bons ..... · 158
8.2.2 Potential 19F markers for GI transit · 162
8.3 In vitro tests of fluorinated compounds · 173
8.3.1 High resolution MRS · 173
8.3.2 T, and T2 of PFOB .
· 177
8.3.3 Susceptibility of PFOB
· 178
8.4 19F coil characterisation
· 180
8.4.1 Methods
· 180
8.4.2 Results.
· 181
8.5 Capsules for GI transit studies.
· 184
8.5.1 Methods
· 184
8.5.2 Results.
· 190
8.5.3 Conclusion.
· 193
Contents v
8.6 GI transit in vivo study with the use of fluorinated markers. . 194
8.6.1 Introduction.
8.6.2 Method
8.6.3 Results.
8.6.4 Discussion and conclusion
8.7 GI transit time using double-labelled
.194
· 194
· 195
· 196
markers . · 198
8.7.1 In vitro test: finding the optimal Gd concentration . 198
8.7.2 In vivo pilot study . 200
8.7.3 Discussion.... . 204
8.8 Studying the GI transit time using double-labelled markers:
mode of action of Moviprep .207
8.8.1 Introduction . .207
8.8.2 Methods .208
8.8.3 Results. .208
8.8.4 Discussion and conclusion .214
8.9 Optimisation of the GI transit markers .217
8.9.1 Introduction . .217
8.9.2 Methods .217
8.9.3 Results. .218
8.9.4 Discussion and conclusion .219
9 Conclusions 221
A Standard operating procedure for the capsules manufacture
for in vivo studies
A.1 Manufacture of the capsules
224
.224
.226
.229
A.2 Preparation of the capsules for in vivo studies
A.3 Leakage test with the spectrophotometer ...
Contents vi
Bibliography 230
Abstract
The overall aim of this work was to develop MRI methods and techniques
to study the physiology and the pathology of the gastrointestinal tract, with
particular attention to the colon. Besides, the development of new methods
was aimed in order to perform quantitative analysis using proton and fluorine
MRI. In particular the first experimental chapter describes the development
and the optimisation of imaging protocols for studying colonic function in
undisturbed physiologically relevant conditions. In addition a texture analysis
method based on Gabor filters is developed and used for the objective assess-
ment of colonic content characteristics. The mechanisms of action of common
anti-diarrhoeal and anti-constipation agents are also investigated. The last
experimental chapter describes the development of methods for using mark-
ers to measure GI transit. Transit time, i.e. the time it takes for a marker
to pass through the entire gut, is often affected by functional gastrointestinal
disorders, therefore it is of primary importance to develop a non invasive and
effective technique for the diagnosis of such gastrointestinal diseases. The use
of fluorinated agents and its many advantages compared to other techniques
is outlined and the first in vivo studies at high field are presented. The use of
gadolinium based compounds as an additional marker is also discussed.
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Chapter 1
Introduction
Magnetic Resonance Imaging (MRI) has been rapidly expanding since its
introduction in the 1970's with thefirst papers from Mansfield [1]and Lautebur
[2]. Several developments were made in the following years and it is now a well
established medical imaging technique which provides a wide range of image
contrasts. The main advantage compared to other imaging techniques is the
absence of ionizing radiation and its non invasive character.
MRI of the gastrointestinal (GI) tract was initially very limited for var-
ious reasons. Firstly, the anatomy of the GI tract presents a very complex
three-dimensional structure which is very variable between individuals and it
also varies within the same subject according to the fed or fasted state and
physical activity. Secondly, respiration and peristaltic movements lead to par-
tial volume artifacts and blurring. With the advent of fast MR imaging, these
problems have been overcome [3,4]. Therefore it is now possible to use this
technique for studying the physiology and the pathology of the GI tract. De-
spite all this, very little work has been published on colonic function. In par-
ticular, symptoms of colonic dysfunction such as diarrhoea and constipation
are very common in the general population leading to a substantial social and
economic impact [5,6]. Hence, the interest in understanding such mechanisms
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and their possible treatment is continuously growing.
1.1 Thesis overview
The overall aim of this work was to develop MRI methods and techniques
to study the physiology and the pathology of the gastrointestinal tract, with
particular attention to the colon. Besides, the development of new methods
was aimed in order to perform quantitative analysis using proton and fluorine
MRI.
The first chapters introduce the background theory of nuclear magnetic
resonance (chapter 2) and magnetic resonance imaging (chapter 3). Definitions
of the main terms and the key basic physics concepts are outlined and the
principal MRI sequences used in this work are introduced.
Chapter 4 describes the main hardware components of an MR system with .
particular attention to the equipment used for the experiments performed in
this thesis.
An overview of the anatomy and physiology of the gastrointestinal tract is
given in chapter 5, in which MRI of the GI tract is also introduced.
Chapters 6, 7 and 8 are the experimental chapters of this thesis.
Chapter 6 describes the development and the optimisation of imaging pro-
tocols for the GI tract and in particular for studying colonic function in undis-
turbed physiologically relevant conditions. In particular the colonic response
to an experimental model of human diarrhoeal disease is presented. The chap-
."
ter includes the development of a texture analysis method based on Gabor
filters,used for the objective assessment of colonic content characteristics.
The methods developed and optimised in chapter 6 are then applied to
pharmacological interventions in the colon. In particular, the mechanisms of
action of common anti-diarrhoeal and anti-constipation agents are investigated
(chapter 7).
In t.xoductiou 3
The last experimental chapter (chapter 8) describes the development of
methods for using markers to measure GI transit. Transit time, i.e. the time it
takes for a marker to pass through the entire gut, is often affected by functional
gastrointestinal disorders, therefore it is of primary importance to develop a
non invasive and effective technique for the diagnosis of such gastrointestinal
diseases. The use of fluorinated agents and its many advantages compared
to other techniques is outlined and the first in vivo studies at high field are
presented. The use of gadolinium based compounds as an additional marker
is also discussed.
A general summary of the results of this work together with the future plan
are outlined in chapter 9.
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Chapter 2
Nuclear Magnetic Resonance
2.1 Introduction
This chapter outlines the basic principles of nuclear magnetic resonance .
(NMR) which have been extensively studied and are reported in numerous
texts [7-10].
The NMR phenomenon refers to the interaction of nuclei with spin angular
momentum with a magnetic field. It was independently discovered in 1946 by
Felix Bloch [11] and Edward Purcell [12] and they were jointly awarded the
Nobel Prize in 1952. In order to fully understand the basic principles of NMR
it is important to understand the properties of atoms and their interaction
with magnetic fields. The basic theory of nuclear magnetic resonance and
relaxation are also explained.
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2.2 NMR basic principles
2.2.1 Atomic structure and MR active nuclei
The atomic structure includes a central nucleus that contains nucleons
(protons and neutrons) and orbiting electrons. The electrons are negatively
charged, protons are positively charged while neutrons have no net charge. The
electrons, protons and neutrons all also have a quantum mechanical property
of spin. The neutrons and protons couple within a nucleus so that a nucleus
with an odd number of protons and neutrons has a net spin.
Because of the electromagnetic induction law, charged nuclei that are spin-
ning acquire a magnetic moment. These nuclei have the property of having
net spin and being able to align their axis of rotation to an external magnetic
field when applied. This alignment can be expressed as a vector sum of all
the nuclear magnetic moments and it is specific for each nucleus, thus giving .
a specific NMR sensitivity.
Table 2.1 gives a selection of MR active nuclei that are commonly used in
NMR together with their main properties.
2.2.2 Boltzmann statistics
Ifwe consider a real system consisting of an ensemble of nuclear spins as, for
example, in a sample of water, the hydrogen nuclei will be randomly oriented
and the total magnetic moment of the sample will be zero. When a magnetic
field is applied the magnetic moments will align with this magnetic field.
According to the quantum mechanics, hydrogen nuclei have two energy
states: the low energy states, where the nuclear magnetic moments align par-
allel to the magnetic field (spin up) and the high energy states, for which the
magnetic moments are antiparallel (spin down). In thermal equilibrium there
will be more nuclei in the lower energy state thus meaning that there is a total
NucleaI" l\Jaf!,nctic Rescnuuice 7
Isotope Nuclear Spin "Y/27f(rad/s/T) Natural Abundance (%)
1H 1/2 267.52 99.9
13C 1/2 67.28 1.1
14N 1 19.34 99.6
23Na 3/2 70.81 100
19F 1/2 251.81 100
31P 1/2 108.39 100
Table (2.1): Properties of somenuclear isotopesused formagnetic resonance [7].
net magnetic moment parallel to the external magnetic field (see figure 2.1).
The distribution of the spins between the two different energy levels can
be described with the Boltzmann statistics:
(2.1)
where NOt and N(3 are the number of nuclei in the lower and higher energy
states respectively, k is the Boltzmann constant (1.38 x 10-23 J/K) and T is
the temperature. Equation 2.1 implies that the net magnetisation is higher for
lower temperature and higher magnetic field strength. Since it is not possible
to decrease the temperature of the sample for in vivo studies, the increase of
magnetic field strength is desired to increase the signal to noise ratio of NMR
experiments.
2.2.3 Precession and Larmor frequency
The hydrogen nuclei in the net magnetisation spin on their own axis and
When an external magnetic field Bo is applied the torque on the magnetic
A B
,.\ • . ·.·.·.·.·.·.·.··0
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Figure (2.1): Illustration of the spin precession when an external magnetic field
Bo is applied. At thermal equilibrium there is a total net magnetisation parallel
to the magnetic field because more nuclei are in the lower energy state. Adapted
from [13].
moment causes them to start precessing around the magnetic field axis at a
specific frequency called the Larmor frequency, with a specific rotation angle,
e that depends on the spin state. This phenomenon is called precession (figure
2.1).
The Larrnor frequency, WL, is given by
(2.2)
where l' is the gyromagnetic ratio, typically described in units of rad/s,
and it is a specific property of each nucleus (see table 2.1). The Larrnor
frequency has a defined sign indicating the direction of the spin precession.
Most nuclei have a positive l' which means that the precession is clockwise.
As the gyromagnetic ratio is a constant for a given nucleus, the precessional
frequency of a nucleus depends on the magnetic field applied.
2.2.4 Resonance and MR signal
When a nucleus is exposed to an external perturbation it gains energy and
it resonates if the energy is delivered at its precise precessional frequency. The
precessional frequency of hydrogen at all field strengths used in clinical MRI
;-\niu-nt AIitglldie Iks()11I1lJ('C' 9
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Figure (2.2): Illustration of the Zeeman splitting of the energy levels in the
presence of an external magnetic field Eo. The transition between the two levels
only happens when the energy equal to the Zeeman splitting tlE is applied.
correspond to the radiofrequency (RF) region of the electromagnetic spectrum.
In order to induce a resonance of hydrogen nuclei in the matter a RF pulse
of energy corresponding to the Larmor frequency must be applied. In that
case, only hydrogen nuclei will be excited even if other MR active nuclei are
aligned with the magnetic field because they have a different Larmor frequency.
When the RF is applied, the nuclear spin state can change by the absorption
of the energy that matches the Zeeman splitting t::.E (figure 2.2), causing the
transition to higher energy states.
The photon frequency 1/required for the transition to happen is given by
the following equation
s» ,Eo
1/=--=--
h 27f (2.3)
where Eo is the static field.
In NMR the nuclei experience two different magnetic fields: the static
magnetic field Eo and the oscillating RF field E1(t) which is several orders of
magnitude smaller than the static magnetic field. This RF pulse is fundamen-
tal in MR because it creates the MR signal: when El (t) is applied the net
magnetisation moves out of alignment by an angle called the flip angle, whose
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magnitude depends on the duration and the amplitude of the pulse. In fact,
this equation applies
(2.4)
where T is the duration of the pulse. For a rectangular pulse envelope the
flip angle can be defined as
(2.5)
When the magnetisation is given enough energy by the RF pulse to tip
through 90°, it is completely transferred into the transverse plane. By con-
vention, "z" is the direction of the static magnetic field while the RF pulse
is given in the ''x'' direction. As a result of resonance, the magnetisation is
then flipped by an angle a and is precessing in phase in the transverse plane.
Magnetic moments are in phase when they are in the same place on the pre-
cessional path at the same time. The precession of the magnetisation in the
transverse' plane produces magnetic field fluctuations in that plane, so if a coil
is placed in the area of that moving magnetic field, a voltage is induced in the
coil as stated by the Faraday's law of induction. This voltage is the MR signal,
whose frequency is the same as the Larmor frequency and whose magnitude
depends on the amount of magnetisation precessing.
2.2.5 Relaxation
Once the RF pulse is turned off, the net magnetisation is still influenced by
the static magnetic field Bo. The process of returning the net magnetisation
to be aligned to Bo is called relaxation. During relaxation, the amount of
magnetisation in the longitudinal plane gradually recovers (recovery) while
the amount of magnetisation in the transverse plane decreases (decay). In
N 11(']( 'ill' ;lfilglJ(,/je n (,SOJJillJ(,(' 11
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Figure (2.3): Illustration of the behaviour of the net magnetisation M in two
different reference frames, the laboratory reference frame (a) and the rotating
reference frame (b). When the RF pulse Bl is applied in the x direction, the
magnetisation vector M spirals down to the transverse plane in the static frame,
while in the rotating frame it appears as a one dimensional flip to the transverse
plane.
order to describe this process it is useful to introduce a rotating reference
frame. Since B, and the net magnetisation M both rotate around the z axis
(the direction of the Bo field) with the angular velocity WL, a rotating frame
will be chosen with the same angular velocity so that the Bl will appear static
in that reference frame. So, by convention, the laboratory reference frame has
coordinates (x, y, z) while the rotating reference frame has coordinates (x', y',
z'). z and z' are considered equivalent. Figure 2.3 shows the effect of an RF
pulse. While in the static laboratory system the magnetisation relaxes with a
spiral motion, in the rotating system it draws a one-dimensional rotation back
to the z direction.
The evolution of the magnetisation is described by the Bloch equation
(2.6)
where B is the total applied magnetic field (superposition of Bo and Bl
effects), T', is the spin-lattice relaxation time describing the recovery of the
longitudinal magnetisation and T2 is the spin-spin relaxation time describing
the decay of the transverse magnetisation.
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The relaxation rates depend on the characteristics of the matter in which
it occurs: for liquids the main mechanism for relaxation is dipole-dipole in-
teraction. Each spin is influenced not only by the main static magnetic field·
Bo but also by the microscopic fluctuating magnetic fields of the surrounding
spins. These fluctuating fields are very small but they can cause relaxation.
Longitudinal relaxation
The longitudinal or spin-lattice relaxation describes the mechanism of the
spins' alignment returning back to the Boltzmann distribution values (Mz=Mo)
following the transfer of energy from the spins to the surrounding lattice. The
behaviour of M; in this process is described by
dMz (Mo - Mz)
--=dt Tl
(2.7)
Tl is specific for different kinds of matter and depends on the magnetic
field strength (Bo): the higher the magnetic field strength the longer the Tl
for the same matter. The most efficient energy transfer occurs from fluctu-
ations of the dipole-dipole magnetic fields at the Larmor frequency. Water
and solids do not transfer energy efficiently as they both have characteristic
molecular motions with frequencies very different to Larmor frequency. On
the contrary hydrogen protons in fat have a natural motion frequency very
similar to the Larmor frequency thus giving a very high efficiency of energy
transfer and short T1• However, it has to be said that the hydrogen protons in
the body ar,enormally bound to macromolecules that reduce their motion thus
producing a shortening of T1• Solving equation 2.7 describing the behaviour
of the longitudinal magnetisation from an initial state Mz(O) it is possible to
write the following equation
(2.8)
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Figure (2.4): Longitudinal relaxation Mz(t) as a function of time for inversion
recovery (red solid line) and saturation recovery (blue solid line) [13].
After a 1800 inversion pulse the longitudinal magnetisation is inverted so
Mz(O)=-Mo so the recovery follows an exponential curve given by
(2.9)
which is illustrated with the red line in figure 2.4.
Following a 900 RF pulse tipping the magnetisation to the x axis, the
magnetisation is flipped into the transverse plane and the recovery curve, rep-
resented in blue in figure 2.4, is given by the so called saturation recovery
curve
(2.10)
Transverse relaxation
Transverse relaxation describes the short-range spin-spin interactions that
produce the dephasing of the spins over time. The transverse component of
the Bloch equation is given by
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where T2 is the transverse relaxation time. A long T2 means that the de-
phasing of the spins is slower, on the contrary, if the molecules have a rigid
structure as in the case of solid tissues, there will be more spin-spin interac-
tions thus giving a short T2• Fat and proteins have an intermediate T2• In
general, T2 is always shorter than Tl (for liquids T2=Td and depends on the
Bo field strength. At thermal equilibrium the transverse magnetisation in zero
(Mx,y=O) and a saturation 90° pulse is needed to flip the entire magnetisa-
tion in the xy plane. The signal decay after the saturation pulse follows the
following exponential curve
(2.12)
and is known as Free Induction Decay (FID).
The spin-spin dephasing is also driven by Bo field inhomogeneities and
this effect produces a faster signal decay. In order to take into account this
additional contribution, another relaxation time constant is introduced: T2*
depends on both the molecular interactions and the Bo variations and is given
by
1 1 1
T; = T2 + T~ (2.13)
where T~"describes the effect of Bo inhomogeneities. T2* is always smaller
than T~ and it generally shortens when Bo increases due to the increased
susceptibility effects. The decay of the transverse magnetisation is illustrated
in figure 2.5.
As already stated, the transverse magnetisation of the precessing spins
produces a detectable electromotive force that is detected by a receiving coil
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Figure (2.5): Transverse magnetisation decay over time: the combined time
constant T2* describes a faster decay as it takes into consideration both the
sample interactions and the external magnetic field inhomogeneities.
T2* envelope
Figure (2.6): Illustration of the FID decay over time showing the T2* effect: the
product of a sinusoidal signal and an exponentially decaying signal results in a
decaying sinusoidal signal.
in the transverse plane. Once the RF pulse is turned off the spins continue to
precess around the z axis but they start loosing their coherence. The received
signal is therefore an oscillating, decaying function, as shown in figure 2.6.
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Figure (2.7): Inversion recovery sequence. Here, and in later figures, the 1800
pulse is drawn at twice the height, for the same width, as the 900 pulse, corre-
sponding to the need for twice the Bl amplitude to get twice the angle of spin
rotation.
2.2.6 Relaxometry
Measuring Tl
The measurements of Tl are based on the Bloch equation 2.7. The most
common way to measure Tl is through the inversion recovery sequence (figure
2.7). This sequence consists of a combination of two RF pulses. The first 1800
pulse inverts the longitudinal magnetisation so that Mz(O)=-Mo. A second
pulse tips the longitudinal magnetisation into the transverse plane so that an
FID can be collected. The time between the two pulses is called the inversion
time T[. The signal as a function of T[ is given by
(2.14)
which has a zero crossing value for T[=T1ln2. When an inversion recovery
sequence is repeated every TR (repetition time) seconds, for signal averaging
or imaging purposes, the signal equation becomes
(2.15)
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Figure (2.8): Spin echo sequence
Measuring T2
The transverse relaxation time T2 can be measured using a spin echo se-
quence that is able to remove the effects of the magnetic field inhomogeneities
(figure 2.8). It is also based on the application of two RF pulses: a 900 pulse
applied along the positive x axis that flips the magnetisation into the xy plane
and a subsequent 1800 pulse applied at a time TE/2 along the positive y axis
to invert the phase that the spins have accumulated. The spins continue to
precess at the same frequency thus rephasing and producing an echo corre-
sponding to maximum coherence after a further time TE/2. The magnitude of
the magnetisation at the echo will still be limited by the T2 envelope because
the dipole-dipole interactions cannot be refocused.
If the time between the RF pulses is known, the amplitude of the echo
measured is related to T2
M M -TE/T2echo = Oe (2.16)
where Mecho is the peak amplitude of the echo. By repeating the sequence
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for different echo times, a series of measurements of Mecho can be collected
and fitted to obtain an estimate for T2• The time between repetitions, TR,
should be more than five times the Tl of the sample, otherwise the signal will
be dependent on Tl in addition to T2 and equation 2.16 will no longer be valid.
The most common technique that employs the spin echo in order to mea-
sure T2 suppressing diffusion effects is called the Carr-Purcell Meiboom-Gill
(CPMG) sequence in which the refocusing pulses is phase shifted by 7r /2 with
respect to the 900 pulse [14]. Therefore, the Bl field of the refocusing pulses
aligns along y while the 900 Bl field is still along x' axis. This modification
makes the spins flip about the y' axis and thus all spin echoes converge along
y' and have the same (positive) phase. By introducing a phase shift between
the 900 and 1800 pulses the sequence becomes
90° - TE _ 180° - [TE - 180°]
x 2 y y n (2.17)
Echoes are formed between successive 1800 pulses as the spin refocus and
the T2 can be calculated by fitting the signal amplitude at each echo with the
following
(2.18)
With this method there is enough information to obtain the T2 in a single
relaxation curve. This sequence is more tolerant of pulse errors: a refocusing
pulse smaller..than 1800 will cause the first echo to be formed above the x'y'
plane but the second echo will rephase back in the x'y' plane. This means
that odd-numbered echoes will be formed above the x'y' plane with reduced
amplitude. Therefore at least 10 echoes are required with a range of echo times
up to three times T2•
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2.2.7 Chemical shift
The magnetic fields experienced by nuclei in the molecule depend on the
chemical environment. The electrons in the molecule produce small changes in
the magnetic field so nuclei in different position in the molecule will experience
a different magnetic field. These differences cause the spins to precess at
slightly different frequencies. This shielding effect is known as chemical shift.
The measured frequencies are described by the following equation
Wmeas = "(Bo(l - u) (2.19)
where Bo is the field applied to the nuclei and a is the chemical shift
shielding constant. Under fully relaxed conditions the ratios of the signals at
different frequencies give the number of protons in that particular chemical
environment. The chemical shift of a nucleus is usually referred to the shift of
a reference peak in parts per million (ppm) and is given by
8(ppm) = W - wref x 106
wref
(2.20)
with wref being the frequency of the reference peak, that is defined as the
resonant frequency of the hydrogen nuclei in tetramethylsilane (TMS). In NMR
spectroscopy the chemical shift is a useful tool that provides information on
the chemical environment of the nuclei and is obtained from a single FID. On
the contrary, these chemical shifts lead to artifacts in MRI.
2.2.8 Susceptibility
Magnetic susceptibility is a natural property of all substances and is given
the symbol x, as depends on the arrangement of the electrons in the material.
It is defined as the extent to which any material becomes temporarily mag-
netised when it is placed in a large magnetic field. There are four regimes of
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different magnetic susceptibilities.
• Diamagnetic materials have no unpaired orbital electrons and when they
are placed in a magnetic field Bo, a weak magnetic field is induced in the
opposite direction, therefore the effective magnetic field is reduced. The
effect on images is, for example, the distortion that occurs at the air-
tissue interface. Diamagnetic substances have a small negative magnetic
susceptibility X (X<O). Most body tissues are diamagnetic, while air and
dense bone have almost zero susceptibility.
• Paramagnetic materials have unpaired orbital electrons and they become
magnetized when placed in a magnetic field Bo producing an increase of
the effective magnetic field. Therefore they have a small positive suscep-
tibility (X>O). In materials containing mobile paramagnetic centres, the
dipole-dipole interactions produce a Tl shortening thus giving a bright
signal in the Tl weighted images. This is why paramagnetic elements
such as gadolinium (Gd) are used as contrast agents (see section 2.2.9).
Other examples are deoxy-haemoglobin and met-haemoglobin.
• Superparamagnetic is a term used to describe materials intermediate
between paramagnetic and ferromagnetic, with susceptibility values be-
tween 100 and 1000. Examples include iron oxide particles (used as MR
contrast agents) and ferritin.
• Ferromagnetic materials experience a large force when placed in an exter-
..
nal field and become permanently magnetized even when the magnetic
field has been turned off. They have a large positive susceptibility. Metal
alloys containing iron, nickel and cobalt are often ferromagnetic.
At the boundaries of tissues with different susceptibility there will be
slightly different magnetic fields that will produce a perturbation of the static
field. The induced magnetisation, Mz,ind, is calculated as
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Mzind ~ KBo (2.21)
, /Lo
where /Lo is the permeability of the free space. It is then possible to define
the effective local magnetic field as
BefJ ~ (1+X)Bo (2.22)
The perturbations induced in the magnetic field by these susceptibility ef-
fects can cause artifacts in magnetic resonance images as will be explained
in section 3.12.4. However, these effects can also be used both for functional
MRI, where the susceptibility difference between oxygenated and deoxygenated
blood allows the visualization of brain activity [15],and for contrast agent stud-
ies [16]. In particular, a paramagnetic rare earth element such as gadolinium
has been used for this work so it is described more in detail in the following
section.
2.2.9 Contrast agents
Exogenous contrast agents such as gadolinium have an effect on tissue
relaxation times that can be best described using relaxation rates instead of
relaxation times. Therefore it is useful to define the following relaxation rates
R2* = 2_
T.*2
(2.23)
that are additive quantities.
For contrast agents it is possible to define a specific relaxivity r to describe
the effect of their concentration on the change in the relaxation rate. For
example, the change in relaxation rate of a tissue due to the presence of the
contrast agent is given by the following equation
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R' = R + rO (2.24)
where C is the concentration of the contrast agent. The relaxivity r may
be different for longitudinal and transverse relaxation rates but in the case of
gadolinium they are approximately the same (4 and 5 mmol-1s-1).
As already stated in the previous section, gadolinium is strongly paramag-
netic because it has seven unpaired electrons in its electronic structure. As a
free ion, gadolinium is highly toxic. However, it is generally regarded as safe
when administered as a chelated compound, i.e, in chemical structures that
chemically shield the gadolinium atom, which eliminate the toxicity preserv-
ing the susceptibility characteristics. Different types of gadolinium-containing
contrast agents are available. Details concerning the physicochemical proper-
ties of some of these agents are given in table 2.2. The first agent developed,
gadopentetate dimeglumine (Gd-DTPA, Magnevist® by Schering), has a lin-
ear structure and is ionic in nature, with a net -2 charge of the gadopentetate
chelate [17]. Magnevist was followed initially by gadoterate meglumine (Gd-
DOTA, Dotarem® by Guerbet) which has a cyclic structure but is again ionic
(with a net -1charge of the gadoterate chelate), and subsequently by Gada-
teridol (Gd-HP-D03A, ProHance by Bracco).
In this work Gadoteridol will be used that has a chemical structure closely
related to the two other compounds but showing lower osmolality. ProHance
and Dotarem have the highest combined thermodynamic and kinetic stability,
reflecting the' greater energy and time required to remove the gadolinium ion
from the ring structure in which it is held. A comparison of the physicochemical
properties of different gadolinium formulations available commercially has been
presented recently by Laurent et al. [18].
The strongly paramagnetic behaviour of gadolinium produces a decrease in
both Tl and T2 relaxation times of the proton nearby. At low concentrations
such as those used in normal clinical practice (rvO.immol per kilogram) the
Molecular structure
Magnevist I Dotarem I ProHance
Linear, ionic Cyclic, ionic I Cyclic, nonionic
Osmolality (Osmjkg) 1.96 1.35 0.63
Viscosity (mPa s at 37°C) 2.9 2.0 1.3
Metal chelate (mgj ml) 469 278.3 279.3
Table (2.2): Physicochemical characteristics of commercially-available,
gadolinium-based MR contrast agents, predominantly renally excreted.
major effect is the T, shortening, and tissues which take up the agent have an
enhanced signal intensity on T1-weighted images. At weak concentration, the
T2 effect of gadolinium chelates is negligible compared to the T, effects. The
T2 effect predominates and is only visible at high concentrations, for example
in the bladder after renal excretion, where a loss of signal occurs.
Perfusion MRI also exploits the magnetic susceptibility effect due to the
first intravascular passage of a concentrated bolus of Gd chelate, responsible
for a drop in the T2 and T2 signal. T2 effect is enormous and occurs due to
the inhomogeneous distribution of Gd in vessels and around.
While the NMR principles have been explained in this chapter, the next
chapters will cover the principles of MR imaging.
Chapter 3
Magnetic Resonance Imaging
3.1 Introduction
Magnetic resonance imaging (MRI) is an imaging technique discovered in-
dependently by Peter Mansfield [1] and Paul Lautebur [2] in 1973. Several
developments followed especially in the group lead by Peter Mansfield includ-
ing slice selection [19],echo planar imaging (EPI) [20],actively shielded gradi-
ents [21] and echo volumar imaging [22]. Peter Mansfield and Paul Lautebur
were jointly awarded the Nobel Prize for medicine in 2003 "for their discoveries
concerning magnetic resonance imaging" (www.nobelprize.org).
This chapter outlines the basic principles of magnetic resonance imaging
(MRI). The basic theories on which MRI is based have been extensively de-
scribed in numerous texts, for example [7,23].
3.2 Gradients
Magnetic field gradients are fundamental for the determination of the spa-
tial information of the NMR signal. A field gradient is an additional small field
variation that produces a linearly varying field. The gradient field strength is
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measured in millitesla per metre (mT /m). In order to create an image from
a sample, it is necessary to have one gradient for each of the x, y and z di-
rections which are called Gx, Gy and G, respectively. As the total magnetic
field is commonly referred to as along the z axis, the three orthogonal spatial
gradients of B, can be expressed as
(3.1)
G _ dBz
y - dy (3.2)
G _ dBz
z - dz (3.3)
The three sets of gradients, normally applied for a short time as pulses,
give MR its three dimensional capability. The total field gradient is therefore
defined as
(3.4)
and the resultant magnetic field at a point r can be written as
Bz(r) = Bo +G . r (3.5)
where r is defined as
r = xi+yj +zk (3.6)
As a consequence of the introduction of the field gradients, the Larmor
frequency, previously defined in equation 2.2, becomes
(3.7)
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This means that when the gradients are applied, the protons (spins) will
experience a different total field according to their position in the three dimen-
sional space, thus resonating faster or slower. Figure 3.1 shows the effect of
field gradient on spins.
L- _+_ X X
x=O
Figure (3.1): Example of the application of field gradients: when only Eo is
applied all nuclei precess at the same frequency (left), when a gradient is applied
as for exam pie in the x direction (right) the spin precession frequency depends
on the position and will be slower or faster.
Depending on their function, magnetic field gradients are called slice-select
gradient, frequency-encoding gradient or phase-encoding gradient. The follow-
ing sections will explain these functions in detail.
3.3 Slice selection
As shown in figure 3.1 the presence of the gradient causes the resonant
frequency to vary according to the position in the gradient direction, being
equal to the normal Larmor frequency when x=O and being higher or lower
along the axis. The slice selection occurs when a selective excitation pulse (RF)
is applied with a centre frequency Wo and a small range of frequencies .6.w, the
transmit bandwidth. Resonance occurs only when the required frequency is
present in the RF pulse's transmit bandwidth. Therefore only spins in a plane
with a Larmor frequency corresponding to the range of frequencies contained
in the RF pulse will be tipped into the xy plane. This is called selective
excitation. The slice-select gradient field, Gz introduces a linear variation of
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the Larmor frequency in the slice (z) direction equal to
(3.8)
The thickness of the slice ~z can be written as
(3.9)
where ~w is the pulse's transmit bandwidth that depends on the shape of
the pulse envelope and its duration. For small flip angles, the slice profile is
proportional to the Fourier transform of the RF pulse. Ideally, the slice profile
should have a rectangular shape, i.e. equal to the maximum inside the slice
and equal to zero outside. This would correspond to a sine! shaped RF pulse
with an infinite number of lobes. In practice, 3 or 5 lobes are used because a
larger number of lobes would increase the minimum echo time (TE) and the
repetition time (TR).
From equation 3.8 it can be deduced that the slice thickness can be manip-
ulated by changing the strength of the gradient or bandwidth of the excitation
pulse, whilst changing the slice position means changing the centre frequency
of the RF pulse, by adding or subtracting a specific frequency offset.
Figure 3.2 shows an example of RF pulse applied together with a gradient
Gz. It has to be underlined that whilst the selective excitation pulse is applied,
the signal being generated is also being dephased by the gradient. For most
pulses this phase shift is corrected by applying a reversing gradient for half the
duration of the pulse.
1A sin~ function is expressed as 8i~(X) and consists of adjacent lobes with alternating
polarity, with a central high lobe.
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w
Figure (3.2): The image on the left showsthe selection of a slicewith a thickness
~z when a linear gradient field Gz is applied together with an RF pulse with a
range of frequencies ~w. On the right it can be seen that after the RF pulse,
a slice selection gradient with negative polarity is applied for half the duration
in order to refocus the dephasing effects induced by the original slice select
gradient.
3.4 In plane spatial encoding
In order to create an image following the slice selection it is necessary to
perform the so called spatial encoding in the two remaining axis. To achieve
this, two processes are performed: frequency encoding and phase encoding.
3.4.1 Frequency encoding
The frequency-encoding gradient ex, also called the readout gradient, is
applied in the x direction to get spatial information in the x-direction, influ-
encing only those spins that have already been excited by the slice selection.
Because the ex gradient is switched on while the NMR signal is being mea-
sured, the signal's frequency depends on the position of the material along the
x direction. According to equation 3.7, the spatial location can be measured
as both Eo and ex are known. However, the resultant signal is a mixture of
many frequency components and a Fourier Transform (FT) analysis is needed
to determine the single frequency components.
Fourier analysis is a mathematical tool that reveals the spectral content of
a signal. In general, a Fourier transform is defined by the equations
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. (3.10)
(3.11)
where s(x) and S(k) are functions of x and k respectively. In MRI x is
the spatial domain and k is the spatial frequency domain. By analogy, a
two-dimensional FT is defined as
S(kx, ky) = if.s(x, y)e-i21rk.,xe-i21rkllYdxdy
and a three-dimensional FT is
(3.12)
(3.13)
The signal received from a point r at time t is proportional to the spin
density p(r) and depends on the local Larmor frequency wL(r, t')
(3.14)
Therefore we can write the signal received from a three-dimensional region
as
(3.15)
where dV __;_dxdydz. When applying a constant linear field gradient in the
x direction, the precession frequency becomes
(3.16)
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therefore the demodulated signal (after 10 removed) can be written as
(3.17)
where k(x) refers to k-space which will be explained in section 3.5.
3.4.2 Phase encoding
In addition to using the slice-select gradient Gz and the frequency encoding
gradient Gx, another gradient is needed for localisation along the y direction.
For this a phase encoding gradient Gy is generally used which produces a
linear spatial variation in the phase of the magnetisation. As a result, the
spins in the same column will have different phases compared to each other
and compared to the spins in the centre of the magnet. The phase-encoding
gradient is usually applied right after the RF pulse or just before the readout.
The amount of dephasing introduced depends on the magnitude of the gradient
applied and on the position in the phase-encoding direction. Therefore
(3.18)
where T is the duration of the phase encoding gradient lobe.
Ifwe add the contribution of the phase-encoding gradient to equation 3.17,
we can write for the signal
S(t) ex J J p(r)ei< /> 'I/+ iXka;dxdy (3.19)
Figure 3.3 shows schematically how the Gx and the Gy gradients are ap-
plied.
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Figure (3.3): The frequency encoding gradient Gx (on the left) linearly changes
the Larmor frequency of the spins along the x axis. The phase encoding gradient
Gy (on the right) introduces a phase shift along the y axis.
3.5 k-space
The concept of k-space, called "reciprocal space" was introduced into MRI
in 1973 by Mansfield and Grannell [1]. K-space can be thought as the raw
data matrix which stores the encoded MR signals, being the Fourier space
(kx, ky kz) in which images are acquired before being Fourier transformed into
the cartesian image space (x, y, z). In other terms, it represents the spatial
frequency distribution of the MR image: low spatial frequencies are close to
the origin and represent the overall brightness or contrast of the image whilst
high spatial frequencies, at the outer regions of k-space, give information on
the details and the edges.
The k-space description of an image is normally composed of two axes per-
pendicular to each other, with the horizontal axis related to frequency encoding
and the vertical axis to phase encoding axis. Figure 3.4 shows the relationship
between k-space and image space.
Immediately after the RF pulse, the signal is at the centre of k-space that
corresponds to the sum of the total MR signal of the object. With the applica-
tion of the frequency encoding and the phase encoding gradients, the sampling
position moves to the bottom left corner. During the frequency encoding,
data points are recorded at regular intervals along a line of kx from left to
right. During the phase encoding the trajectory across the k-space is altered
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Figure (3,4): Schematic of the image space (left) and k-space (right),
to the second line bottom line, In order to sample the whole image, the four
quadrants of the k-space must usually be covered by the readout.
A generalized form for an arbitrarily shaped gradient G, k is defined as
k = '"Y it G(t)dt (3.20)
which defines any k-space trajectory. The Field of View (FOV) is deter-
mined by the separation of the ky lines and of the samples along each kx line
1
FOVx,y=~
x,y
(3.21 )
The pixel size is defined by the total length of the k-space axes.
3.6 Gradient echo sequence
Figure 3.5 shows the MR pulse sequence diagram for the gradient echo
(GE) imaging sequence. In the GE, a frequency selective RF pulse is applied
together with a linear slice-selective gradient Gz, thus allowing the rotation
of the magnetisation into the transverse plane. The refocusing component of
the z gradient of opposite polarity is used to remove the phase shift across the
slice.
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Figure (3.5): Basic gradient echo MR imaging sequence and corresponding sam-
pling in the k space. The top line shows the RF pulse which is applied simultane-
ously with a slice selective gradient Gz, shown in the second line. The third line
shows the phase encoding gradient Gy and the fourth line shows the frequency
encoding Gx with the two lobes. The data acquisition is shown with the blue
squares and they correspond to a line in the k space. It has to be underlined
that the rate of decay is given by T2 *. See text for more details.
The third line of the diagram shows the phase encoding gradient Gy which
is applied orthogonal to the slice selection. Finally, the frequency encode gra-
dient Gx is applied in the third orthogonal direction. The frequency encoding
gradient consists of two lobes with opposite polarity. The first portion, called
dephasing or pre-phasing lobe is applied for a time T and it is used so that
the signal is a symmetric echo (rather than FID). When the pre-phasing gra-
dient is applied, the spins have a different phase depending on their position
in the gradient field. The second portion of the frequency encoding gradient
is the one with opposite polarisation and it is applied for a time 2T. When
this readout gradient is applied, data are acquired at points along the k space
line, shown in blue squares. The opposite polarity of the two gradients re-
verses the phases of the spins, therefore producing an echo when the area of
the readout lobe equals the one of the pre-phasing lobe. In more detail, in the
GE sequence the negative pre-phasing gradient lobe causes rapid dephasing of
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the transverse magnetisation, faster than the normal FID. After the negative
lobe, a positive gradient is applied which reverses the magnetic field gradient.
Therefore, spins that were previously dephasing are now rephasing and after a
certain time they will all come back into phase forming the gradient echo. It is
important to underline at this point that the positive gradient only compen-
sates for the dephasing due to the negative gradient and it does not refocus
the dephasing due to the main magnetic field inhomogeneities or the spin-spin
relaxation. This is why the height of the echo depends on the decay of the
FID which depends on T2*.
After the gradient echo, the spin system is then allowed to relax to equilib-
rium before the sequence is repeated to sample a different line in the k space
with a different strength of the Gy gradient, until the 2D k space is complete.
The time between the application of two subsequent RF excitation pulses is
called the repetition time TR, therefore the total scan time is
Scan time = NSA x Ny x TR (3.22)
where NSA is the number of signal averages and Ny is the number of phase-
encoding steps. NSA is chosen to have a certain signal to noise ratio (SNR)
due to the relation SNR<XVNSA and Ny is usually used to have a specific
resolution, hence the only parameter that can be changed in order to reduce
the scan time is the repetition time TR. However, the TR cannot be too short
if a 90° RF pulse is applied because in that case the longitudinal magnetisation
wouldn't be given enough time to recover to a reasonable value thus causing
a reduction in the transverse magnetisation and therefore a reduction in the
SNR itself. In order to overcome this problem, a smaller flip angle can be
used, as for FLASH sequences (section 3.10.1), thus leading to an incomplete
flipping of the longitudinal magnetisation into the x-y plane. In this way, even
for small TRs, there will be enough longitudinal magnetisation for the next
cycle.
I1Jagnctic Resounuce Imaging 35
3.7 Spin echo
The spin echo (SE) sequence is similar to the gradient echo sequence just
explained but the main difference is the way the echo is formed. Figure 3.6
shows a schematic example of the gradient configuration in the case of a spin
echo sequence. After the 90° RF pulse, the magnetisation vector M; is flipped
into the transverse plane. At the beginning all the spins are in phase precessing
at the same frequency Wo but they start to dephase due to the T2* effects. Next,
a 1800 RF pulse is applied to flip the spins about the x axis as shown in figure
3.7. This pulse doesn't change the precessional frequencies of the spins but it
reverses their phase angles. After a time 7 equal to the delay between the 90°
and the 1800 pulse, all the spins come back into phase forming the spin echo.
We call 27, the echo delay time TE which is the time after the 900 pulse when
we get maximum signal again. In this manner, the echo height depends now
on T2 and not on T2* as for the gradient echo. In other words, the decay of the
original FID and the decay of each subsequent echo is given by e-t/T2* , whereas
the decay of the curve corresponding to the maximum signal reached by each
echo is given by e-t/T2• However, only static inhomogeneities are eliminated in
a SE sequence. The signal decay due to diffusion in inhomegeneous magnetic
fields is not recovered in either SE or GE sequences.
3.8 Echo planar imaging
Echo planar imaging (EPI) was developed by Sir Peter Mansfield in Not-
tingham in 1977 [20] and it is the fastest MRI technique available. The basic
idea is to fill k-space following a single RF pulse (single-shot EPI) during one
T2* decay rather than using multiple RF excitation to sample k-space. A
schematic diagram of EPI pulse sequence is shown in figure 3.8. In the gradi-
ent echo EPI sequence (GE-EPI), an RF excitation pulse is applied to create
a FID (often a 900 pulse to maximise the signal in the transverse plane or
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Figure (3.6): Schematic of a simple spin echo sequence and corresponding sam-
pling in the k space. A 1800 pulse is applied at time T, causing the spins to get
in phase at time 2T (TE), leading to the formation of an echo from the FID. See
text for more details.
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Figure (3.7): Refocusing effect of the spin echo sequence. Spins initially in phase
dephase naturally until the 1800 pulse is applied. Immediately after their phases
are reversed and they start refocusing forming an echo.
long TR). The sampling strategy for EPI consists of using a series of bipo-
lar readout gradients (from +Gx to -Gx) in combination with phase encoding
gradients to generate a train of gradient echoes. Each time the frequency gra-
dient is switched, the spins dephase and rephase resulting in a gradient echo.
The number of echoes produced following an RF excitation pulse is known as
echo train length (ETL). In order to allow the rapid on and off switching of
the gradients, high performance gradients are required. In general, gradient
strengths of over 20 mT [u: and gradient rise times of less than 300 usee are
needed.
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A large initial phase encoding gradient is applied to place the first echo
at the periphery of k-space. The first line of k-space is sampled by traversing
from -k; to +kx and, once complete, a blipped phase encoding gradient +Gy
is applied. The next frequency encoding gradient is applied with the opposite
polarity to traverse the k-space from +kx to -k.: The zig-zag trajectory of the
k-space sampling is shown in figure 3.8. The alternating polarity during the
acquisition must be taken into account before the data is Fourier transformed.
The presence of small gradient imperfections or eddy currents will cause the
alternating polarity of the k-space lines to produce a shift in the echo posi-
tion. In the reconstructed image this shift will appear as an artifact called
the Nyquist ghost, a lower intensity ghost of the image seen along the phase
encode direction.
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Figure (3.8): Pulse sequence diagram of an EPI (left) and corresponding sam-
pling in the k space (right).
Spin echo EPI (SE-EPI) employs an additional refocusing 1800 RF pulse
in the transverse plane. In this case, gradient echoes are formed under the
envelope of a spin echo, due to the application of refocusing RF pulse before
signal acquisition, rather than an FID. For this reason the images are more
T2-weighted. Another difference of the SE-EPI compared to GE-EPI is that
the prephasing gradient lobe Gy has to be applied before the refocusing pulse
with the same polarity of the readout and phase encoding gradients to reduce
the TE.
Inversion recovery EPI (IR-EPI) is another version of the EPI based on the
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Tl relaxation time which makes use of an inversion recovery module prior to
either GE or SE-EPI pulse sequence acquisition. IR-EPI is normally 'used to
attenuate cerebrospinal fluid (CSF), produce T1-weighted images or produce
Tl maps.
3.9 Fast spin echo
The fast spin echo is a fast imaging sequence that was initially called RARE
(rapid acquisition with relaxation enhancement), but different manufacturers
have different names for it: fast spin echo (FSE) for GE, Hitachi and Toshiba
and turbo spin echo (TSE) for Siemens and Philips. In this thesis this sequence
will be called RARE [24].
RARE is based on a multi echo sequence with evenly spaced multiple refo-
cusing pulses (usually 180°) forming an echo train. The primary advantage is
the reduction in scan time compared to conventional spin echo sequences given
by the use of different phase encoding gradients. Figure 3.9 shows the pulse
sequence diagram. In the RARE sequence the formation of the first spin echo
is entirely conventional. However, the extra echoes are not used to acquire
images with different TE but to acquire multiple lines of data, i.e. to have
different phase encoding for each echo. This is done by using rewinding phase
encoding gradients to undo the dephasing of the spins between echoes. To do
this a phase encoding step of equal strength but opposite in sign is applied
after the completion of the data acquisition. The whole sequence repeats after
TR with different phase-encoding steps.
The time between successive echoes, the inter echo spacing, is a fixed value
because the RF pulses are all evenly spaced apart in time. As for the con-
ventional spin echo, the ETL is the number of echoes in the spin echo train.
Therefore the total scan time is
90°
RF .A.
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Figure (3.9): Fast spin echo (RARE) sequence with an echo train of three. The
effectiveTE is given by the time from the initial excitation to the second echo.
. NSA x Ny x TR
Scan time = ETL (3.23)
where Ny is the number of phase encoding steps. This means that a RARE
sequence with, for example, 16 echoes, will run 16 times faster than the equiv-
alent spin echo.
In RARE sequences, lines of k-space are acquired from different echoes.
The manner in which the k-space is filled is shown in figure 3.10: each echo
within the train is phase encoded into a k-space band. Echoes at the same
position in the echo train from different acquisitions are assigned the same slab
of k-space. The number of phase encoding lines in each slab corresponds to
the number of lines required to fill the whole k-space.
The greatest amount of signal comes from the centre of k-space. If we
choose an ETL of 3 echoes as in figure 3.9, we will have 3 slabs in the k-space,
with each slab having a number of lines equal to the number of shots. Each
slab corresponds to a different echo. Because the central slab corresponds to
the lowest phase-encoding gradient, it will have the least amount of dephasing.
The central slab is assigned to the echo corresponding to the chosen effective
TE for which, by definition, there is the maximum signal. The effective TE of
the sequence is given by the time between the 900 pulse and the echo obtained
with no phase encoding. The signals from the other echoes will be placed in
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Figure (3.10): Data acquisition (k-space) filling for the RARE sequence. Each
echo is phase encoded into s k-space band.
the other slabs so that the echoes that experience progressively greater phase-
encoding gradients (therefore less signal) fall into slabs further away from the
centre slab, and those experiencing the weakest phase-encoding gradients are
placed closer to the centre slab. In other words, by appropriately picking the
slabs, we put most of the weight on the echo corresponding to the effective
TE. By altering the order by which k-space is sampled, the T2 contrast can be
length of TR.
manipulated. The number of slices that can be sampled is determined by the
The main disadvantages of RARE imaging involve higher RF exposure and
the reduced coverage (number of slices).
3.10 Fast imaging in the steady state
One major difference between GE and SE pulse sequences consists in the
transverse magnetisation at the end of the cycle. For GE sequence, TR may
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be too short to allow for complete dephasing (i.e, T2* decay) of the spins in
the transverse plane before the next RF pulse, whilst for SE imaging' the TR
is long enough to allow complete dephasing. After a few cycles, this residual
transverse magnetisation reaches a steady state value, called Mss. There are
two types of steady state imaging: coherent and incoherent. The first type
regards the sequences that eliminate the steady state magnetisation before
the next RF is applied (balanced turbo field echo). During the steady state
incoherent sequences, Mss is added to the transverse magnetisation created
by the following RF pulse, thus increasing the length of the vector in the x-y
plane (fast field echo). These two types of sequences will be used in this thesis,
therefore more details are reported below.
3.10.1 Fast field echo
The fast field echo (FFE) sequence, also called SPGR (spoiled gradient re-
called echo), FLASH (fast low angle shot) or spoiled GRASS (gradient recalled
acquisition in steady state), is a gradient echo pulse sequence primarily used
for anatomical imaging. This sequence eliminates the steady state transverse
magnetisation by applying RF spoiling, by applying variable gradient spoilers
or by using a long TR. RF spoiling consists of a phase offset added to each
successive RF pulse, which causes a phase shift in successive Mss vectors. By
maintaining a constant relationship between the transmitter and the receiver,
successive Mss vectors cancel each other out. The spoiling achieved by using
gradient spoilers consists of the introduction of an additional gradient with
variable strength from cycle to cycle. Spoling of Mss can also be achieved by
lengthening TR so that there is enough time to allow complete dephasing of
the spins in the transverse plane (TR > T2)' This is similar to the SE sequence.
The sequence consists of a train of RF pulses of flip angle a separated by
a time TR, see figure 3.11.
The magnetisation after the first pulse is for the longitudinal and the trans-
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Figure (3.11): FFE pulse sequence diagram.
verse components:
(3.24)
Mx,y = Masin a (3.25)
Since the sequence uses flip angles of about 20° -30°, i.e. much less than
90°, a short period for recovery of the longitudinal magnetisation can be used
and thus a short repetition time TR. At the same time, the transverse mag-
netisaion is also decaying. The longitudinal magnetisation experiences a series
of identical excitation pulses with flip angle a, evenly spaced in time. When
sufficiently repetitions have occurred, the system reaches a steady state so that
the same magnetisation values occur after each RF pulse.
The maximum signal can be obtained for a flip angle equal to the Ernst
angle aE
TR
aE = arccos (e- 1'1) (3.26)
The Ernst angle lies between 0 and 90° and increases with the ratio TR/T1.
IIIagnrtic Resonance Iineguig 43
3.10.2 Balanced turbo field echo
The balanced turbo field echo (bTFE, also called FISP for fast imaging
with steady state precession) produces images of high signal to noise ratio
(SNR). It is a sequence which has balanced, rewinding gradients in all three
directions, i.e. all gradients are balanced over one TR period. Therefore
it requires high-performance gradient technology to obtain a very short TE
and good shimming. If all imaging gradients are balanced then the phase of
the transverse spin magnetisation is preserved and all the spins evolve under
equivalent free precession conditions over each TR without being affected by
the phase and frequency encoding gradients. Figure 3.12 shows the pulse
sequence diagram for a bTFE.
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Figure (3.12): bTFE pulse sequence diagram.
Essentially, bTFE is a fast version of the FFE sequence and this allows
preparation steps to be added before start of readout. Preparation steps are
very useful because in fast GE techniques, the use of ultra-short TR doesn't
give an optimal tissue contrast. The preparation step, i.e. before the RF
pulse, allows the tissues to develop a certain contrast. If we consider the
inversion recovery prepared method, a 1800 pulse is applied before the RF
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pulse, providing Tl weighting and allowing the suppression of different tissues.
In this work the bTFE has been used for the T2 quantification. In particular, a
T2-prep bTFE has been used, consisting of a bTFE preceded by the spin echo
preparation step
(3.27)
This pulse sequence, similar to SE, provides T2-weighted contrast before
the RF pulse. The longer the prep time, the more T2 decay occurs and the
more T2 weighted the tissue contrast becomes. The bTFE sequence is very
useful in the abdomen where EPI shows susceptibility artifacts.
3.11 Image contrast
There are three main parameters that the operator can control to modify
the tissue contrast: the flip angle O!, TR and TE.
O! When we consider a small flip angle in a FFE sequence or similar, a large
amount of longitudinal magnetisation is left after the application of the
RF pulse and therefore less time is needed for it to recover. This means
that Tl recovery plays a minor role and therefore Tl differences between
two tissues are less apparent for small flip angles. In other word, small
flip angles reduce Tl weighting.
From equation 3.25 it can be deduced that the transverse magnetisation
is directly proportional to Mo, therefore the tissue contrast is dominated
by the proton density.
On the contrary, a large Q means a better differentiation of the Tl char-
acteristics, leading to a better T, weighting. However, this is true as
long as TR is large because otherwise ther will not be enough time for
Tl recovery.
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TR A short TR implies that the transverse magnetisation has not enough time
to decay before the next pulse. The residual transverse magnetisation
(exp(-TR/T2*)) will contribute to the next signal, therefore there will be
T2* weighting. Conversely, a long TR will reduce the steady-state com-
ponent thus reducing T2* weighting and it will also allow more recovery
of the Tl curves. In other words, a longer TR enhances Tl weighting.
TE The role of TE is similar in both GE and SE sequences. A short TE
reduces T2*/T2 weighting and increases Tl and proton density weighting.
A long TE will enhance T2*/T2 weighting.
3.12 Artifacts
There are many sources of artifacts in MRI. Image processing, patient and
gradient related and magnetic susceptibility artifacts are briefly described here.
3.12.1 Image acquisition related
Chemical shift Protons from different molecules precess at slightly different
frequencies as discussed in section 2.2.7 and this chemical shift increases
with increased field strength or lower gradient strength. The chemical
shift affects the images in particular at water/fat interfaces. The pro-
tons in water precess slightly faster than those in fat, with a difference
of about 3.5 ppm and frequency separation ~f increases with the static
field strength Bo. In this case, a misregistration of the signal from fatty
tissues occurs, since fat and water spins are encoded as if they were in
different voxels. This artifact only occurs in the frequency encoding di-
rection and results in the formation of a bright band toward the lower
frequencies and a dark band toward the higher frequencies. It is pos-
sible to increase the strength of the frequency encoding gradient thus
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increasing the bandwidth per pixel so that fat and water are contained
in the same voxeL It is also possible to use the so called STIR (Short TI
Inversion recovery) sequence. In this case by selecting the TI carefully
the signal from fat can be nulled: the appropriate TI depends on the Tl
and should be about 70% of the T1• For example, fat has a Tl of 220 ms
at 1.5T, so if the TI is set to be equal to 150 ms then the signal from
fat can be suppressed. Fat has a very short T, compared to water, white
or gray matter therefore it reaches the null point quicker. At the null
point for fat, if we draw the T2 decay curves, fat starts at zero and stays
at zero. There will be no transverse magnetization from fat in the x-y
plane and water will have the usual T2 curve. This means that after a
1800 inverting pulse, we wait a time TI=0.693T1(fat) and we give the
900 pulse. All other tissues will have longitudinal magnetization that
will flip into the x-y plane, whilst fat will give no signal in the x-y plane
because there is no longitudinal magnetization to flip. Other techniques
to eliminate the fat signal include the use of spectrally selective pulses
prior to the imaging sequence. A spectrally selective pulse flips only the
longitudinal magnetisation of fat into the transverse plane providing that
the pulses bandwidth is wide enough to cover the lipid frequencies. The
transverse magnetisation of fat is then canceled using spoilers so that
the subsequent excitation pulse will flip the longitudinal magnetisation
vector of water protons only into the transverse plane. The time between
the saturation pulse and readout pulse is usually short to offset the fast
recovery of fat magnetisation.
Nyquist ghost It is a phase ghost that arises because of imperfections in the
rephasing-dephasing cycle of the rapidly switching frequency encoding
gradient. The origin of the Nyquist ghost is a mis-positioning of every
alternate refocusing of the FID in EPI. Alternate line of k-space are
therefore mis-registered. As a result, following the Fourier transform, an
!lIagnct,ic ReSOnaJlCC Imaging 47
extra periodicity is introduced in the image. Phase correction filters can
be derived from a reference scan and can be applied to every lirie of the
image data.
Aliasing (wraparound) It consists of some of the anatomy being displaced
to the opposite side of the image. This is due to the part of the body
which are outside the FOV which are assigned a frequency that is not
included in the range of Nyquist frequencies, i.e. the frequencies be-
tween the maximum frequency at one end of the FOV and the minimum
frequency at the other end. The computer cannot distinguish these fre-
quencies and therefore it will assign lower frequencies. The perceived
frequency will be the actual frequency minus twice the Nyquist frequency.
This artifact only occurs in the phase encoding direction, since in the
frequency encoding direction a low-pass filter is used so that frequencies
higher than the Nyquist limit are eliminated. If the aliasing occurs in the
phase encoding direction, it is possible to increase the number of phase
encoding steps, at the expenses of time.
3.12.2 Patient-related
This type of artifacts regard the voluntary or involuntary motion of the
patient and are also only in the phase encoding direction. The motion due
to blood flow is periodic and will therefore cause a ghost artifact in the AP
direction (corresponding to Gy). In this case, cardiac gating or flow compen-
sation can be used. Random motion is caused by the patient's voluntary or
involuntary movements, including breathing and swallowing. These artifacts
are predominant when imaging the abdomen. To reduce these artifacts, the
patient can be properly instructed or given sedatives or drugs like glucagon to
reduce bowel peristalsis.
Respiratory compensation or breath hold imaging are also useful to over-
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come the breathing motion artifacts.
3.12.3 Gradient-related
Eddy currents are small electric currents generated when the gradients are
rapidly switched on and off. During ramp periods and especially when high
slew rates are used, stray parts of the changing gradient fields can pass through
the surrounding conducting structures inducing eddy currents. Cryostat and
radiation shields in the case of superconducting magnet are the most likely to
be affected because they are close to the gradients and their resistance is very
low. Because each metal structure has its own resistance and inductance, a
voltage V is induced in these structures according to Faradays law of induction
V=d4>/dt. This voltage induces eddy currents I that cause a distortion in the
gradient profile which in turn causes artifacts in the image. Also, gradients
are not perfectly linear and therefore there can be local magnetic distortions
and image artifacts. Spatial distortions can be minimised by reducing the
FOV or by decreasing the frequency bandwidth while keeping the gradient
field strength constant.
3.12.4 Magnetic susceptibility
As previously discussed (section 2.2.8), all substances get magnetised when
immersed in a magnetic field to an extent that depends on the magnetic sus-
ceptibility. Differences in local tissue susceptibilities, for example at tissue
boundaries, produce spatial variations in the magnetic field. Since spatial en-
coding relies on a homogeneous magnetic field, this inhomogeneity can result
in artifacts in MR images. Typically, susceptibility artifacts produce geomet-
ric distortions as well as signal loss and image blurring. Because they are
caused by inhomogeneities, susceptibility artifacts are generally worse on GE
images than SE images and can be also marked in EPI. These artifacts can be
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minimised by using a short TE but they cannot be completely removed. The
susceptibility artifact can also be advantageous because it can be used to get
information on the properties of the tissues. In particular, neural activation
can be detected by using the blood oxygenation level dependent (BOLD) con-
trast based on the local magnetic susceptibility difference between oxygenated
and de-oxygenated blood.
This chapter has presented the main principles of MRI. The next chapter
will introduce the components of the MR hardware and its safety issues.
Chapter 4
Instrumentation
4.1 Introduction
This chapter gives an overview of a magnetic resonance imaging system
with particular reference to the hardware used for the experiments presented
in this work. The following sections will describe the main components of an
MRI scanner: the main magnet, the shim coil, the gradients and the RF coil.
These components are controlled by a computer station where the user is able
to change the parameters for the scanning. Safety regulations are also given
at the end of the chapter.
4.2 Main magnet
The experiments performed in this thesis were performed on two Philips
Achieva scanners (1.5 T and 3.0 T). Figure 4.1 shows a schematic diagram
with the principal components of an MR system.
For MRI experiments, the magnetic field produced by the main magnet is
required to be highly spatially uniform and to have good temporal stability.
Inhomogeneities of the field produce line broadening and image distortions be-
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Figure (4.1): Schematic of a whole-body MRI scanner with the principal com-
ponents. Courtesy of [25].
cause of the varying frequency offset while temporal variations produce image
blurring. To produce an intense homogeneous magnetic field, MRI scanners
usually use superconducting materials that are able to support large electric
currents without requiring an external power supply. For the Philips systems
used, the superconducting wires are made of Niobium-Titanium (Nb- Ti) alloy
with critical temperature around 10K. In order to maintain the superconduc-
tivity a cooling system consisting of liquid helium is used and it is maintained
with water and air cooled chillers.
Another characteristic of the main magnet is the field outside the bore
(fringe field) and how far it stretches. For safety reasons, access is usually
restricted to areas above 0.5 mT for people with particular conditions, such
as having pacemakers or metal implants. In order to reduce the fringe field,
magnets can be passively or actively shielded. Active shielding involves placing
loops of superconducting material to cancel out the fields from primary coils
[26]. Passive shielding is used for ultrahigh field systems: large amounts of
ferromagnetic material, commonly iron, are placed around the magnet.
In:..strumentni un: 52
4.3 Shim coils
To ensure that the main magnetic field is as homogeneous as possible, a set
of shim coils are set in the bore of the magnet. There are two shims systems
in our magnets: passive and active shims that are subject specific. Passive
shimming is used in most clinical magnets and involves placing ferromagnetic
material in the bore [27]. Active shimming is performed after a subject or a
sample are placed in the bore. The active shimming consists of copper coils
inside the bore that can produce a spatially varying magnetic field that can be
adjusted for each subject. On the Philips system some automated preparation
steps mapping the field homogeneity are included in the pulse sequence set-up
process.
4.4 Gradient coils
Gradient coils are used to vary the magnetic field homogeneity for frequency
and phase encoding and for slice selection. They consist of large resistive, low
inductance coils wound on a cylindrical surface and water cooled to prevent
overheating. There are several characteristics that define a gradient coil per-
formance such as acoustic noise, peripheral nerve stimulation (PNS), efficiency,
resistance and inductance. PNS is caused by the rapid switching of the gra-
dients that induces an electric field in the human body stimulating peripheral
nerves (see section 4.6). Gradient coils are also shielded to avoid eddy currents
being produced in the bore and in particular in cooled cryostat which has low
resistance so eddy currents can persist for very long.
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Figure (4.2): Configuration of a basic coil.
4.5 RF coils
Radiofrequency coils are used for transmission and reception of RF signals
and are positioned closest to the subject. A basic coil consists of a loop of
wire with two capacitors (figure 4.2). The value of CT enables the coil to be
tuned to the Larmor frequency of the nucleus of interest, e.g. 19F. Moreover,
the impedance of the RF coil needs to be matched to the impedance of the
amplifier so that the reflections are minimised and the signal transmitted and
received is maximised. The tuning and matching of the coil are very important
because the positioning of a subject or a phantom can influence the 'loading'
of the system.
4.5.1 Body coil
The body coil is the largest coil associated with the Philips scanners and
it is a fixed part of the magnet and can be used for both transmission and
reception. Usually, local receive coils are used in order to increase the signal to
noise ratio (SNR); since SNR decreases as 1/r2, the receive coils are positioned
as close as possible to the area to be investigated. This is easily done with
surface coils as they are usually small and flexible but they do not provide the
same large field of view as the body coil. In the work described in this thesis
the body coil at 3T has been used to acquire proton imaging in the human
body and in conjunction with the fluorine coil. For the proton imaging at 1.5T
a SENSE 4-element abdominal body coil has been used, represented in figure
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Figure (4.3): The SENSE 4-element abdominal body coil used for proton imag-
ing on the Philips Achieva 1.5T scanner.
4.3.
4.5.2 Fluorine coil
The fluorine coil used is a PulseTeq Flexible 20 cm Surface Coil Pair de-
signed for imaging of the internal organs of the trunk (figure 4.4). It is possible
to use the coil pair together, one at the front of the body and the other on the
back as shown in the figure 4.5.
It has both transmit and receive capability at fluorine frequency at the field
strength of 3T. It is compatible with a transmit body RF coil and it can be
left in position whilst low flip angle pilot hydrogen studies are undertaken.
In this work several tests have been performed on this coil in order to
characterise its performances. Details are provided in section 8.4.
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Coil only length
Width
Height
Operating frequency
Weight (coil, cable, traps and interfaces)
32 ern
27 cm
2.3 cm
120.2 MHz
4.5 kg
Table (4.1): Technical specifications for the PulseTeq fluorine coil.
4.6 Safety
MRI is a relatively safe imaging technique because it does not involve ion-
izing radiation. However, the MRI system and its environment are potentially
very hazardous to both patients and staff working in the MRI unit.
The primary hazard associated with the static magnetic field is that of
ferromagnetic attraction. When a ferromagnetic object is brought close to
the magnet, it will experience a force. If sufficiently close, this can turn the
object into a dangerous projectile. People with pacemakers, ferromagnetic
foreign bodies or metallic implants should not be allowed to go near to an
MRI scanner. As previously stated, the fringe fields can also be a possible
Figure (4.4): PulseTeq Fluorine Coil
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Figure (4.5): Position of the fluorine coil on a subject: one coil is on the subject's
front and the other coil on the back over the desired imaging area
hazard so a controlled area is defined within the vicinity of the magnet.
The MR scanner is very noisy during operation especially at high field.
This is due to the Lorentz force generated by the coils when a current is
pulsed through them in the presence of the static magnetic field. Appropriate
ear protection must be worn (ear plugs and/or headphones) to reduce the noise
level.
The main biological effect of RF is the heating of tissue. The human body
has the ability to remove this heat by both conduction and blood flow. Some
poorly vascularised structures (lenses) and structures with no pain sensors
(brain) can be affected if no control on the RF heating has been done. There-
fore there is a restriction on all scanner for the amount of power that can be
deposited, the specific absorption rate (SAR). The SAR measures the rate at
which the energy is absorbed by the body and it is defined as the power ab-
sorbed per mass of tissue (watts per kilogram). In particular SAR is defined
as follows
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where
r2: square of conductor loop
p: square of Larmor frequency
B;: square of RF field
p: mass density
D: duty cycle (=total RF pulse times/TR). Power deposition is manifested
as an increase in tissue temperature. A rise of less than 1 Co (corresponding to
2W/kg) is generally acceptable to a normal healthy person. SAR level can be
reduced by using quadrature rather than linear coils for transmission, avoiding
the whole body coil when other transmission coils can be used, increasing TR,
reducing number of slices, reducing echo train length in fast sequences and
reducing the RF tipping angle. Tattoos can also lead to overheating because
of the presence of ink containing metal.
There is a small risk of patients receiving burns through the coupling of
RF energy into wires or cables that are touching the patient. Care must be
exercised in ensuring that cables are not formed into loops prior to imaging.
There is also the risk of cold burns due to cryogenic liquids.
The switching of the gradients induces electrical currents in conducting
tissues according to Faradays induction law. These currents in the tissues may
cause peripheral nerve stimulation (PNS) that may result disconcerting to
the patient but is not itself hazardous. Theoretically there is also the hazard
of stimulating the cardiac muscle. To reduce these risks, there is a dB/dt
limitation set by the American and European regulatory agencies.
Contrast agents can be potentially harmful because of their adverse effects.
The most common intravenous contrast agents contain gadolinium (see section
2.2.9). They are considered safe if administered intravenously but they are not
indicated for patients with renal failure. Restrictions on the use of contrast
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agents may apply during pregnancy and to nursing mothers because they can
enter the bloodstream.
Chapter 5
MRI of the gastrointestinal
tract
Over the past years a lot of effort has gone into the development of methods
to monitor the GI tract after administration of drugs and the investigation
of the anatomical changes due to GI diseases [28]. However the study of
normal physiology of the GI tract, including its response to food and functional
disorders, is still only investigated with MRI by very few centres.
Imaging the anatomy and the function of the GI tract is challenging for var-
ious reasons: firstly its three-dimensional structure is highly variable between
individuals, secondly respiration and peristaltic movements cause artifacts and
increase partial volume errors between bowel and adjacent tissues and this is
worsened by the fact that bowel can assume varying signal intensity including
that of normal or abnormal tissues. It also has to be taken into account that
two different states, fasted and fed, are normally considered and they vary
depending on the physical activity as well.
MRI of the GI tract was initially very limited because of the presence
the artifacts mentioned but the advent of fast MR imaging allowed greater
anatomic coverage in a single breath hold thus making possible to acquire a
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single section in less than 1 second. In comparison with MRI, other methods
such as X-rays and CT scans have excellent spatial resolution and are fast and
relatively cheap but the delivery of ionising radiation to the subject doesn't
allow the study of GI physiology in healthy volunteers. On the other hand,
ultrasound could be used because it is a safe and cheap technique but the
presence of air and fat in the abdomen makes it difficult to obtain clear images.
MRI is therefore an irreplaceable technique for physiological studies of the GI
tract, for the lack of ionising radiation delivered to the subject, for the superb
contrast and resolution available for the observation of anatomical structures
and the possibility of observing the GI tract without any invasive procedure
such as enemas and delivery of contrast agents.
This chapter introduces the main features of the gastrointestinal tract and
some of the MRI methods that are used in this work to study the function of
the GI tract in both healthy and diseased subjects.
5.1 The gastrointestinal tract
5.1.1 Anatomy and physiology of the gastrointestinal
tract
The gastrointestinal tract is a muscular tube starting from the oral cavity,
where food enters the mouth, continuing through the pharynx, oesophagus,
stomach and intestines to the rectum and anus, where food is expelled (figure
5.1). The entire GI tract has a similar basic structure (figure 5.2) even if local
variations occur in the different specialised parts. The most internal part is
the epithelium which can be simple or stratified, depending on the function,
and that is supported by a tissue containing blood vessels, nerves and glands
that support the mucosa. The different layers of mucosal muscles allow the
contraction of the tube thus changing the shape of the lumen and providing
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Figure (5.1): The gastrointestinal tract [29].
the peristalsis of the food, which is controlled by specific neural innervations.
The outer layer of the GI tract is formed by fat and another layer of epithelial
cells called mesothelium.
The main purpose of the gastrointestinal tract is to digest food and absorb
the nutrients, to provide energy to the body. A whole set of different organs
cooperate to this aim by secreting enzymes: salivary glands, liver, pancreas
and gall bladder play an important role.
When food is ingested into the mouth digestion begins both with the me-
chanical process of chewing and with the softening action of saliva which con-
tains an enzyme called amylase. Following this first processing the food enters
the stomach via the oesophagus, where further digestion takes place. The hor-
mone gastrin is secreted on the arrival of food in the stomach and the enzyme
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Figure (5.2): Basic structure of the GI muscular tube [30].
pepsin is produced in order to break down proteins. From the stomach the
chyme is transferred to the small intestine, where the majority of digestion and
absorption of nutrients takes place. The small bowel is approximately 6m in
length and consists of duodenum, jejunum, and ileum. When the chyme enters
the duodenum, the gallbladder releases the bile produced by the liver, in order
to emulsify the fat and neutralise the acid. The jejunum is where the majority
of digestion and absorption occurs. The last part of the small intestine, the
ileum, is responsible for the absorption of vitamin B12, bile salts and any un-
absorbed nutrients. It empties into the caecum at the ileocaecal junction. The
caecum is the first part of the large intestine which consists of the appendix,
caecum, ascending, transverse, descending and sigmoid colon, and the rectum
(figure 5.3). It has a length of approximately 1.5 m and a width of 7.5 em.
The main functions of the large intestine are the reabsorption of water, salts,
sugar and vitamins and the accumulation of unabsorbed material to form fae-
ces. Under normal conditions, approximately 90% of salt and water entering
the proximal colon (650-800 ml) is absorbed [31]. This happens despite the
non-villous structure of the colon which results in a smaller capacity for ab-
sorption compared to the small bowel. Therefore, the contact time and the
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Figure (5.3): The colon [32].
motor activity is an important factor for the fluid transport in the colon. The
ability of the colon to remove water from faeces necessitates a tight epithelium
and osmotic gradients.
The wall of the colon is made up of several pouches (haustra) that are
held under tension by three thick bands of muscle (taenia coli). The mucosal
surface is flat with several deep intestinal glands. Colonic contents are far
from homogenous with a spatially organised bacterial flora which others have
described at a microscopic level [33].
The rectum is the final 15 cm of the large intestine. It expands to hold
faecal matter before it passes through the anorectal canal to the anus. Thick
bands of muscle, known as sphincters, control the passage of faeces.
Following ingestion of food, a combination of four involuntary movements
facilitates the passage of intestinal contents along the gastrointestinal tract
toward the rectum. These contractions are defined as pendular, segmental,
peristaltic and vermiform. Pendular and segmental movements are responsi-
ble for the mixing of the food in the stomach as a result of smooth muscle
contraction. Peristaltic movements push the mixed contents from the stomach
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along the gastrointestinal tract through a digestive process that lasts approx-
imately three to four hours to reach the colon. The contraction of the colonic
smooth muscles allows the movement of the food contents towards the ascend-
ing, transverse, descending and sigmoid colon and terminate at the rectum.
The digestive mechanism and the physiology of the gastrointestinal tract
determine the consistency of contents in the different parts of the gut. In
the cecum and in the ascending colon, intestinal contents are fluid. As the
water gets absorbed in the ascending colon, the contents arrive semisolid in
the transverse and descending colon. The passage of contents in the colon is
crucial to understand pathologic mechanisms. In particular, diarrhoeal disease
implies a non efficient absorption of water in the ascending colon, thus entailing
a watery and unformed stool. On the contrary, if food passes too slowly
through the colon, there will be too much fluid absorbed and the stools result
hard and dry, the primary sign of constipation.
The food reaches the rectum after several more hours following ingestion
and it causes rectal distention, contraction of muscles and relaxation of the
internal anal sphincter and the impulse and decision to defecate. A normal
number of bowel movements for adults varies from person to person and may
range from three per day to three per week, depending on numerous factors.
The diagnosis of bowel disease has to consider this great subjective variability
in order to correctly identify significant changes from normal physiology.
5.1.2 Definition of colon regions
In this work, quantitative analysis is performed on the different regions of
the GI tract, for instance volume measurement and the anatomical location
of ingested capsules within the gut. Some of the analysis has been performed
by different operators in order to calculate the inter-observer variability of
our methods. For this reason and given the high anatomical variability of
the subjects, the exact definition of the different regions in the gut is very
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Figure (5.4): The definition of the regions of the colon according to Watts et
al [34].
important, especially in the colon. To this aim, we referred to the same criteria
used by Watts et al. [34],shown in figure 5.4. If not otherwise stated, the colon
images were divided into four regions by simply drawing a diagonal line across
the colon on the turning points: the ileo-caecal junction (ICJ), the ascending
colon, the transverse colon, and the descending colon/rectum.
5.1.3 Colonic motility and transit
In a healthy subject, colonic motility includes two types of motor activity:
segmental and propagated contractile events. Segmental activity is the most
frequent and regards the low amplitude contractions that allow the optimal
absorption of the contents. The contractions are non-propulsive and can be
recorded as increases in luminal pressures. Propagated contractile events are
occasional propulsive movements (mass movements), which are generally hard
to record because they occur rarely. They can happen in both forward and
backward directions, on average more than 100 time a day, and are responsible
for the transport of fluids within the colon. The high amplitude propagated
contractions that precede the defecation are much less frequent, with a large
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inter-individual variation [35].
Although much less pronounced than small bowel motility, colonic motility
also shows some rhythm, with a strong inhibition during sleep and maximum
activity after awakening and after meals. This postprandial increase in colonic
activity lasts usually for at least 2 hours, being longer for more fatty meals.
Most information about the colonic contractions have been obtained from
balloon catheter measurements of the rectum and distal colonic segments, be-
cause of the difficulties of intubation along the entire tract. As an example,
Haggar et al [36]described a colonic manometry study where they showed that
the intake of a meal increases the motility for both normal and constipated
patients. Other techniques include the application of scintigraphic measure-
ments that allow the investigation of the entire gastrointestinal tract. This
technique is particularly useful to study the transit of dosage forms in the gut.
Colonic transit is of great relevance when considering in vivo/in vitro re-
lationships for oral controlled release dosage forms. The importance of the
technology for oral drug delivery is due to the possible increase of efficacy of
the drugs with minimised side effects. Even if the colon is not as important as
the small bowel in the absorption process, its additional surface for absorption
can prolong the time of treatment and it can make the difference when trying
to increase the interval between doses. The transit of dosage forms through
the colon is therefore of great interest.
5.1.4 Colon disorders
Functional disorders of the bowel most commonly affect the colon and the
rectum and the direct cause is frequently unknown. The most common diseases
are irritable bowel syndrome (IBS), Crohn's disease and diverticulitis.
IBS is a functional bowel disorder characterized by chronic abdominal pain,
discomfort, bloating, and alteration of bowel habits in the absence of any
detectable organic cause. Diarrhea or constipation may predominate, or they
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may alternate (classified as IBS-D, IBS-C or IBS-A, respectively). Even if the
cause is not known, it may begin after an infection or after a stressful event.
Even if IBS doesn't lead to more serious conditions, it is still considered to
affect the quality of a sufferer's life and it can also be of high economical and
social impact.
Crohn's disease is a chronic, inflammatory condition of the intestine that
can affect any area of the digestive tract but it is usually confined to the lower
end of the small intestine (ileum) and the colon. Even if the cause is not
known, Crohn's disease is thought to be linked to a problem with the body's
immune system which leads to chronic inflammation. The symptoms include
intermittent attacks of diarrhea and abdominal pain, weight loss, and fever.
Rarely, the intestine may become blocked or ulcerate.
Diverticulitis results if a diverticulum in the colon becomes inflamed, thus
increasing the risk of infection from the bacteria that can spread in the ab-
dominal cavity if the diverticulum bursts open. This can cause a potentially
fatal illness (peritonitis). Sometimes inflamed diverticula can cause narrowing
of the bowel, leading to an obstruction. Also, in some cases there can even be
a break in the colon and stool can flow into other organs.
5.2 Functional MRI of the GI tract
MRI of the gastrointestinal tract was limited during the early days of MRI
because of the artifacts caused by breathing and peristaltic motion. With the
advent of fast MRI sequences these problems were overcome. In particular,
EPI allows the imaging of the stomach even at low field thanks to the excellent
contrast between water-based liquid meals and the surrounding tissues [4,37].
No additional contrast agents are necessary. Unfortunately imaging the small
intestine and colon with EPI is not suitable because of the susceptibility arti-
facts especially at higher fields where the artifacts due to the air/water inter-
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face worsen. In this case, ultra-fast imaging techniques such as fast spin echo
(FSE, RARE or HASTE), balanced turbo field echo (bTFE) and fast field
echo (FFE or FLASH) have been optimised and applied for use at both low
and high field strength. However, with increased field strength the imaging
time also increases because of the increase in RF power deposition, limited by
the specific absorption rate (SAR) safety limits. The availability of different
ultra-fast sequences on commercial scanners allow the optimisation of imaging
techniques suitable for all the different regions of the GI tract.
5.2.1 Measuring gastric volume
The evaluation of the gastric emptying plays a key role in the studies in-
volving digestion of food and satiety. The rate of gastric emptying depends on
a series of different factors including the physical and chemical state of food
but also external factors such as stress or intense pain. The importance of
measuring the stomach volume is evident in both physiological and patholog-
ical conditions. In this study MRI sequences have been optimised at 1.5 T
to allow automatic segmentation. The stomach volumes were measured from
a balanced turbo field echo (bTFE) sequence using Analyze® software (Mayo
Clinic, Rochester, MN, USA) by drawing around the contents of the stom-
ach as regions of interests (ROIs) and then summing all the volumes. The
Analyze software available provides an edge-finding tool that can be used to
easily identify the definition between stomach contents and air or surrounding
tissues, thus improving the accuracy of the measurement.
5.2.2 Measuring small bowel water content
The measurement of the small bowel water content (SBWC) is of fundamen-
tal importance when studying the gastrointestinal physiology and pathology
such as irritable bowel syndrome (IBS) and celiac disease. SBWC depends
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on the complex interactions between the liquids absorbed and secreted. The
balance between the liquids coming from the stomach and the liquids secreted
by the small bowel and also the amount of water absorbed and the progres-
sion to the colon determine the SBWC. The intestinal motility also plays a
key role on this regard. It is regulated by the central nervous system and it
changes between the fed and the fasted state. Fasting intestinal motility is
highly episodic with propulsive events occurring every 1-2 hours. The fed
state is characterised by constant small movements in order to improve the
absorption.
In order to visualise the anatomical details of the small bowel, it is often dis-
tended by administrating water and preparations that prevent absorption and
also by using contrast agents to improve the image quality. These procedures
are not ideal when investigating the physiology of the normal gastrointesti-
nal tract because they are highly invasive and they alter the normal balance
between the absorption and the secretion of liquids in the gut.
In this work the SBWC has been measured by using a non-invasive method
developed by Hoad et al. [38]. It uses a heavily T2 weighted RARE sequence
originally used to study the biliary tract [39],optimised at 1.5 T. The hypoth-
esis is that in the TSE images any pixel with a signal intensity above a given
threshold is filled with "free" water. As this technique is based on MR signal
intensity rather than measured parameters, the signal must be normalised.
Cerebral spin fluid (CSF) is an ideal internal normalising marker because it is
present in most slices and it is in the centre of the field of view thus overcoming
variations due to the scanner instabilities and repositioning.
After the acquisition, an in-house software written in IDL® (Research Sys-
tems Inc. Boulder, Colorado, USA) by Dr Caroline Hoad allows the evaluation
of the SBWC. The operator selects the centre of the CSF on each slice in which
it is visible and then the ROIs can be drawn.
This methods assumes that only pixels with a signal bigger than the thresh-
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old contain water, which can lead to an underestimation of the amount of free
water because of partial volume effects. Improving the resolution would re-
duce this problem but it would increase the scanning time therefore introducing
other sources of errors such as movement of the water through the bowel. In
addition this method has never been validated in the colon, where normally a
much smaller amount of water is present. In the next chapters, the extension
of this method to the colon is presented, together with the optimisation of
other MRI methods to investigate the colonic function in health and diseased
subjects.
Chapter 6
Methods for measuring
physiology of the colon
6.1 Introduction
This chapter describes the development of techniques to image colon func-
tion under physiological condition with proton MRI. In particular, the pro-
cessing of the colonic contents is monitored with a multilateral approach: the
change in geometric volumes and in the amount of water in the ascending colon
is monitored. Tl and T2 values are measured in vitro and in vivo. In addi-
tion novel methods to characterise the colonic contents are introduced with
a texture analysis approach to define the mesoscopic structure of the colonic
contents.
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6.2 Colonic response to an experimental model
of human diarrhoeal disease
6.2.1 Introduction
This study aims at an improved understanding of the water distribution
within the ascending colon (AC) both in functional and organic colonic disease
conditions. In particular an aim was to determine the approximate time course
of the physiological response in the colon to assist in planning future exper-
iments. The MRI techniques used allow the monitoring of colonic function
without invasive bowel preparations, which are often used to improve anatom-
ical detail in clinical MRI of the colon. In this work, two contrasting test meals
have been used: a readily absorbable glucose drink (the control meal) and a
non absorbable mannitol drink, which provides a model of acute diarrhoeal
disease. The response of the gut over time to these two different meals was
observed. This study also presents some preliminary results regarding motil-
ity scans for the observation of peristaltic movements in the AC. The colonic
movements are one of the main factors to distinguish the difference between
physiologic and pathologic conditions. In particular, diarrhoea is thought to
result from colonic hypermotility, while constipation is associated with un-
deractivity of the muscle. However, these phenomena are poorly understood
and have only been investigated with invasive techniques as the manometry to
measure colonic intraluminal pressures [40,41]. Being able to study the colonic
motility with a noninvasive technique is therefore fundamental for future re-
search and clinical applications.
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6.2.2 Methods
Volunteer selection
This 2-ways randomized double blinded study was approved by the Univer-
sity of Nottingham Medical School Ethics Committee and all volunteers gave
written informed consent before the experiment. Healthy volunteers (n=10; 6
female, 4 male; mean age 26.3 years, age range=20-33) without known con-
traindications to MR imaging were recruited from the Nottingham University
student population to take part in the in vivo study. All volunteers had no his-
tory of gastrointestinal disease, they were free from medication likely to alter
GI motility and they were free from food allergy or intolerance. They were also
asked to follow restrictions to diet and lifestyle for the day prior to the study
day, including avoid taking foods with high fibre content to avoid excessive
residue in the bowel on the study day, avoid spicy food since it can stimulate
bowel secretions and avoid caffeine, alcohol and strenuous exercise for 18 hours
before the study start time. Volunteers were asked to fast overnight (>12 h)
except for a small cup of water on the morning of the study if it was consumed
>1 h before arriving at the centre. The first two subjects were used to deter-
mine the length of the experiment, being imaged hourly up to 8 hours. The
remaining subjects were imaged hourly up to 5 hours.
Study protocol
All imaging was carried out on a 1.5 T Philips Achieva scanner with a
SENSE 4-element abdominal body coil. Volunteers attended on two separate
experimental sessions: they were first imaged at the fasted state as a baseline
scan; subsequently they were given a drink containing either 5% mannitol or
5% glucose powder in 350 ml of still water (conditions randomized). Mannitol
is a common laxative known to stimulate small intestinal secretion and can be
used as a model for a range of diarrhoeal diseases, while glucose is known to
Method» for mensuring physiu10gv of thc colon 74
be rapidly absorbed. Volunteers were scanned at 60 minutes intervals for three
hours after the drink, after which they were fed a large 1000 kcal test meal
(400 g macaroni cheese, 100 g cheese cake and 250 ml still water) to elicit the
colonic response to feeding. They were then scanned again every hour up to
5 hours after the drink (8 hours for 2 additional pilot subjects), see figure 6.1.
A range of MRI sequences were used to image the ascending colon:
• For structural details of colonic contents: high resolution bTFE (TR=3.2
ms, TE=1.58 ms, acquired resolution = 1.50 mm x 1.50 mm, recon-
structed resolution = 0.86 mm x 0.86 mm, 8 slices of 5 mm thickness,
0.58 mm gap, 16 seconds duration) acquired sagittally in order to have
the whole length in one image;
• For the measurement of colonic geometrical volumes: a dual gradient
echo (dual-echo fast field echo, FFE, TEl = 2.3, TE2 = 4.6, TR = 158
ms, acquired resolution = 2.01 mm x 2.87 rom, reconstructed resolution
= 1.76 mm x 1.76 mm, 24 slices of 7 mm thickness, 13 seconds duration);
• For free water content measurements: a single shot, fast spin echo se-
quence (RARE) (TR=8000 ms, TE=320 ms, acquired resolution = 1.56
mm x 2.90 mm, reconstructed resolution = 0.78 mm x 0.78 mm, 24 slices
of 7 mm thickness, 24 seconds duration);
• ForT2 measurements: a T2-prep bTFE sequence (TR= 3.0 ms, TEprep
values (ms): 20, 29, 43, 63, 93, 137, 201, 295, 434, 637, acquired resolu-
tion = 2.00 mm x 1.56 mm, reconstructed resolution = 1.56 mm x 1.56
mm, 7 mm thickness, 150 seconds duration);
• For motility measurements: bTFE sequence single slice, sagittal (TR=3.0
ms, TE=1.5 ms, acquired resolution = 1.50mm x 1.50 rom, reconstructed
resolution = 0.86 mm x 0.86 mm, 15 mm thickness, acquired every 2.5
sees for 2 mins).
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Figure (6.1): Protocol of the study for each occasion. The subjects were scanned
fasted and immediately after the drink (mannitol or glucose) and then hourly
for up to 5 hours after the drink. Details of the drinks and the meal are given
in the text.
With the exception of the motility sequence, each image set was acquired on an
expiration breath-hold with a duration between 13 and 24 seconds depending
on the sequence. Including set-up and imaging the volunteers spent approx-
imately 10 min inside the magnet for every time point, spending the rest of
the time sitting upright in an adjacent room. The sequence for the motility
measurement was set to be of 2 minutes because of time constraints of the
complete study.
6.2.3 Results
All volunteers tolerated the experiment well, with no side effects experi-
enced.
Figure 6.2 and 6.3 show the variation in the water content for the whole
bowel and the AC averaged over the 10 volunteers, quantified from the RARE
sequence: very little free water was seen in the small bowel and in the AC
after the control drink, while a large amount of free water was visible in both
regions after the mannitol drink.
Following the glucose drink the volume of free mobile water in the whole
bowel did not vary significantly from the fasting baseline being 124±24 versus
112±27 ml at 90 min, p<0.9. Conversely, after the mannitol drink, the water
in the whole bowel rose from baseline 109±36 ml to 590±73 ml at 90 min,
p<0.008. The difference in the amount of free water that reached the AC
at 90 min was particularly marked being 2±1 ml after the glucose drink and
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Figure (6.2): (Mean ± STD) Total water content of the whole bowel measured
using a RARE sequence showing a larger quantity of fluid after the mannitol
drink compared to after the control drink.
73±20 ml after the mannitol drink, p<0.008. The water that arrived in the
AC readily mixed with the colonic contents and caused distension of the AC.
The second larger meal was followed by a significant fall in total bowel
water content from 396±58 ml at time 150 min to 198±37 ml at time 210
min with the mannitol drink (p<O.OOl1),whilst no corresponding change was
observed for the glucose drink (p-ctl.7). The same trend was reflected in the
total volume of the AC (figure 6.4). Its total (geometric) volume at 90 min
was 146±17 ml for glucose and 230±18 ml for mannitol, p<0.0004.
The T2 values calculated from the T2-prep bTFE sequence showed an overall
increase in the values for the mannitol case, while constant values around 50
ms were found for the control at all time points. Figure 6.5 shows the average
values for all the volunteers including the two pilots that were imaged up to 450
minutes. This longer time scale allows to see the full change of the T2 values,
increasing up to a maximum of 160 ms at 210 minutes and slowly decreasing
toward normal physiologic values of around 50 ms at 450 minutes.
Further analysis was performed for the two pilots on the T2 in the ascending
colon. The T2 were calculated in 3 different regions of the ascending colon in
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Figure (6.3): (Mean ± STD) Ascending colon water content of the whole bowel
measured using a RARE sequence showing a larger quantity of fluid after the
mannitol drink compared to after the control drink.
order to evaluate any eventual difference in contents along the AC. Figure 6.6
shows an example for the ROIs defined as cranial, middle and caudal. The
corresponding T2 values are shown in figure 6.7: a higher variability in n
values between the regions is found from 180 to 270 minutes thus implying a
greater heterogeneity of the colonic contents on the arrival of the fluids. No
specific characteristics were found on the regions depending on their position,
i.e. higher or lower in the AC. The average of values of the 3 regions shows
higher values for the mannitol case compared to control, thus reflecting the
same overall trend of figure 6.5.
The motility scans tended to show more peristaltic movements in the AC
for the mannitol case compared to the control. However, the events over
two minutes resulted to be very rare and equal to zero for most cases, thus
leading to very small numbers as reported in figure 6.8. Therefore no statistical
analysis was performed. It was not possible to scan for longer than two minutes
for time reasons. The number of peristaltic movements in the AC is highly
subject dependent and a two minutes observation may not be efficient to fully
describe physiologic changes. Nevertheless, the MRI motility sequence was
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Figure (6.4): (Mean ± STD) AC geometric volumes calculated from the dual
echo FFE sequences.
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Figure (6.5): (Mean ± STD) T2 values in ms calculated in the ascending colon
from the T2-prep bTFE sequence. The values obtained after the mannitol case
are significantly higher than the control case, reaching a maximum averaged
value of 160 ms at 210 minutes. For the control, the T2 of the contents stayed
constant at a value of about 50 ms at all time points. The last points, marked
with the asterisk, refer only to the data corresponding to the two pilots, who
were imaged for longer.
optimised to study colonic function in undisturbed, physiologically relevant
conditions and was able to detect any eventual movement in the AC.
The high resolution bTFE images clearly showed the colonic response to
feeding over time for both conditions (figure 6.9). After the mannitol drink the
Figure (6.6): Example of the ROls drawn in the cranial, middle and caudal
regions of the ascending colon. The image corresponds to the T2-prep sagittal
image described in the section.
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Figure (6.7): T2 values and average in ms calculated in the 3 regions of the
ascending colon: a higher variability in T2 values between the regions is found
from 180 to 270 minutes thus implying a greater heterogeneity of the colonic
contents on the arrival of the fluids. The average shows higher values for the
mannitol compared to the control, as shown previously for the overall trend T2
of all the volunteers.
arrival of water in the AC was observed at 90 minutes, which readily mixed
with the colonic contents and caused distension of the colon. At 150 minutes it
was possible to observe a bright, homogeneous signal in the AC. The following
scans showed that as the water signal was declining darker material appeared
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Figure (6.8): (Mean ± STD) Number of peristaltic movements counted during
the 2 minutes scan averaged for all the volunteers. A higher number of peristaltic
movements is found for the mannitol case but the differences are not statistically
significant.
particularly around the folds. After the control drink the scans showed a very
heterogeneous, low signal in the colon at all times.
6.2.4 Discussion and conclusions
The MRI images acquired at 1.5 T provided a whole range of information
regarding the colonic function in undisturbed, physiologically relevant condi-
tions. The technique proved to be a feasible and effective method to obtain
multiple parameters of the gastrointestinal function. The unabsorbable, os-
motically active mannitol solution causes secretion in the small bowel causing
a great amount of fluids drawn in the gut, with a peak value of about 600 ml
at 90 minutes after the drink. After that, the small bowel water content starts
to fall within two hours.
The arrival of fluids in the ascending colon is shown to be at 90 minutes
after the drink: when the secretions arrive in the colon they distribute hetero-
geneously. Figure 6.3 and 6.4 show that the water carried into the colon by
the mannitol was a small fraction of the total colonic contents which was oth-
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erwise dominated by solid material and gas. The change in total AC volume
with mannitol can largely be explained by the increase in free water content,
although this was not true at the last time point, possibly due to the increase
in the mass of the bacterial biofilm, where intracellular water will give reduced
signal compared to free water in the colon. In the colon mannitol is rapidly
fermented to short chain fatty acids which are known to be co-transported with
sodium causing associated water absorption. The mannitol metabolism will
also increase bacterial mass which will incorporate water intracellularly where
it would appear to give a low signal. The high resolution images of the ascend-
ing colon reported in figure 6.9 showed varying signal characteristics, with a
definite more homogeneous bright region for the mannitol case compared to
the more heterogeneous and darker area of the control case. The images of
the ascending colon at 390 and 450 minutes for the mannitol case show how
the water gradually gets absorbed thus leaving the colonic contents dark and
heterogeneous as in the control. The characteristics of the colonic contents
have also been investigated with the T2 calculation. The T2 values for the
mannitol case reflect the fact that the mannitol drink draws a great amount
of fluids into the ascending colon, because the T2 values, in various regions
of the colon, are higher than the control and can reach values of hundreds of
milliseconds. The T2 in the control was calculated to be constant at a value
of approximately 50 ms. This technique is potentially very useful for future
clinical studies, because the different T2 values can lead to a completely nonin-
vasive diagnosis of eventual gastrointestinal disease. First attempts were also,
performed to study gut motility. Some peristaltic movements were recorded
after the mannitol drink while for the control drink almost no movements were
found. Gut motility is highly subject dependent and in the fasted state it is
also very rare. Nonetheless, the MRI sequences used proved to be efficient to
record all the events happening in the time of the scan.
It can be concluded that these methods are very efficient, non invasive and
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well tolerated by the subjects, thus proving to be a very useful tool for the
investigation of the gastrointestinal diseases. This technique has been' used to
evaluate mechanisms of diarrhoea and drug intervention as described in the
following chapter and it can be further implemented for clinical studies.
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6.3 Measuring the T1 and T2 of the colonic con-
tents in vitro
6.3.1 Introduction
The determination of Tl and T2 is fundamental to understand the inherent
properties of the contents of the colon and tissues and also measure changes
due to disease. However Tl and T2 of colonic contents are very short and
reasons for this are not clear. Some hypothesis would see the cause due to the
presence of iron or the low free water fraction.
This section presents in vitro work performed with faecal samples. The
samples are imaged at intervals before and after lyophilization because of the
hypothesis that the water is normally included in bacterial macromolecules.
The addition of water after lyophilization should give a different water distri-
bution.
6.3.2 Methods
A single stool sample from a healthy subject was collected and imaged in
a 1.5 T Philips Achieva system according to the schedule in figure 6.10. After
a baseline scan it was centrifuged to separate the water from solid materials.
At this point the sample was weighted and imaged again. Successively it was
freeze dried overnight and imaged again the next morning. Distilled water was
then added in order to reconstitute the initial weight and another scan was
performed on the suspension straight after mixing and after 15 minutes. A
final centrifuge was undertaken to be sure that all particulate matter had been
removed and a final scan was performed on the liquid fraction.
At each time point a series of scans was performed:
• For structural details: high resolution bTFE (TR=3.2 ms, TE=1.58 ms,
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Figure (6.10): Schedule for the in vitro study of faecal samples.
acquired resolution = 1.50 mm x 1.50 mm, reconstructed resolution =
0.86 mm x 0.86 mm, 8 slices of 5 mm thickness, 0.58 mm gap);
• ForT2 measurements: a T2-prep bTFE sequence (TRITE = 3.0/1.5 ms,
TEprep values (ms): 20, 29, 43, 63, 93, 137, 201, 295, 434, 637, acquired
resolution = 2.00 mm x 1.56 mm, reconstructed resolution = 1.56 mm x
1.56 mm, 7 mm thickness);
• ForTI measurements: a IR-bTFE sequence (TRITE = 3.0/1.5 ms, TI
values (ms): 0.025, 0.175, 0.425, 0.925, 1.425, 1.925, 2.925 and 4.925,
acquired resolution = 2.00 mm x 1.56 mm, slice thickness 7 mm);
T2 data sets were processed drawing a region of interest and then using
the mean signal of this region at all the different echo times to calculate the
T2 of the tissue using a program in-house which modelled the effect of the T2-
prepared scheme and subsequent imaging sequence for the T2-prepared bTFE
sequence [42]. TIS were also obtained by fitting the data with the appropriate
TI values.
6.3.3 Results
Good SNR was obtained for the high resolution images at all time points.
The lyophilization process resulted in loss of water equal to the 70% of the total
weight. Adding the water after freeze dry resulted in a different distribution
of water with the stool being separate from water even after centrifugation.
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Table 6.1 summarizes the results for the 'T, and T2 for this in vitro study.
The data for the time point after the freeze dry is not available as there was
no signal from the sample, as expected. After the addition of distilled water
the stool didn't mix properly, therefore the T, and T2 values were measured in
two different areas, shown in figure 6.11.
Figure (6.11): High resolution images for the in vitro sample at the different
time points: (a) baseline, (b) after first centrifuge, (c) after the water addition
of distilled water and (d) after the last centrifuge. Figure (d) shows how the
faecal matter stays separate from water. In this case the T; and T2 values were
measured in the two areas separately, shown by the arrows (top arrow for watery
ROI and lower for the sample ROI).
Baseline Centrifuge Lyophilization Water addition Centrifuge
i. 118 101 na 96 95t 59+,
T2 7 6 na 17 8t 6+,
Table (6.1): Tl and T2 values in ms at the different time points. t for the watery
ROI, + for the sample ROI shown in figure 6.11.
6.3.4 Discussion and conclusion
This in vitro experiment showed particular characteristic of the faecal mat-
ter which are helpful for the understanding of the colon MRI scans. One first
interesting result is that the faecal matter used here contains a small amount
of water which leads to very short Tl and T2 values for the baseline condition
and the water is not bound in cells. The persistence of very short Tl and T2
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values after water addition may imply that the quenching of the signal is due
to ferrous ions present in faecal matter. However it has to be considered that
this experiment has been performed at room temperature, which is much lower
than body temperature and this may have affected the Tl and T2. In addi-
tion, this study only involved a single sample, therefore no conclusion may be
assessed on the variability and Tl and T2 may be considered only as estimates.
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6.4 Defining the characteristics of the ascend-
ing colon contents
6.4.1 Introduction
Tl and T2 can assess water content of colon and can be measured on an
ROI or on a voxel basis but heterogeneity is a particular feature of the MR
scans of colonic contents. This section aims to develop a method to assess the
heterogeneity of the colonic contents and its microscopic structure.
The first approach is to use a subjective method based on the visual assess-
ment of the composition of the AC contents. Following this, two automated
methods for the objective assessment are compared.
These methods have been validated on the data sets presented in section
6.2, corresponding to the study of colonic response to the model of human
diarrhoeal disease.
6.4.2 Methods
Subjective assessment
In order to take into account the inter-observer variability in the AC con-
tents subjective assessment, two observers (myself and Dr. C.L. Hoad), with
substantial experience in studying MRI images, independently graded the high
resolution bTFE images from 8 different data sets (single score per time point
covering all 8 slices), between 1 (all dark) and 5 (all bright) with 3 having a
mixture of dark and bright patches (fig 6.12). To calculate the intra-observer
variability of the AC contents assessment, I measured the same 8 data sets on
two different occasions, separated by one month gap to avoid any partiality.
The inter-observer and intra-observer variability for the subjective measure-
ments were assessed by calculating the weighted kappa from the subjective
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Figure (6.12): Examples of the 5 scores given to the AC contents, between 1
(all dark) and 5 (all bright) with 3 having a mixture of dark and bright patches.
The AC is contoured in red.
data according to the Bland-Altman method [43-45].
First automated method: histogram and Bi-Gaussian fit
ROTs of the AC were manually drawn using Analyze® software (as in figure
6.12) and the data were normalized by the mean intensity of the kidney where
a small ROT was drawn. The histogram of the signal intensity in the ROT over
the AC was fitted to the following Gaussian equation using Matlab:
_ (X-~l) _ (X-~2)
2c + e 2c2Yfit = al . e 1 a2 . (6.1)
where Cl and C2 were constrained 2: 0.1 (10 times bigger that one bin)
and a2 was constrained 2: O. The ratio a2/ al was used to assess AC content
composition, as a measure of the ratio of dark to bright signal fractions.
Second automated method: feature extraction using Gabor filters
Gabor filtering is an useful signal processing technique that can extract
local spatial frequencies of an image, by representing signals as a combination
of elementary functions [46]. Spatial frequencies and their orientation charac-
terise the texture of an image. Methods like Fourier analysis have long been
used for the spectral decomposition in signal processing but the main prob-
lem is that the spectral features from different parts of an image are mixed
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together. Gabor filters make it possible to have this spatial information and
to obtain localised features of an image [47,48].
A complex Gabor filter can be viewed as a sinusoidal plane of particular
frequency and orientation, modulated by a Gaussian envelope. Figure 6.13
shows how a Gabor filter is obtained for a 2D case, while figure 6.14 shows
some examples of filters with different frequency and orientation.
It is possible to write the function describing a Gabor filter in 2D as
2 2
g(x, y, e, ¢) = e-X ;1' . e27rOi(xcosrj;+ysin¢) (6.2)
where e is the spatial frequency, ¢ the orientation and (J" the standard
deviation of the Gaussian kernel which depends on the spatial frequency and
it is chosen to take into account all the range of frequencies.
If we have an image J(x, y), we can obtain the Gabor feature G(x, y, e, ¢)
by convolving the Gabor filter and the image as follows
G(x, y, e, ¢) = J J J(p, q)g(x - p, y - q, e, ¢)dpdq (6.3)
Gabor filters have been used as an automated method to extract features
from images of the colon. The 5 grades of typical colonic contents, described
in the previous sections and displayed in figure 6.12, present a variety of pat-
Figure (6.13): A complex Gabor filter as in (C) can be viewed as a sinusoidal
plane of particular frequency and orientation (A) modulated by a Gaussian
envelope (B).
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Figure (6.14): Examples of different Gabor filters.
terns which depend on a variety of factors such as brightness, wall thickness,
homogeneity, contrast etc. These features can be extracted as image textures
and the images can be then classified according to that texture.
The entire process of this automated method for the definition of the char-
acteristics of the ascending colon is embedded in a Matlab code! and consists
of 4 main parts: the data analysis and scaling, the Gabor feature extraction,
the co-occurrence matrix feature computation and a support vector machine
(SVM) discrimination analysis. Texture analysis for a whole data set for one
subject (consisting of about 6 sets) takes less than 3 minutes and it is fully
automated.
Data analysis and scaling: The entire analysis is performed only on
the colonic region so, ROIs were manually drawn on each slice using Analyze
software (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN,
USA). In addition, for scaling purposes, an ROlon a small homogeneous region
of the kidney is also drawn. The kidney has been chosen since it has been
recognized as the most homogenous region across all the subjects. The input
of the Matlab code consists of the two ROIs and the images in Analyze format.
IThe Matlab code has been written in collaboration with Dr. A. Napolitano.
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Gabor feature extraction:
A Gabor filter bank consisting of 17 frequencies and 8 orientations is'applied
on the set of scaled images, i.e. the colonic images normalised with the intensity
signal of the kidney. The 17 frequencies were chosen based on the equation
10In= p (6.4)
where 10=0.5 cycle/pixel and n varies from 0 to 16 [49]. The chosen orien-
tations were 0, 45, 90, 135, 180, 225, 270, 315 degrees so that the images are av-
eraged across the 8 orientations to make the analysis orientation-independent.
In addition, the images are reconstructed by cumulatively summing the images
from the lower frequencies to the higher ones. The choice of the summing order
is based on the fact that the colonic content is more visible at lower frequencies
than higher ones where, conversely, the colon edges and wall are more visible.
Therefore, by summing the reconstructed images from the lower to the higher
frequencies, the contribution from the walls is minimised.
The flow chart reported in figure 6.15 represents the main steps of the
Gabor feature extraction program. The reconstruction of the images by cu-
mulatively summing on the frequencies is reported as an example in figure
6.16. The mean signal of the reconstructed images up to the 17th frequency is
also calculated and will be called "mean Gabor signal" .
Co-occurrence matrix feature computation: The third part of this
automated method computes the main features on the set of images obtained
from the Gabor texture analysis.
Before computation of the co-occurrence matrix, the images previously
normalised to the kidney mean signal are scaled to lie in the range 0-10 by
using maximum and minimum values calculated on the whole set of data.
These images will be called "binned images" .
The co-occurrence matrix (also called gray levels co-occurrence matrix,
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Data input:
Image, F{)I colon, R)I kidney
,
SAling data with the kidney
mean value
Gabor filters applied:
17 frequendes x
8 orientations
ROlon the colon:
Image reconstrudion
MAXand MIN of all images
of every subject to be
analysed
Gabor
feature
extraction
Figure (6.15): Schematic diagram of the Gabor feature extraction program.
(a) pt reconstruction (b) 3rd reconstruction (c) 5th reconstruction
(d) 7th reconstruction (e) 9th reconstruction (f) 11th reconstruction
(g) 13th reconstruction (h) 15th reconstruction (i) 17th reconstruction
Figure (6.16): Reconstruction of the high resolution image by cumulatively
summing the Gabor single frequency images.
GLCM) is a two-dimensional array in which both the rows and the columns
represent a set of possible image values, and the GLCM is a measure of the
spatial similarity of the signals across the image.
A GLCM of a binned image is defined by first specifying a displacement
vector (L1x,L1y) and counting all pairs of pixels separated by (L1x,L1y) having
gray levels i and j. The displacing vector will be referred to as offset. Figure
6.17 shows a schematic for 2 binned images where two pixels are compared:
the low offset (1,1) takes into account more local effects whilst the high offset
(5,3) considers longer distances, thus reducing the effect of the the medium
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scale vertical oscillation due to the presence of the colonic walls.
(a) Low offset (1,1) (b) High offset (5,3)
Figure (6.17): Example for the different offsets used: (1,1) to take into account
local effects, while (5,3) considers the longer distances in the ascending colon in
the vertical direction as for the AC shape.
The GLCM is therefore defined over a binned image to be the distribution
of co-occurring values at a given offset. If we consider an nxm image I, then
we can write the co-occurrence matrix C as
. . _ n In {I if I(p,q)=i and I(p+~x, q+~y)=j
Cl::.x,l::.y(~,J) - I:P=lI:q=l
o otherwise
(6.5)
The GLCM has dimension l xl, where I is the number of gray levels in the
image, 10 in our case. It can be noted that the GLCM is not symmetric, since
the number of pairs of pixels having gray levels (i,j) does not necessarily equal
the number of pixel pairs having gray levels (j.i), Figure 6.18 shows an example
of the creation of a GLCM from a binned image with an offset of (1,1).
Gray level co-occurrence matrices contain properties of texture but they are
not directly useful for further analysis, such as the comparison of two textures.
Instead, numeric features are computed from the co-occurrence matrix. Among
all the possible features, the following have been considered as important:
• Homogeneity, which is a measure of the closeness of the distribution of
elements in the GLCM to the GLCM diagonal, i.e. homogeneity=l for
lUetllOds Ior nicnsuting physiology of the colon 96
a diagonal GLCM. It can be written as
Homogeneity =L p~i.' j) . 1
.. 1+ z - J
t,)
(6.6)
where p(i,j) is the value in the GLCM. This means that for the low
offset (1,1), high homogeneity means clustered signals, whilst for the
high offset (5,3) a high homogeneity value means that the signals repeat
at distances. A heterogeneous image will result in an even spread of p(i,j)
and a low homogeneity value.
• Contrast: it is a measure of the local variations present in an image and
it is 0 for a constant image.
Contrast = L 1 i - j 12 p(i,j)
i,i
(6.7)
If there is a large amount of variation in an image the p(i,j) values will
be concentrated away from the main diagonal and contrast will be high.
• Entropy: as the term comes from thermodynamics to define the the quan-
tity of energy that is permanently lost to heat, in the context of texture
analysis entropy represents a measure of disorder, i.e. the randomness of
intensity distribution. The equation is
N-l
Entropy = LP(i,j)(-lnp(i,j))
i,i
(6.8)
Entropy is highest when all p(i,j) are of similar magnitude, and small
when p(i,j) values are very different.
• Correlation: it returns a measure of how correlated a pixel is to its neigh-
bor over the whole image. Correlation is 1or -1 for a perfectly positively
J\1etllOds iot mensuiing physiology of the colon 97
or negatively correlated image. Correlation is NaN for a constant image.
Correlation =L (i - J.ti)(j - J.tj)p(i,j)
• . (J'i(J'j
~,J
(6.9)
where
(6.10)
Correlation will be high if an image contains a considerable amount of
linear structures .
• Energy: it is the sum of squared elements in the GLCM and it is 1 for a
constant image.
Energy = LP(i,j)2
i,j
(6.11)
Figure 6.19 shows some examples of binned images with the features calculated
for an offset of (1,1). Among all these features, homogeneity and contrast were
chosen as they were more representative for our data. For these two features,
the cumulative integrals were performed over different ranges of Gabor fre-
quency values, for different offsets.
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Figure (6.18): Schematic diagram of the creation of a GLCM (right) from a
binned image (left), with an offset of (1,1). For each pixel in the binned image
on the left the neighbor is considered and their values (e.g. 9 and 3 in green)
count as a 1 in the co-occurrence matrix. This is done for each pixel in the
binned image with the chosen offset.
1IIct.hods iot Il1(>asllrhJg physiology of the colon 99
10 10
(a) Contrast: O. Correlation: 1. En- (b) Contrast: 45. Correlation: -0.1.
ergy: 0.5. Entropy: 0.7. Homogene- Energy: 0.2. Entropy: 1.4. Homo-
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(c) Contrast:
Energy: 0.6.
geneity: 0.8.
16. Correlation: 0.2. (d) Contrast: 28. Correlation: 0.04.
Entropy: 0.8. Homo- Energy: 0.4. Entropy: 1.1. Homo-
geneity: 0.7.
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(e) Contrast:
Energy: 0.2.
geneity: 0.6.
36. Correlation: 0.1. (f) Contrast:
Entropy: 1.4. Homo- Energy: 0.2.
geneity: 0.6.
36. Correlation: 0.1.
Entropy: 1.4. Homo-
Figure (6.19): Example binned images with correspondent texture parameters
calculated with an offset of (1,1).
Methods for measuring physiology of the co1011 100
Support Vector Machine discrimination analysis:
The support vector machine (SVM) discrimination analysis was performed
in order to have a complete automated method to combine measurements
of MRI signal characteristic into scoring values in analogy with the visual
subjective method and the first automated method. A SVM is one of the
most powerful learning method for data classification. The goal of SVM is
to produce a model based on a set of characteristic data, that will be called
"training data" on which the texture analysis is performed. All the features
obtained on this set of training data are then used to build a model. Afterwards
this model can be used to classify any set of data available which will be called
"testing data" .
The set of training data was chosen from the mannitol data presented
previously (section 6.2). In particular the images chosen corresponded to the
ones that were visually scored the same value by the two observers in the
subjective method (myself and Dr. C.L. Hoad). The whole set of training
data included: 7 images for score 1, 6 images for score 2, 6 images for score
3, 17 images for score 4 and 12 images for score 5, for a total of 48. For
this data the following features were considered for the classification: mean,
CV, contrast, entropy, contrast homogeneity ratio, homogeneity, homogeneity
mean ratio, each of which calculated for low and high offset.
However, in order to explain the SVM discrimination analysis, we can con-
sider a simple case of two classes with 1 features. We have a set of given data
points which either belong to class 1 or class 2. The goal is to decide which
class a new data point will belong. In the case of SVM, a data point is con-
sidered to be a n-dimensional vector Xi, with i=L, ... ,l, where the elements of
the vector correspond to different features of the data point (eg. homogeneity,
contrast, mean, etc). We can then consider an indicator vector Yi which is
equal to either 1 or -1, so that if Xi is in class 1 then Yi is 1 and if Xi is in
class 2 then Yi is -1. In order to distinguish the two classes, one option is
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to choose a hyperplane that represents the largest separation between the two
classes (see figure 6.20). A general hyperplane can be written as the set of
points satisfying the following equation
•
•
/
..,"/ X2
"
//
Figure (6.20): Schematic diagram of the hyperplane and margins for an SVM
trained with samples from two classes.
wT. x } b = 0 (6.12)
where· denotes the dot product, w is the normal vector to the hyperplane
and blllwil being the offset of the hyperplane from the origin along the normal
vector w. We want to choose wand b to maximize the distance between two
parallel hyperplanes that are as far apart as possible and separate the data.
These hyperplanes can be described by the equations
wT. X + b = 1 (6.13)
and
wT. X + b =-1 (6.14)
such that
wT . Xi + b ~ 1 if Xi is in class 1 (6.15)
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and
wT . Xi+ b ~ -1 if Xi is in class 2 (6.16)
The distance between wT. xi+b=1 and wT• Xi +b=-1 is defined as
2 2
M= VwTw (6.17)
so we want to minimize Ilwll.
The optimization problem presented, i.e. the choice of w and b, is not easy
to solve because it depends on Ilwll which involves a square root (equation
6.17). One common strategy is to substitute Ilwllwith i IIwll2without chang-
ing the solution (same values for wand b). The factor ~ is introduced for
calculation convenience. Therefore we have a quadratic optimization problem
as the following [50,51].
(6.18)
subject to
Yi (wT •Xi+ b) ~ 1 with i = 1, ..., l (6.19)
where Yi is the indicator vector equal to 1 or -1 already introduced.
At this point it becomes necessary to take into account possible class mixing
in the training set. This would imply that there is no hyperplane that can
exactly split the data in either one class or the other. Therefore another term
in the optimization can be introduced with this form
(6.20)
where C > 0 is an additional constraint and ~ > 0 measures the degree of
misclassification of the data.
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Up to this point we have considered a linear classification. However, it
may be necessary to introduce the function ¢ to map the vectors Xi into a
transformed space, see figure 6.21, in which the classes can be separated by a
hyperplane [50,52].
Since guessing the ¢ function is not a trivial task, a "kernel trick" [52] is
introduced: the kernel function K(Xi; Xj)=¢(Xi)T ¢(Xj) is defined to help with
the calculation. From this point onward the kernel structure in terms of ¢ is
replaced by studying the possible structures of the kernel. This allows the algo-
rithm to fit the hyperplane in a transformed feature space. The transformation
may be nonlinear and the transformed space high dimensional.
Many possible kernel functions are found in literature", but in this work
the radial based function (RBF) kernel has been chosen for its fewer numerical
difficulties. An RBF kernel is defined as
(6.21)
where ,>0 is a kernel parameter.
A matlab library for support vector machines (LIBSVM) from Chang et
al. [53]3 has been used for the prediction of information of a data set based on
the set of training data. LIBSVM basically compares the data to different pairs
of classification in turn. If k is the number of classes, then k(k-1)/2 classifiers
are constructed. Each binary classification is considered to be a voting so that
at the end a point is chosen to be in a class with the maximum number of
votes. The testing data were then classified according to the resulting model
2Four main basic forms for the kernel functions are found in literature:
• Linear; K(Xi;Xj)=X'[ Xj'
• Polynomial; K(Xi;Xj)=(-yXiT xj+r)d, 7>0.
• Radial basis function (RBF); K(Xi;Xj)= exp(-7 II Xi - Xj 112),7>0.
• Sigmoid;K(xi;xj)= tanh(7xiT xj+r))
where 7, r and d are kernel parameters.
3Software available at http://www.csie.ntu.edu.tw/-cjlin/libsvm
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Figure (6.21): Schematic of a non linear transformation.
and both final predicted classification (scoring), and underlying probabilities
of belonging to one of the classes (scores)were reported. Also a probability
weighted score was computed in order to associate each data to a continue
rather than discrete level. In our case, with the 5 scores as different classes,
the sum of the 5 probabilities is equal to 1.
Accuracy for ROI drawing and reproducibility:
Further analysis was performed to optimise the method and the time needed
for the analysis. In particular, the required accuracy of drawing ROIs was
tested, being the most time consuming step. Even if some software packages
provide tools to assist the recognising of the edges in an image, the accuracy
in drawing the ROIs still influences the analysis time. For this study the ROIs
were defined precisely around the walls of the colon. Therefore a comparison
between a coarse and a precise type of contouring was performed. In particular,
a set of 3 subjects was analysed by two observers and in the two different
contouring approaches, as in figure 6.22. The results for the scoring from the
classification analysis for the precise and coarse ROIs were subtracted and
their difference was considered to quantify the accuracy.
The reproducibility of the ROI contouring was also similarly tested, by two
observers (the author and Dr. Caroline Road) on two different subject sets.
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(a) Precise (b) Coarse
Figure (6.22): Example for the difference accuracy of drawing the regions.
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6.4.3 Results
Subjective assessment
For the intra-observer reproducibility, 75% of the scored values were iden-
tical and 25% were 1 bin different, thus having a weighted kappa for the intra-
observer of 0.84 which indicates a very good agreement. For the inter-observer
variability, 75% of the scored values were also the same, 24% were 1 bin differ-
ent and 1% was 2 bins different, and the calculated weighted kappa was equal
to 0.82 which also indicates a very good agreement.
Figure 6.23 shows the average scores for the 8 volunteers in the 2 conditions,
scored by E.P. For the mannitol case, the colonic contents are given much
higher scores, in agreement with the results of brightness and homogeneity
presented in the previous chapter, due to the arrival of water in the AC after
the mannitol. In particular this is shown in figure 6.24 which shows the scores
and the ACWC together versus time: the higher scores for the mannitol case
mirror the bigger amount of free water in the AC, while for the control a more
heterogeneous and dark signal correspond to the low amount of free water.
The similarity in the trend shows that the scoring system is robust.
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Figure (6.23): (Mean ± STD) Average scores versus time for the 8 volunteers
scored by E.P. For the Mannitol case the scores result to be much higher for all
the volunteers compared to the control: the AC contents were more homoge-
neous and bright for the Mannitol case.
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Figure (6.24): (Mean ± STD) Average scores by E.P. (primary axis) and ACWC
in ml (secondary axis) versus time for the 8 volunteers. The higher scores for
the mannitol case mirror the bigger amount of free water in the AC, while for
the control a more heterogeneous and dark signal correspond to the low amount
of free water.
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First automated method: histogram and Bi-Gaussian fit
Figure 6.25 shows the histograms and the fits of the images shown in figure
6.12 as an example of this method (histogram in grey, 2 gaussians plotted as
blue and light blue and the total fit in red).
Yfit
Score 1 Score 2 Score 3
Intensity (a.u.)
Score 4 Score 5
Figure (6.25): Histograms for colonic ROls from the 5 images in figure 6.12 with
the a2/al values calculated on 5 sets of images for each score. The five graphs
are plotted in the same horizontal axis for convenience.
Table 6.2 summarises the results for the a2/ al ratios calculated on 5 sets
for each score from different subjects. The a2/al values are sensitive to the
different grades except for score 1 and 2 that give similar values.
Figure 6.26 shows the results for one subject for the mannitol case com-
pared to subjective scores, showing a very good accordance and a more smooth
transition between dark and bright compared to the scores. The high resolu-
tion images used for this analysis are reported in figure 6.9.
Scores
1
2
3
4
5
a2/al(mean ± STD)
0.1 ± 0.1
0.2 ± 0.1
0.5 ± 0.1
1.9 ± 0.8
3.5 ± 0.5
Table (6.2): Results for the analysis with the histogram and Bi-Gaussian
method. a2/ al values calculated on 5 sets of images for each score.
Methods for tneesuriug physiology of the colon 109
6 5
Drink Meal
5 4
4
III 3
»e 3 N0
">u 2V)
~2 ,,
,
,
,
11
,
,
.... '
....0----6
0 0
-50 50 150 250 350 450
Time (min)
4-SCOreS -o-A2/Al
Figure (6.26): Visual subjective scores (primary axis) and a2/al values versus
time for one subject for the mannitol case. The high resolution images are
reported in figure 6.9.
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Second automated method: feature extraction using Gabor filters
For the texture analysis, the ratio between contrast and homogeneity is
reported in figure 6.27 for the two different offsets in order to take into account
also long range effect and integrated up to either the 11th or the 17th frequency.
The sum up to the 17th frequency shows more evident differences between the
texture features of the two arms of the study.
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Figure (6.27): (Mean ± STD) Contrast/homogeneity ratio averaged on the 8
subjects and plotted as a function of time for the control and the mannitol cases.
Figure 6.28 gives an example of the texture analysis for four different colonic
contents. The mean signal calculated is higher for more homogeneous regions
(figure 6.28(b)). The cumulative integral of the contrast homogeneity ratio
calculated with the high offset is plotted as a function of frequency in figure
6.28(c): the difference in intensity increases with the frequencies, with the
more heterogeneous area having less intensity.
Figure 6.29 shows the results for the weighted scores calculated with the
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SVM classification, while figure 6.30 shows the mean Gabor signaL The aver-
age on the 8 subjects is plotted with the standard deviation as a function of
time.
The cross validation in case of the training data showed an accuracy of
95.3%. For the testing data, corresponding to the study of control and man-
nitol cases, the cross validation showed an accuracy of 92.4%.
Reproducibility:
Figure 6.31 represents the difference of weighted scores computed on the
basis of ROIs drawn by the same observer twice on two different subjects. This
intra-observer variability proved to be reliable as the difference in scores was
about 7%.
The inter-observer variability was also performed on two sets of data. Fig-
ure 6.32 reports the difference in scores for subject 1 and subject 2, averaged
on the two observers' results. As the previous case, the inter-observer variabil-
ity was less than 10%, which implies that the same score is given on the same
set of data if two different operators perform the analysis.
Accuracy of drawing the regions:
The results for the scoring for the 3 sets of data analysed with a coarse and
a precise ROI were subtracted and plotted according to the two experimental
conditions. In both cases, the difference in scores is less than 5%, figure 6.33.
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(a) Examples for the four different ar-
eas taken into account for the Gabor tex-
ture analysis: walls (red), walls and con-
tents together (green), homogeneous con-
tents (black) and heterogeneous contents
(blue).
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Figure (6.28): Feature analysis for different AC regions.
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Figure (6.29): (Mean ± STD) Weighted scores calculated with the SVM classi-
fication.
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Figure (6.30): (Mean ± STD) Mean Gabor signal over time.
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Figure (6.31): Intra-observer variability calculated on two sets of different sub-
jects. The scores difference is about 7% meaning that the variability doesn't
imply a change in the score.
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Figure (6.32): Inter-observer variability calculated on two sets of data. The
difference is less than 10%, which implies that the same score is given on the
same set of data if two different operators perform the analysis.
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Figure (6.33): Difference in scores for the two types of accuracy in drawing
ROIs. For both control and mannitol cases, the difference between precise and
coarse is less than 5%, meaning that the same score is given in every condition.
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6.4.4 Discussion
The subjective scoring system proved to be robust and both the intra-
observer and the inter-observer resulted in a good accordance (75 % for both
cases). However, being a subjective method, the observer needs to be properly
trained and it also relies on the person's judgment. In addition, the observer
scores the images while looking at all the slices available together, thus leading
to possible biases.
The Bi-Gaussian fit and the Gabor texture analysis methods provide an
improved objective assessment of the AC contents compared to the subjective
scoring, providing continuous values for the different AC characteristics. The
Bi-Gaussian fit method requires the input from the operator to verify the
accuracy of the fit. For that reason no discrimination was performed with this
method but the method was only reported for completeness.
The feature analysis proved to be reliable, with an inter- and intra-observer
variability much smaller than the subjective method (more than 90%). The
only inputs required are the ROIs of the AC and of a small region in the kidney
thus providing a very efficient objective method. The computation time is very
short as it allows the analysis of a whole set of data in a few minutes. The
scores and the mean were found to be higher in time and for the mannitol
case compared to the control (figure 6.29 and 6.30), thus reflecting the results
obtained previously with the water content in the ascending colon, see figure
6.3. These results reflect the scoring performed subjectively (figure 6.23) but
they have the advantage of being obtained without any operator intervention.
This method has also been used for the calculation of features that can be
applied to any sets of data. In particular, chapter 7 will present the results of
the features of the colonic contents under pharmacological intervention.
Further improvements may include the possibility of drawing the ROls in
Matlab as it was proven that a coarse definition of the region is sufficient, thus
avoiding the use of other licensed softwares.
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The feature analysis method was a preliminary attempt to solve the com-
plex and time consuming problem of characterising colonic contents. More
work needs to be done to optimise such method. Firstly, a systematic study of
the role of the filters must be undertaken in order to consider the importance
of each frequency for the feature discrimination. Secondly, a deeper study of
the features needed for the discrimination needs to be performed so that only
dominant features are considered. In addition a more detailed comparison be-
tween different offsets can be performed in order to further investigate the role
of the colonic walls contribution in the features results.
This will not only potentially simplify the analysis but also provide new
information about changes in colonic content over time.
Chapter 7
MRI of pharmacological
interventions in the colon
7.1 Introduction
Symptoms of colonic dysfunction such as diarrhoea and constipation are
very common in the general population; both symptoms may coexist and can
have a major impact on the quality of life [5,6]. However, they are often
embarrassing and underreported thus leading to poor diagnosis of eventual
underlying pathologies.
Acute diarrhoea is a disorder that occurs in a majority of adults at least
once a year [54]. There is a number of causes for acute diarrhoea including
food intolerance, psychological stress and adverse reactions to medications. In
most cases diarrhoea is due to infections caused by viruses and bacteria but
it can also be non-infectious. Many patients report symptoms associated with
their diarrhoeal illness including abdominal pain, bloating, flatulence, nausea
and vomiting. Diarrhoeal diseases usually resolve spontaneously within 3-5
days occasionally aided by over the counter medication; however, being such a
common illness, diarrhoea can have a substantial social and economic impact.
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Constipation is a common heterogeneous condition that affects more than
15% of the population in the western world [55]. It is defined by several
symptom criteria (ROME IIIl) determined by the association with abdominal
discomfort or pain. The frequency of constipation is higher in the elderly, in
non-whites and in subjects of lower socioeconomic status [57], thus suggesting
the influence of environmental factors. Constipation is poorly understood be-
cause of the difficulties of access to the small and large bowel. The majority
of cases can be treated with dietary changes or mild medications but there
is a group of patients in whom the symptoms are more acute and persistent
and are thought to be due to impaired colonic transit and/or to obstructed
defecation [58].
Advances in understanding the pathophysiology of the colon as a guide to
treatment of patients with constipation and diarrhoea is a continuing impor-
tant goal. Imaging has therefore become fundamental to this aim and to inves-
tigate the mode of action of treatments. In this work, novel MRI techniques
have been developed that allow imaging in great detail the characteristics of
the small bowel and the colon non invasively, to study the physiology of the
undisturbed state.
This chapter presents the application of these MRI techniques developed
and explained in the previous chapters to the pharmacological interventions in
the colon.
IThe Rome criteria is a system developed to classify the functional gastrointestinal dis-
orders, in which symptoms cannot be explained by the presence of structural or tissue
abnormality, based on clinical symptoms. Rome criteria apply not only to constipation but
also to irritable bowel syndrome, functional dyspepsia and functional heartburn [56].
JURI of pbniniecologicel iuiervoution« it: the colon 119
7.2 Novel insights into the mechanisms of ac-
tion of Metamucil
7.2.1 Introduction
Metamucil® (Procter and Gamble, USA) is a bulking agent for the treat-
ment of constipation which is also used as a dietary fibre supplement as it
doesn't contain any chemical stimulants. The active ingredient, psyllium, is
the husk of the seed of Plantago ovata or P. psyllium characterised by a high
mucilage content. Mucilages are clear colourless gel forming materials obtained
by milling the outer layers of the seed which bind water, increasing in volume
of 10 fold or more when added to water. Metamucil has been used together
with Gd-DOTA (Dotarem) as an orally administered contrast agent in MRI
studies for the imaging of the small bowel [59]and for the measurement of the
small bowel flow rate measurement [60]but its mechanism of action has never
been studied with MRI.
This pilot study investigates whether it is possible to visualise the effects of
Metamucil on the colon and in particular to assess the effects of Metamucil on
small bowel water content, colonic water content and ascending colon motility.
Variations of such parameters would give information regarding the mode of
action of the product thus providing useful information for possible future
developments of technology. This pilot study has been funded by Procter and
Gamble for visualisation of the product in three subjects only.
7.2.2 Method
This study was approved by the University of Nottingham Medical School
Ethics Committee and all volunteers gave written informed consent. For this
pilot study we recruited volunteers who attended the imaging centre twice (at
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least one week apart), having fasted overnight on each occasion. 3 healthy fe-
male volunteers, without known contraindications to MRI imaging (e.g. metal
implants in their body), participated in the study. They had normal BMI and
were aged 22-39 years. All images were acquired with a 1.5 T Philips Achieva
system using a range of MRI sequences including:
• A balanced gradient echo (bTFE) sequence (TR = 2.4 ms, TE = 1.19
ms, acquired resolution of 2.50 mm x 1.56 mm and slice thickness of 10
mm, scan duration 11 seconds) to measure the gastric volumes.
• A high resolution bTFE to image the contents of the ascending colon
(AC) (TR = 3.2 ms, TE=1.58 ms, acquired resolution = 1.50 mm x 1.50
mm, 8 slices 5 mm thick, 0.58 mm gap, scan duration 16 seconds).
• A thicker slice bTFE used to identify the peristaltic movements in the
AC (TR = 3.0 ms, TE = 1.49 ms, acquired resolution = 1.50 mm x 1.50
mm, 15 mm thick acquired every second for 3 minutes). No longer scans
were possible for timing restrictions.
• A single shot, fast spin echo sequence (RARE) to acquire in a single
breath-hold 24 coronal images with in-plane resolution interpolated to
0.78 mm x 0.78 mm and a slice thickness of 7 mm, with no gap between
slices (TR = 8000 ms, TE = 320 ms, acquired voxel size = 1.56 mm x
2.90 mm, scan duration 24 seconds). This sequence yields high intensity
signals from areas with liquid fluid and little signal from body tissues
and is used for the small bowel and colon water content estimation.
With the exception of the motility sequence, each image set was acquired on an
expiration breath-hold with a duration between 13 and 24 seconds depending
on the sequence. Including set-up and imaging the volunteers spent approxi-
mately 10 min inside the magnet for every time point, spending the rest of the
time sitting upright in an adjacent room. The volunteers underwent a baseline
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Figure (7.1): Protocol of the study for each occasion. The subjects were scanned
fasted and immediately after the drink (Metamucil or placebo) and then hourly
for 7 hours. A single data point at 24 hours was also acquired. Details of the
drinks and the meal are given in the text.
scan before being administered Metamucil (one rounded teaspoon in 227 ml
still water) or placebo (6.9 g glucose in 227 ml still water to match calories and
water volume of active). They were then scanned immediately after this and
then hourly for 7 hours (8 hours in total). The subjects were imaged again the
following morning to acquire a single data point at 24 hours after dosing.
On the first study day the subjects also received a breakfast meal compris-
ing a standard rice pudding meal used in previous studies [61]. It consisted
of:
• 220 g Sainsbury's creamed rice pudding
• 15 g coarse wheat bran (Holland and Barratt)
• 34 g Sainsbury's seedless raspberry jam
• 100 ml Sainsbury's pure orange juice from concentrate
The total caloric content for this meal was 362 kcal.
The subjects were dosed again with the active or the placebo twice accord-
ing to the schedule reported in figure 7.1 and to the product instructions.
7.2.3 Results
All volunteers tolerated well the Metamucil and the placebo drinks and
the study procedures. There were no adverse events reported in this study.
No statistical analysis was performed on the sets of data, given the number
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of subjects. However these data could be used to plan and to calculate the
power for future studies. The results are shown below as mean and standard
deviation.
Gastric emptying showed no significant difference between the two condi-
tions (figure 7.2). The Metamucil and placebo drinks emptied rapidly as shown
by the data from the third dosing of the day. The first two dosings overlap
with the emptying of the solid meal. The behaviour of intra gastric volume of
air is not different between conditions, figure 7.2(b).
The small bowel water content showed characteristic drop after feeding but
no difference between the two conditions was observed in the small bowel free
mobile water content as measured from the RARE images, figure 7.3. At later
times it was possible to visualise the arrival and persistence of a bright bolus
of material in the colon of all three volunteers. The graphs showing the total
colon contents over time is shown in figure 7.4(a). After the Metamucil drink a
big amount of fluid arrives in the colon, whilst the total colonic water contents
stays low for the control. Figure 7.4(b) reports the area under the curve of
the total colon water content over time, showing an evident increase of about
900%.
In particular, two volunteers showed the arrival and the persistence in the
ascending colon between 2h and 5h post dosing, showed in figure 7.5. An
example of the arrival of fluid in the transverse colon is given in figure 7.6.
At every time point a dynamic MRI scan of the ascending colon was ac-
quired to visualise ascending colon walls movements. These movies showed
very little motility on either arm of the study. However ascending colon mo-
tion was observed in the presence of the Metamucil bolus in the first volunteer.
7.2.4 Discussion and conclusion
This pilot study showed that it was possible to visualise the arrival and
persistence of a bright watery bolus in the colon of all 3 volunteers after dosing
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(a) (Mean ± STD) Stomach contents excluding air over time averaged
over all subjects.
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(b) (Mean ± STD) Intra gastric air over time averaged over all subjects.
Figure (7.2): Average values for the gastric contents and air over time.
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Figure (7.3): (Mean ± STD) Average values for the small bowel water contents
over time.
with Metamucil using MRI. No such bright mass was seen on the placebo
condition. We can infer that changes in the appearance and time to peak
and time of persistence of the active bolus in the colon, in addition to the
assessment of gastric emptying and small bowel water content would relate to
the product mode of action of metamucil. The MRI visualisation could also
provide unique non-invasive insights and novel information regarding the mode
of action of different products thus potentially aiding future pharmacological
developments.
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Figure (7.4): Average value for the water contents in the lower gut.
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(a) Coronal RARE single slice images of the arrival and persistence of a bright bolus of
material in the ascending colon of the second volunteer after drinking Metamucil at different
time points. The corresponding images after the placebo (glucose) drink underneath showed
no such filling.
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(b) Corresponding dual echo fast field echo coronal anatomical roadmaps of the ascending
colon.
Figure (7.5): An example from the second volunteer's ascending colon.
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Figure (7.6): Coronal RARE single slice images of the arrival and persistence
of a bright bolus of material in the transverse colon of the third volunteer after
drinking Metamucil at different time points. The corresponding images after
the placebo (glucose) drink underneath showed no such filling.
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7.3 Defining the mode of action of loperamide
and loperamide plus simethicone using an
MRI model of acute diarrhoea
7.3.1 Introduction
As previously stated, acute diarrhoea is a very common disorder that can
have a significant social and economic impact. The majority of patients suc-
cessfully obtain symptomatic relief of acute diarrhoea with over-the-counter
medication; however, until now there is no single medication that can ef-
fectively act on both diarrhoea and gas-related discomfort. Loperamide hy-
drochloride is a widely used anti-diarrhoeal agent shown to be efficacious in
diarrhoea of both infectious and non infectious origin. Its mechanism of action
has been extensively studied [62,63]. Early works in humans and more recent
studies in animals show that loperamide reduces the peristaltic movements
and slows the gastrointestinal transit. In particular, Schiller et al. [64]in 1984
showed that loperamide is responsible for a change in the motor function of
the intestine. They studied this mechanism during experimental diarrhea pro-
duced by the rapid intragastric infusion of electrolyte solution. They suggested
that this change in the motor function results in a delay in the passage of fluids
through the intestine thus implying that this delaying mechanism, rather than
a change in rate of absorption by intestinal mucosal cells, is responsible for the
antidiarrheal effect of loperamide.
Sandhu et al. in 1981 [65] and then in 1983 [66] suggested from animal
studies that loperamide may also have an anti-secretory effect, and concluding
that this process is mediated via opiate receptors.
More recent studies include the work from Szilagyi et al. [67]investigating
the influence of loperamide on lactose handling and oral-caecal transit time.
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They showed that the main effect of loperamide appears to be an increase
in oral-caecal transit time of 30-50%. Similar studies using 0.1 rag/kg by
mouth in pigs showed this was able to reverse the strong secretory effect of
hypertonic mannitol and enhance colonic water absorption [68]. Human studies
using jejunal, ileal and colonic perfusion showed that 12 mg of loperamide
by mouth increased the frequency of migrating motor complexes, decreased
irregular motor activity and increased jejunal but not ileal transit time [69].
Simethicone is a silicone polymer which acts as a surfactant: it has a very
low surface tension and it forms a thin film. For this reason it is often used as
an antiflatulent in gas and bloating conditions. Loperamide and simethicone
combination would therefore provide a better relief from the diarrhoeal symp-
toms. A study from Kaplan et al. [63] demonstrated that the combination
of loperamide and simethicone improved not only the relief of symptoms but
it also improved the control of diarrhoea itself, thus increasing the efficacy
speeding onset of action. The reason for faster· onset of action is unclear but
scintigraphic studies suggest a more even spread throughout the bowel which
might enhance its action which is largely local since very little is absorbed
systemically [70]. It has also been suggested that the interaction between lop-
eramide and simethicone may induce a different distribution of loperamide,
leading to a prolonged action of the drug locally in the GI mucosa.
Based on these assumptions, it was hypothesized that the predominant
effect of loperamide in treating acute secretory diarrhoea originating in the
small bowel will be to delay transfer of fluid from small bowel to the colon.
It was also hypothesized that it is the rapid transfer of fluid to the ascending
colon which causes propulsive motor patterns in the colon and hence urgent
bowel movements.
Until recently proving such hypotheses involved arduous intubation experi-
ments, which were highly unphysiological since as it has been recently showed,
intestinal intubation alters gut motility, accelerating transit [61]. This thesis
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presents the development of an MRI technique to investigate the colon non-
invasively and non-ionising, based on the work recently validated on the small
bowel water content [38]to demonstrate the marked secretory effects of man-
nitol with increase in small bowel water content and delivery of free water to
the colon [61].
In this study a model of acute diarrhoea has been used in which marked
small bowel secretion occurs. Loperamide is thought to cause pooling of fluid
in the small bowel and to reduce the amount of free water transferred to the
ascending colon thereby preventing diarrhoea. Loperamide and loperamide
plus simethicone are compared in order to determine if this greater coating of
the small bowel causes faster onset of action in the small bowel and whether
it reduces total water reaching the colon.
A range of different MRI sequences have been optimised in order to char-
acterise the ascending colon. Movements of the colonic walls are also observed
with a motility scan over 3 minutes. The ascending colon contents are de-
scribed by means of their T2 values: this is important because knowledge of
the composition of the colonic contents would avoid other more invasive di-
agnostic techniques to assess eventual disease progression. In addition, the
texture analysis described in section 6.4 was performed in order to have an
objective information regarding the ascending colon content.
Aim
The aim of this study is to assess the effect of loperamide and of loperamide
plus simethicone in prolonging small intestinal transit, delaying time to peak of
total colon water content and reducing peak and integrated total colon water
content.
AIRI of pharmacological iuterveutiuus in the co1011 131
Power of the study and dosing
Using our mannitol MRI model of acute diarrhoea [61]we have previously
found (section 6.2) in 10 healthy subjects a marked rise in total small bowel
free water content with time. Small bowel water content at its peak was 398
± 198 ml (mean ± standard deviation) so if we aim to detect an increase
of 33% i.e. 130 ml this would require n=12. We planned to recruit up to
18 healthy volunteers to increase power for other outcomes. Similar previous
studies in pigs showed loperamide 0.1 mg/kg, equivalent to 7 mg in a 70 kg
man, could completely block the effect of mannitol [68]while studies in man
suggest 12 mg will delay small bowel transit by 50% [71]. We suggested that
we use 12mg dose which is well tolerated to ensure we would get a clear effect.
The loperamide and simethicone capsules were reencapsulated by Nottingham
University Hospitals QMC Pharmacy who also provided the placebo. The
Pharmacy dispensed the study drugs according to a randomisation schedule
provided by our Clinical Trials Unit. This was an Investigator Initiated Study
which was funded by a research grant from McNeil Consumer Healthcare.
7.3.2 Method
Study design and population
This was a randomised, double blind, placebo controlled, 3-ways, crossover
study in healthy adult volunteers.
18 healthy subjects (11 female and 7 male, age range 20-45 years) without
known contraindications to MRI imaging and normal BMI participated in the
study. All volunteers had no history of gastrointestinal disease, they were
free from medication likely to alter gastrointestinal motility and they were free
from food allergy or intolerance. This study was approved by the University of
Nottingham Medical School Ethics Committee and all volunteers gave written
informed consent.
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Figure (7.7): Protocol of the study for each occasion. Schedule of the experi-
ment: a first baseline scan is performed after an overnight fast; a second baseline
after dosing and followingscans every 45 min after the mannitol drink.
Study protocol
The volunteers were asked to follow restrictions to diet and lifestyle for
the day prior to the study day, including avoid taking foods with high fibre
content to avoid excessive residue in the bowel on the study day, avoid spicy
food since it can stimulate bowel secretions and avoid caffeine, alcohol and
strenuous exercise for 18 hours before the study start time. Volunteers were
asked to fast overnight (from 8 pm the night before) except for a small cup of
water on waking on the morning of the study.
All imaging was carried out on a 1.5T Philips Achieva scanner with a
SENSE 4-element abdominal body coil.
Volunteers attended on three separate experimental sessions: they were
first imaged in the fasted state as a baseline scan; subsequently they ingested
capsules containing placebo or 12 mg loperamide or 12 mg loperamide + 125
mg simethicone. The timelines of the study day are summarised in figure 7.7.
100 minutes later they underwent a second baseline scan and 15 minutes
after that they received a drink containing containing 5% mannitol in 350 ml
of water. Mannitol is a common laxative known to stimulate small intestinal
secretion and can be used as a model for a range of diarrhoeal diseases and we
used it in the same dose previously [61]. The subjects then underwent serial
imaging at 45 minutes intervals for 4.5 hours after the drink.
A range of MRI sequences were used to image the abdomen including:
• A balanced gradient echo (called balanced turbo field echo, bTFE) se-
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quence (TR = 2.4 ms, TE = 1.19 ms) to acquire 25 transverse images
each with an in-plane acquired resolution of 2.50 mm x 1.56 mm and
slice thickness of 10 mm, with no gap between slices. This is used for
gastric volumes.
• A high resolution bTFE to image the contents of the ascending colon
(AC) (TR = 3.2 ms, TE = 1.58 ms, acquired resolution = 1.50 mm x
1.50 mm, 8 slices 5 mm thick, 0.58 mm gap). These images were used
for the texture analysis.
• Motility bTFE used to identify the peristaltic movements in the AC
(TR = 3.0 ms, TE = 1.50 ms, acquired resolution = 1.50 mm x 1.50
mm, single slice 15 mm thick acquired every second for 3 minutes).
• A single shot, fast spin echo sequence (RARE) to acquire in a single
breath-hold 24 coronal images with in-plane resolution interpolated to
0.78 mm x 0.78 mm and a slice thickness of 7 mm, with no gap between
slices (TR = 8000 ms, TE = 320 ms, acquired resolution = 1.56 mm x
2.90 mm). This sequence yields high intensity signals from areas with
liquid fluid and little signal from body tissues and is used for small bowel
water content.
• A dual gradient echo (dual-echo fast field echo, FFE, TEl = 2.3, T E2 =
4.6, TR = 158 ms) imaging sequence was used to visualise the anatomy
acquiring 24 coronal images with in-plane acquired resolution 2.01 mm
x 2.87 mm and a slice thickness of 7 mm, with no gap between slices.
• A T2-prep bTFE sequence (TR = 3.0 ms, TE values (ms): 20, 29, 43,
63, 93, 137, 201, 295, 434, 637, acquired resolution 2.00 mm x 1.56 mm
and a slice thickness of 7 mm) to measure the T2 values in the ascending
colon [42].
With the exception of the motility sequence, each image set was acquired
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on an expiration breath-hold with a duration between 13 and 24 seconds de-
pending on the sequence. Including set-up and imaging the volunteers spent
approximately 10 min inside the magnet for every time point, spending the
rest of the time sitting upright in an adjacent room.
Analysis
Measurements of the gastric contents and AC volumes have been carried
out by manually tracing the region of interest on each slice using Analyze®
software (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN,
USA) and summing across all the slices to determine the total volume at each
time point. In particular the gastric volumes were analysed distinguishing the
contents and the gas, with the gas being the dark area in the stomach. The
total gastric volume is the sum of the contents and the gas. The manual tracing
of an entire stomach or colon takes approximately 1 minute.
The volume of freely mobile water content, in both the small bowel and
ascending colon, was calculated for each volunteer using methods validated by
duodenal infusion intubation studies [38,61]. At each time point, the volume
of all image pixels above a threshold was integrated, after exclusion of signal
from regions other than bowel.
The Gabor texture analysis introduced in section 6.4 was performed on the
high resolution images of the colon for every subject with the exception of one
because the volunteer had an ectopic kidney which meant that no kidney was
visible in the slices and therefore no normalization was possible and the subject
had to be excluded from the analysis. For the other 17 subjects the texture
analysis was performed as described previously (section 6.4.2) and spot checks
were carried out to check the accuracy of the classification in comparison with
the visual scoring procedure.
T2 data sets were processed, firstly using Analyze® software to generate a
region of interest in the ascending colon chyme avoiding small 'pockets' of free
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water (high intensity signal) if present. Then using the mean of this region at
all the different echo times to calculate the T2 of the tissue using a program
in-house which modelled the effect of the T2-prepared scheme and subsequent
imaging sequence for the T2-prepared bTFE sequence [42].
Net secretion was assessed by subtracting the ingested 350 ml and the
baseline values for the fluids in the bowel from the sum of stomach contents,
small bowel water contents and ascending colon water contents. Previous work
with mannitol showed that gastric emptying is rapid and effectively complete
by 135minutes [61]. Therefore, the total observation time (from 0 to 270 min)
was divided into the "early phase" 0 to 135 min when the small bowel water
content is strongly influenced by gastric emptying and "late phase" 135 to 270
min when the SBWC depends more on absorption and rate of transit into the
colon.
Statistical analysis
Statistical analysis was carried out using Prism 4 (GraphPad Software Inc.).
All data was tested for normality using the Shapiro-Wilk's Test. Two-way
analysis of variance (ANOVA) was used to assess the significance of differ-
ences over time, followed by post-hoc tests corrected for multiple-comparison.
Paired comparisons were performed using two-tailed Student's t test for nor-
mal, and two-tailed Wilcoxon's test for non-normal data. A p-value < 0.05
was considered to be statistically significant.
7.3.3 Results
All volunteers tolerated the experimental procedures well. One of the 18
volunteers experienced an acute diarrhoea episode that lasted for less than 2
hours but did not withdraw from the study.
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Gastric emptying (figures 7.8, 7.9 and 7.10)
As expected gastric emptying was rapid and effectively complete by 135
minutes. Loperamide and loperamide + simethicone accelerated the emptying
of the gastric contents by 17% and significantly reduced the overall area under
the curves (AUCs) of the gastric contents in the early phase (0-135 mins), p
< 0.03.
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Figure (7.8): Gastric volumes over time and corresponding AUe (ml x min).
Both combinations of drugs also reduced the amount of gas in the stomach
by 40%. In particular in the early phase as can be seen in figure 7.9(a) the
drugs had an effect on the intra gastric air (p < 0.01), reducing the amount of
gas by 33%.
For the overall AUC there is a significant difference for the drugs compared
to the placebo (p = 0.004). Post tests showed a significant difference of both
loperamide and loperamide + simethicone versus placebo, both p < 0.01.
Figure 7.10(a) shows the total gastric volume over time. The individual
data are normally distributed and show a significant effect of the drug proved
with a 2-ways ANOVA test, p < 0.0001. Post test show a significant effect
of the drugs at 45 min and 90 min (loperamide versus placebo p < 0.01 for
both time points and loperamide + simethicone versus placebo p < 0.01 and
p < 0.05 respectively).
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(b) AUe (ml x min) for the gastric gas in the
early phase.
Figure (7.9): Gastric gas over time and corresponding AUe (ml x min).
For the AUC reported in figure 7.10(b), there is an overall effect of the
drugs (p < 0.0026), in particular Dunnett's post tests showed placebo versus
loperamide p < 0.01 and placebo versus loperamide + simethicone p < 0.01.
During the early phase loperamide and loperamide + simethicone signif-
icantly reduced the AUCs of the total gastric volume (p < 0.0094). The
Dunnetts comparison post tests showed a significant difference of loperamide
+ simethicone versus placebo, p < 0.05, and also a significant difference for
loperamide versus placebo, p < 0.01.
During the late phase there is also a significant difference between lop-
eramide and placebo p < 0.01 and between loperamide + simethicone versus
placebo, p < 0.01.
Small bowel water content (fig 7.11)
As expected from the accelerated gastric emptying, the peak of the small
bowel water content which occurred during the early phase was slightly higher
with loperamide and loperamide + simethicone being 578±32 ml and 600±30
ml respectively but the differences were not statistically different (repeated
measures ANOVA p < 0.2) compared to placebo 564±38 ml. No post tests
were carried out.
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(b) AUe (ml x min) for the total gastric vol-
ume in the early phase.
Figure (7.10): Total gastric volume over time and corresponding AUe (ml x
min).
The graph representing the SBWC over time shows an initial increase of the
water content for the loperamide + simethicone compared to placebo. This is
explained by the faster gastric emptying. However, even if the amount of wa-
ter in the small bowel is higher for loperamide and loperamide + simethicone
at 45 and 90 mins, it is significantly reduced at a later phase (135-270 min).
This means that the drugs act on either accelerating the absorption of fluids or
on inhibiting the secretions in the small bowel. Loperamide and loperamide +
simethicone reduced the overall AVCs of the small bowel water content volumes
from a min to 270 min compared to placebo (not shown). The differences were
just outside the statistically significant threshold (repeated measures ANOVA
p < 0.07), so no post tests were carried out. Figure 7.11(b) shows that during
the late phase loperamide and loperamide + simethicone markedly reduced
the area under the curves (AUCs) of the small bowel water content volumes
from 135 min to 270 min, which result significantly lower than placebo values,
Friedman's p < 0.009. Dunn's multiple comparison post tests showed a signif-
icant difference of loperamide versus placebo, p < 0.05, whilst loperamide +
simethicone versus placebo was not significantly different, p > 0.05.
Further analysis has been performed considering four areas in the small
bowel: upper left and right, lower left and right. Figure 7.12 shows the areas
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Figure (7.11): Small bowel water content over time and corresponding AUe (ml
x min).
under the curves for 180 minutes and 225 minutes.
Ascending colon water content and geometrical volume (figures 7.13,
7.14 and 7.15)
The change in total volume and in water contents for the ascending colon
show how the drugs delay the arrival of fluids in the AC, figures 7.13 and
7.14(a) respectively.
The drugs reduced the amount of free water in the AC, p < 0.04, shown by
the overall AUC from 0 min to 270 min, figure 7.14(b). Figure 7.15 shows the
AUC for the early and late phases. During the early phase (time 0 to 135 min)
loperamide and loperamide + simethicone significantly reduced the AUCs of
the ascending colon water content volumes by more than 40%, p < 0.004. The
Dunnett's comparison post tests showed a significant difference of loperamide
+ simethicone versus placebo, p < 0.05, and also a significant difference for
loperamide versus placebo, p < 0.01.
During the late phase (time 135 to 270 min), there was no significant dif-
ference between loperamide and placebo, but there was a significant reduction
due to loperamide and simethicone, p < 0.04, figure 7.15(b).
~\[RI of pluituu« ojop,icfll uiu-tvcutious ill Ihi' colon 140
18 225min 30 180min
16
25
#.
14
#.
+-'
12
+-'
20
c C
<lJ 10 2+-' 15c c
0 0
U U
~
6 ~ 10<lJ
+-'
ro 4 roS S
0 0
• PLA • LOP • LOP+SIM • PLA • LOP • LOP+SIM
(a) Upper right (b) Upper left
60 225min 50 225min
45
50 40
#. #. 35
+-'
40 +-'
C c 30
<lJ OJ
+-' +-' 25c 30 c
0 0
u u 20
~
20
~
OJ <lJ 15+-' +-'
ro ro
S S 10 .10
0 0
• PLA • LOP • LOP+SIM • PLA • LOP • LOP+SIM
(c) Lower right (d) Lower left
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Figure (7.13): Ascending colon geometric total volume versus time. The AC
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showing the delay of fluid arrival in the AC.
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Figure (7.14): Ascending colon water content over time and corresponding AUe.
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High resolution sagittal images of the ascending colon (figure 7.16)
The high resolution sagittal bTFE images provided detailed anatomical
images, figure 7.16. In particular, the baseline images for the three conditions
show very heterogeneous and dark contents. At 45 minutes after the man-
nitol drink the placebo already shows the arrival of fluids in the ascending
colon and a corresponding distention of the ascending colon volume while with
loperamide and the loperamide + simethicone the AC image remained hetero-
geneous and dark. The arrival of fluids for the drug arms of the study occurs
at 90 minutes and the ascending colon remains bright and homogeneous for
the following hours, gradually decreasing in volume and brightness.
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Figure (7.16): High resolution bTFE sagittal images of the AC for the same
volunteer.
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Texture analysis on the high resolution colonic images (figures from
7.17 to 7.21)
The spot checks conducted on the data showed a similar accuracy as for
the glucose versus mannitol study (section 6.4.3): out of the 20 colon images
checked, 18 were in accordance with the visual scoring procedure and the 2
remaining were just one score different.
Figure 7.17 shows the mean signal from the texture analysis up to the 17th
frequency for all subjects as a function of time: even if a general increase in
mean signal is visible, there is no significant difference between the drugs and
the placebo.
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Figure (7.17): (Mean ± SEM) Cumulative integral of the mean signal up to the
17th frequency.
However, the results of the texture analysis alone showed that the contrast
homogeneity ratio was significantly higher for the placebo than for the drugs
at all time points, ANOVA repeated measurements p<0.034, for the high offset
case integrated over the first 11 frequencies (figure 7.18(a)). In addition, post
hoc tests showed a significant difference between loperamide and placebo (p<
0.041) and loperamide+simethicone and placebo (p<0.042), figure 7.18.
Figures 7.19 and 7.20 show the results of the text ure analysis for the subject
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(a) (Mean ± SEM) Integral of contrast homogeneity ratio, calculated with a high
offset and for integrated over the first 11 frequencies, for all subjects as a function of
time, showing a significant reduction due to the drugs at all time points, p<O.034.
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(b) AUe for the contrast homogeneity ratio, represented in figure 7.18(a).
Figure (7.18): Integral of contrast homogeneity ratio (high offset integrated
over the 11 frequencies) for all subjects: a significant reduction was found for
the drug cases, p<O.034.
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represented in figure 7.16, with both the Gabor reconstructed images and the
contrast homogeneity ratio.
Figure 7.21 shows the weighted scores calculated with the score discrimi-
nation analysis method. It can be seen that the scores increase with time after
the mannitol drink for all conditions with a peak at 135 min and then decrease
slowly. However, there was no statistically significant difference between the
drugs and the placebo.
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Figure (7.19): Texture analysis for one subject, with high offset and integrated
up to the 11th frequency.
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(a) Gabor reconstruction of the high resolution images of the AC for the same
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(b) Integral of contrast homogeneity ratio for subject represented in figure
7.16, calculated with a high offset and integrated over the 17 frequencies.
Figure (7.20): Texture analysis for one subject, with high offset and integrated
up to the 17th frequency.
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Figure (7.21): (Mean ± SEM) Weighted scores calculated with the discrimina-
tion analysis method, section 6.4.2.
_URI (If pluuiuncologicn! intcrn'llti()IlS in tile colon 149
T2 in the ascending colon (fig 7.22)
Longer T2 values reflect a greater amount of unbound water in the AC.
Both loperamide and loperamide + simethicone reduced the T2 measured in the
ascending colon compared to placebo with a significant overall effect (p<O.OOOI
calculated on the data normalized by log transformation), figure 7.22. Post
hoc tests showed a significant difference at 90 minutes, with the placebo having
a T2 of 144±28 ms versus 79±4 ms for the loperamide and 67±6 ms for the
loperamide + simethicone (both p=O.OOI). Loperamide + simethicone also
showed a statistically significant reduction of T2 from 130±22 ms to 82±6 ms
at 180 min, with p=O.01.
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Figure (7.22): (Mean ± SEM) T2 values measured in the ascending colon as
a function of time. The data corresponding to the two baselines have been
averaged and plotted as a single point.
Net secretion (figure 7.23)
Net secretion was assessed by the formula: Net secretion = total gut water
(gastric + SBWC+ ACWC) - (ingested + basal). Figure 7.23(a) represents
the data over time: it clearly shows that there is an overall effect of the drugs
in reducing net secretion in the gut (p<0.004). This reduction was most ob-
vious during the late phase, see figure 7.23(b), both for loperamide (p<O.OI)
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and loperamide + simethicone (p<O.Ol) which decreased the amount of net
secretion in the gut by more than 25%.
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(a) (Mean ± SEM) Net secretion over time. The data corresponding to
the two baselines have been averaged and plotted as a single point.
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(b) AUe (mlxmin) for the net secretion in the late phase.
Figure (7.23): Net secretion in the gut over time and corresponding AUe in the
late phase (rnl x min).
Motility scans to monitor the wall movements in the AC
The number of colonic wall movements counted in the 3 minute motility
scan increased after the mannitol drink for both the placebo and the drug arms
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of the study. However, a bigger number of events was found in the loperamide
and loperamide + simethicone cases in the later phase. These differences are
evident in the graph 7.24 but they are not statistically different. It has to be
considered that the colonic motility is much less pronounced than small bowel
motility and the postprandial increase in colonic activity lasts usually for 2
hours. Our observation, equivalent to 3 minutes every 45 minutes, is therefore
insufficient to draw any conclusions regarding the effect of the drugs on the
motility.
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(a) (Mean ± SEM) Number of colonic wall
movements counted in 3 minutes.
(b) AUe (countsxmin) for the number of
colonic wall movements in 3 minutes in the
late phase.
Figure (7.24): Number of colonic wall movements counted in 3 minutes and
corresponding AUC.
7.3.4 Discussion and conclusion
The study showed that the optimized MRI protocol constitutes a powerful
and well tolerated method for studying the gastrointestinal tract response to
pharmacological agents. The unabsorbable mannitol solution caused secretion
in the small bowel and provided a model of secretory diarrhoea which proved to
be effective and highly accepted by the volunteers compared to other techniques
[64]. This is a second study with too short a time for measuring peristaltic
movements.
Both drug combinations significantly increased the gastric emptying rate
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of the non-nutrient meal, possibly because loperamide increases the frequency
of migrating motor complexes [69]. The increase in gastric emptying rate
led to a higher amount of water in the small bowel for the loperamide and
loperamide + simethicone in the early phase as for the aims of the study. This
mechanism may also be the reason why no significant delay in the time to
peak of the small bowel water content was found, as initially hypothesised.
The reduction in gastric air content suggests an increased tone in the wall of
the stomach. A paper from Cann et al [72]showed that loperamide accelerated
gastric emptying of a test meal as confirmed by Yeoh et al. [73]suggesting that
loperamide has an effect even in the fed state.
In the late phase, a significant reduction in the small bowel water content
was observed both for loperamide and loperamide + simethicone. One advan-
tage of MRI over intubation techniques is that we can assess total gut water.
Combining gastric, small bowel and ascending colon water and subtracting
the basal water and ingested volume we could calculate a net secretion. This
showed that mannitol does induce a net secretion of several hundred milliliters
for the first few hours and that loperamide shortens this phase. This could
be due to either stimulation of absorption or inhibition of secretion, which is
more important, could only be determined by measuring flux of labeled water
or ions.
It was also shown that loperamide and loperamide + simethicone delayed
the arrival in the ascending colon, thus increasing the orocolonic transit time
in agreement with previous studies in animals [68]. The drugs also reduced
the area under the curve of total colon water content as assessed by MRI.
Both drugs reduced the T2 of the chyme in the ascending colon. Although
the ACWC indicated a significant difference between drugs at the late phase,
this difference between drugs however was not reflected in the T2 values at
corresponding times. This was the case for two reasons, firstly the T2 data was
acquired for a single slice only and so may have missed the 'pockets' of free
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water, and secondly, if 'pockets' of free water were visible on the images these
were avoided as we were more interested in the properties of the chyme, hence
the 2 techniques measure two different parameters of the AC .
The high resolution images reflect the characteristics of the colonic con-
tents, with great detaiL The texture analysis performed on the data showed
a significant reduction in contrast homogeneity ratio due to drugs at all time
points. The weighted scores calculated with the discrimination analysis showed
a variation in time for all cases but that change was not statistically significant.
The texture analysis proved to be robust and reliable for the objective assess-
ment of colonic content structure. Compared to the T2 analysis, the texture
analysis method has the main advantage of considering the whole colon giving
information on the mixing of the contents, while for the T2 calculation only a
small more homogeneous region is taken into account.
Motility scans have also been performed but no conclusions can be drawn
because of the small time interval of observation. The duration of the scan
couldn't be increased because of time constraints of the complete study.
In conclusion, the optimised MRI sequences and analysis methods provided
a non invasive method of monitoring a number of different parameters that
provide novel insights that are likely to be useful in defining the mode of
action of new drugs coming on to market with both pro- and anti-secretory
/ motility effects. In particular, this study allowed the quantification of the
gut total free water content, thus showing that loperamide and loperamide +
simethicone reduced the net secretion after a mannitol challenge and prolonged
upper GI tract transit.
Chapter 8
Using markers to measure GI
transit
Many achievements have been made in the use of MRI for monitoring
gastrointestinal physiology but directly monitoring transit through the gut
remains an unsolved problem in MRI. Transit time, i.e. the time it takes
for a marker to pass through the entire gut, is often affected by functional
gastrointestinal disorders, therefore being able to measure the transit is a very
valuable tool for diagnosis of gastrointestinal diseases. A number of techniques
have been used in the past since the first experiment performed by Hertz et al
with bismuth [74]. Some methods use single doses of a coloured marker [75],
others use radiopaque markers [76]or non-absorbable markers [77]calculating
the transit time on the basis of the appearance of the marker in the x-ray
or in the stools. Scintigraphy [78] and manometry [79] are also used. The
main disadvantage of these techniques is the use of radiation, thus limiting the
potential use because of the exposure. In addition, some of these approaches
measure the transit through the gut using the analysis of a single stool [80],thus
limiting the estimate of the real transit time. Another important method which
has been recently developed is the use of a device called Smartpill'v (SmartPill
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Corporation, Buffalo, NY), a wireless motility capsule able to me~sure pH,
temperature and pressure. This device has been shown to be effective for the
investigation of colonic and whole-gut transit [81]but it has to be considered
that it is a very expensive technique and is subject to electrical faults.
Transit measurement with MRI would simplify patient management and
speed up patient throughput since it could be combined with other MR mea-
surements of GI function in a single examination.
Fluorinated agents have particular advantages in this application: there is
a negligible amount of fluorine in biologic tissues so no background noise is
present, 19F is the only naturally occurring isotope of fluorine and it has the
highest MR sensitivity after proton. Finally if the marker is designed to be
absorbed, then since it has a large range of chemical shifts, metabolic changes
are easily resolved in vivo. Fluorinated agents would ideally be given as an
emulsion that would mix with a meal in order to show the transit of the meal.
However, given the toxicity of fluorine compounds, the more realistic use of
encapsulated 19F will be investigated. In particular, during the course of this
work, some studies on this regard have been presented. Hahn et al. presented
some initial work on the visualization and quantification of intestinal transit
by means of real-time tracking of labelled capsules in humans [82].
This chapter provides an introduction to 19F MRI and it describes the
development of methods to use 19F MRI to study the GI transit times. The
studies presented in this chapter have already been accepted on peer-reviewed
conferences [83,84]. The use of gadolinium based compounds as an additional
marker will also be described. The main advantage of gadolinium compared to
fluorine markers is that it does not necessitate a dedicated coil, thus improving
the cost effectiveness of the method and also facilitating its translation to
standard scanners. The last sections will compare the efficacy of the two
markers.
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8.1 Fluorine MRI
19F MRI and MRS of exogenously administered agents have been used
largely in biomedical application and this is because of the particular properties
of the fluorinated agents as in vivo MR probes.
The sensitivity of 19F is 83% that of protons, at the same magnetic field
strength and molar concentration, so its MR signal is comparable to the most
sensitive nucleus. This has also a very useful practical consequence: since
IH and 19F have very similar gyromagnetic ratios b(19F)=0.94,),(lH)) their
resonance frequencies are also very close.
Naturally occurring fluorine exists entirely in one stable isotope (19F), thus
preventing any signal loss per mole of fluorine.
A particularly interesting feature of fluorine is the lack of endogenous
fluorine-containing metabolites in the soft tissues, so that the signal obtained
can be assigned exclusively to the contrast agent administered exogenously.
The intensity of the 19F MR signal will then be proportional to the amount
of contrast agent present in the GI tract. By monitoring the change in the in-
tensity level, it is possible to track the movement of the contrast agent inside
the gut noninvasively.
Another aspect to take into account is that a fluorine nucleus in a molecule
is on average surrounded by 9 electrons, rather than a single electron as is the
case with hydrogen: this implies that the range of fluorine chemical shifts is
much higher for fluorine than hydrogen. For example, a protein in which all
tryptophan residues have been replaced by a fluorinated tryptophan analog
will typically exhibit a resolved signal in its fluorine NMR spectrum for each
tryptophan position of the sequence, while the proton spectrum of the same
tryptophan residues in the native protein will be appreciably overlapped. In
other words, while the chemical shift for proton is up to 20 ppm, the range
for fluorine may exceed 300 ppm [85]. Therefore, metabolic changes are likely
to produce large chemical shift changes that can be easily resolved in vivo.
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However this can also cause of severe chemical shift artifacts that may be
overcome by exciting only a narrow chemical shift range containing one or a
small group of resonances [86]. Even if this approach is effective, it is necessary
to consider that it suppresses the signal available from the fluorine atoms in
the molecule.
Despite their excellent properties as contrast agents, fluorinated compounds
have not been widely used for human studies. This is primarily due to the
difficulties related to finding an efficient and safe agent for human use.
An overview of the properties of fluorine containing compounds is given in
the following section.
8.2 Compounds for human 19F MRI
Fluorine containing chemicals have excellent characteristics for the use as
contrast agents in MRI but there are several aspects to consider in particular
regarding safety. As the most electronegative of all elements, fluorine has very
special properties [87]. It forms compounds with other elements very easily
and it is very toxic in the gas state. Therefore a stable fluorinated molecule
must be used as a contrast agent. In order to get a good NMR signal the
density of the fluorine atoms should be as high as possible and the chemical
groups containing fluorine should be chemically equivalent, i.e. the fluorine
atoms should have an identical microscopic environment so to have only one
peak in the NMR spectrum.
The most common fluorine compounds for in vivo use are called perfluoro-
carbons (PFCs) because they are composed of carbon and fluorine atoms only.
PFCs can be arranged in linear, cyclic or polycyclic shape and can change
their properties depending on the functional group attached.
The physicochemical and biologic aspects of the PFCs are presented in
detail in the following sections.
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8.2.1 Perfluorocarbons
Physicochemical aspects
Fluorine is a relatively small atom but is significantly larger than hydrogen
(van der Waals radius 1.47 A vs 1.20 A). This has two main consequences:
firstly, the perfluoroalkyl (F-alkyl) chains (CnF2n+1) are more bulky than the
hydrogenated ones (cross sections: 30 A2 vs 20 A2), secondly, there is the
greater stiffness of perfluorinated chains. Besides, because there is the over-
lapping of the orbitals, the C-F bond is the most stable single bond found in
organic chemistry (",,485kJ moZ-1 as compared to ",,425kJ molr" for a stan-
dard C-H bond). The bond strength further increases with increasing fluorine
substitution. As a consequence, fluorocarbons are thermally and chemically
very stable. They are also biologically inert. Another characteristic is that the
dense electron cloud of the fluorine atoms results in a repellent sheath that
protects the perfluorinated chain against the approach of reagents.
Fluorine is also very difficult to polarize and for this reason there are low
van der Waals interactions between fluorinated chains and low cohesive energy
densities in liquid fluorocarbons. The most valuable properties of fluorocarbons
are consequences of these low interactions. These properties are: very low
surface tensions, excellent spreading properties, high fluidity, low dielectric
constant, high vapor pressure, high compressibilities and high gas solubilities.
The effective fluidity and the spreading properties allow PFCs' molecules to
spread evenly over a surface. This can be used, for example, to form a barrier
in the lungs thus preventing further growth of a malignant disorder [88].
There are also other fluorocarbon's properties which are important in the
biomedical field: high density, antifriction properties and magnetic suscepti-
bility values close to that of water.
The typical high hydrophobicity of the fluorine atoms is due to the com-
bined effect of the larger surface of the fluorinated chains (the hydrophobic
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effect of the chain is roughly proportional to its area in contact wi~h water)
and the low polarizability of the fluorine atoms. Perfluorinated chains have two
contradictory properties: they are extremely hydrophobic but also lipophobic
and this means that they repel water and fat at the same time. The low water
solubility of PFCs leads to their slow diffusion and a long stay at the target site
in their natural form. This can be of obstacle for their medical applications
and their preparation as water emulsions has been proposed [89].
One of fluorinated compounds most important properties is their oxygen
affinity, discovered in the 1960swhen mice and cats were shown to survive com-
plete immersion in oxygenated PFCs, followed by long-term survival without
apparent ill-effects [90]. However, it was not until the 1980s that the chemical
inertness of PFCs and, more specifically, their inability to be metabolized were
fully documented.
Biological aspects
The biocompatibility of liquid fluorocarbons is well documented as a result
of the intensive efforts that are being devoted to developing materials for liquid
ventilation, oxygen delivery and imaging [91,92]. Fluorocarbons intended for
biomedical uses can be linear or cyclic, and may contain hydrogen, halogen,
or nitrogen atoms. Although several hundreds of such compounds have been
screened over the past twenty years, very few were found to meet the appropri-
ate physicochemical and biological criteria for in vivo oxygen delivery. These
criteria include high purity, rapid excretion, ability to form stable emulsions,
absence of clinically significant side-effects, and at large scale, cost-effective
industrial feasibility. Even at large doses, most fluorocarbons appear to be
innocuous and physiologically inactive [93]. One exception is the volatile per-
fluoroisobutylene, (CF3hCF = CF2, which is extremely reactive and toxic.
In particular, fluorocarbons do not show any of the side effects that have been
reported for hemoglobin-based oxygen carriers and their pharmacology is sim-
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pler and better understood. It is essential for fluorocarbons for biomedical uses
to be thoroughly purified in order to remove any toxic impurities. There is
no evidence of metabolism for fluorocarbons. Also, for intravascular use, flu-
orocarbons need to be excreted rapidly. The fluorocarbon emulsion droplets
are cleared from the circulation by macrophages, and the fluorocarbon is tem-
porarily stored in the liver, spleen and bone marrow. The fluorocarbon is then
slowly reintroduced into the circulation in dissolved form by lipid carriers, at a
rate that depends primarily on molecular weight and lipophilicity, eventually
released through the pulmonary capillary bed and excreted unchanged as a
vapor with the expired air.
The potential of highly fluorinated molecular materials in medicine
and biology
PFCs find many applications in medicine and biology thanks to the prop-
erties just discussed. For example, oxygen delivery can be enhanced using
a fluorocarbon emulsion and that is of vital importance when a patient's
hemoglobin level is declining. Such emulsions are expected, when combined
with blood transfusion strategies, to playa major role in surgery by increasing
safety at low hematocrits and avoiding or reducing donor blood transfusions.
Fluor6carbon-based oxygen carriers should also prove beneficial in trauma sit-
uations, especially during the prehospital "golden hour" period which has a
large impact on outcome for the patient and during which blood is usually
not available, or during which transfused blood has not yet reached its full
effectiveness.
Fluorocarbon-in-water oxygen-delivering emulsions also have potential for
the treatment of conditions of restricted blood flow such as those which occur
in myocardial infarction or stroke; for the prevention of ischemia during the
coronary angioplasty procedure; to protect the heart during cardiopulmonary
bypass surgery; during extracorporeal circulation; to improve oxygen deliv-
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ery to certain tumors, making the tumor more responsive to radiation and
chemotherapy; and for organ and tissue preservation. Diverse gaseous mi-
crobubbles, generated or stabilized by :fluorocarbons, are in advanced stages of
development as contrast agents for ultrasound imaging.
In addition to the so-called "blood substitutes", a neat :fluorocarbon may
also be used for the treatment of the respiratory distress syndrome by liquid
ventilation. In particular, per:fluorooctyl bromide (PFOB, CSF17Br, also called
Per:flubron) has been investigated for the treatment of this severe condition
with high mortality for which no satisfactory treatment is available yet [87].
In comparison with ventilation with a gas, liquid ventilation eliminates the
gas-liquid interface, thus reducing the alveolar surface tension and leading to
improved lung compliance and lung oxygenation in patients with severe respi-
ratory failure. Due to its low surface tension, PFOB is uniformly distributed
and reaches gas exchange regions at low insufflation pressures, which is par-
ticularly valuable in case of insufficiency. A detailed description of PFOB will
be presented in section 8.2.2.
Drugs for absorption
The measurement of drug concentrations in an organ for evaluation of dis-
tribution volumes was previously only feasible in animals because it requires
biopsy. NMR has been shown to provide a method to estimate local concen-
trations of some compounds in humans in vivo, in a repeatable non invasive
manner. Fluorine magnetic resonance spectroscopy (MRS) has been applied
to estimate the characteristics of some drugs which have :fluorineatoms in their
active form in humans in vivo [94].
Compared to a simple aqueous solution, the relaxation properties of a
drug/compound in vivo will be influenced by the biophysical and chemical
makeup of the microenvironment within which it resides. Many fundamental
biological processes, including cell signaling and enzyme action, are acutely
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sensitive to the biophysical state of the microenvironment. There is, therefore,
a considerable incentive in developing methodologies that could non-invasively
assess such biophysical processes in vivo.
8.2.2 Potential 19F markers for GI transit
Biocompatibility and non-toxicity are the most important considerations
in choosing a fluorine agent for imaging the gastrointestinal tract in humans.
It is also necessary to maximize the NMR signal by choosing molecules with
high density of fluorine atoms and possibly a single resonant peak.
Most PFCs are very inert and safe. However in the multiplicity of PFCs
available, not many of them can be used for biological studies. The main
reasons for this is because of some inconveniences like instability, split 19F
signals and excessive retention times of the agents within the organs [95]. Fur-
thermore even if most PFCs are innocuous and inert, the main concern about
using them for biological applications is the potential presence of impurities
which need to be checked for non-toxicity. This implies a very expensive and
time consuming process to both perform toxicology tests and to obtain the
permission to use those compounds in humans.
An overview of the potential19F markers to be used in vivo is given below.
1. Perftuorooctyl-bromide
As with other PFCs, perfluorooctylbromide (also called perflubron or
PFOB) has no hydrogen atoms, is chemically inert and has a low surface
tension. It can easily be emulsified with egg yolk phospholipids and is
rapidly excreted from the body, especially because of the presence of the
single bromine atom on the terminal carbon which provides a very high
lipophilicity, see figure 8.1. The retention half-time is about 4 days [96].
Even if PFOB is immiscible with aqueous systems, including blood, it
can be safely injected into the bloodstream as an emulsion. This is
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why it is used as temporary, intravascular respiratory gas-carrier and tis-
sue oxygenating fluid ("blood substitutes"). In particular, a commercial
perflubron-based formulation, Oxygent™ 1 has been widely used and
it has been approved for clinical use, but unfortunately it is no longer
produced.
PFOB shows a complex 19F MR spectrum because of nonequivalent
chemical environments for the individual fluorine atoms within the molec-
ular configuration. Therefore a chemically selective imaging method that
excites only one of those peaks is needed, thus degrading the SNR. Lee
et al. [86]developed a reduced-bandwidth imaging method for two main
aims: firstly, in order to simplify the misregistration problems due to the
complicated spectrum by reducing the receiver bandwidth and secondly
to improve the SNR increasing the data acquisition time.
PFOB is a clear, inert liquid with no taste and no odour and has no side
effects when ingested orally. It has also been used as negative contrast
agent for proton MRI in the gastrointestinal tract [97-99]. Since it lacks
hydrogen, PFOB creates no proton MR signal, therefore like air it creates
a signal void both in T1- and T2-weighted proton images. This mechanism
is expected to be equally effective at all field strengths and with all pulse
sequences. These studies in rats and in man show that PFOB has great
potential for use as oral MR contrast agent. Since it is immiscible with
water, it layers out in water and so it never mixes with the bowel contents.
Besides, because it has a magnetic susceptibility similar to that of tissues,
it does not influence the relaxation properties of bowel or adjacent tissue
protons.
Mattrey et al. [97] in 1987 presented a human study where two volun-
teers were given up to 525 ml of PFOB to swallow, thus achieving the
lOxygent™ is developed by the Alliance Pharmaceutical Corporation in San Diego. It
ia an intravascular oxygen carrier in clinical development as a temporary "blood substitute"
to reduce or eliminate the need for donor blood transfusions during surgery.
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complete filling of the small bowel. In the stomach, the PFOB allowed
the identification of the gastric wall. PFOB was very well tolerated: one
subject had an oily sensation in the mouth and neither of the volunteers
had any gastrointestinal symptoms. PFOB was then excreted in liquid
form in the stool within 18 hours of ingestion. Therefore, PFOB proved
to be safe and effective.
Another paper from Mattrey et al. [100]shows the assessment of PFOB
MR imaging of the abdomen in a multicenter trial. A total of 127 subjects
were imaged before and after the ingestion of PFOB, showing that it
increased the bowel darkening in over 92% of subjects with different
sequences and field strengths. Also in this study, PFOB proved to be
safe and its efficacy was unaffected by pulse sequences or magnetic field
strengths. The subject were given up to 1,000 ml of perflubron which
was mostly eliminated in the first few hours with no side effects.
The use of perflubron as a gastrointestinal agent for MR imaging of
patients with Crohn disease was the object of a study presented by An-
derson et al. [98]. 12 subjects were imaged before and after the ingestion
of 600 ml of perflubron without bowel preparation or fasting instructions.
PFOB was shown to effectively mark the bowel in patients with Crohn
disease and to improve the clarity of bowel wall visualization when used
in conjunction with glucagon. However, there was no significant increase
in the detection of bowel wall abnormalities related to Crohn disease.
Among various applications of PFOB for clinical imaging, Pisani et al.
[101]showed the characterization of polymeric nano/rnicrocapsules filled
with a single core of liquid PFCs such as PFOB. These could be used
to increase the stability of ultrasound contrast agents in order to enable
the qualitative and quantitative evaluation of blood flow. It would also
be possible to use ultrasound to trigger the drug release from contrast
agents encapsulating a drug, thus opening a great potential for targeted
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Figure (8.1): Chemical structure of perfiuorooctyl bromide (PFOB,
CSF17Br).
treatment.
The use of PFOB emulsions as delivery media for hyperpolarized xenon
has also been investigated [102], showing its potential in animal models
for in vivo magnetic resonance applications.
Sotak et al. [103] measured the Tl and T2 relaxation times of PFOB:
Tl varied approximately between 1.1 and 1.2 s, while T2 shows a strong
dependence on the molecular location of the fluorine atoms, see figure 8.1.
For PFOB, the terminal -C F2Br and -C F3 groups display considerably
longer T2 relaxation times than the -CF2- groups in the chain.
In conclusion, PFOB has several advantages over competing gastroin-
testinal contrast agents. Its low viscosity results in rapid bowel transit
even in the absence of active peristalsis. It is immiscible with water and
therefore resistant to concentration-dependent signal changes. The in-
traluminal signal void produced by perflubron causes no artifact increase
and it also produces little or no appreciable magnetic susceptibility art i-
fact.
More importantly, PFOB has been approved for clinical use by the U.S.
Food and Drug Administration.
Therefore our interest regarding its use has been increasing and it has
been used for a wide range of in vitro and in vivo experiments. The
certification for a complete absence of impurities still remains as a major
concern and for this reason efforts have been focused on finding a safe
way to encapsulate the PFOB for delivery to subjects.
Using markers to J)WI1S1ll'C GT treusit 166
o
H H
I
CI :J
CHa
0<::
,
,
,
'eaOH
Figure (8.2): Chemical structure of flucloxacillin (C19H16ClF N3N a05S)
[104].
2. Flucloxacillin
Flucloxacillin belongs to a group of antibiotics called penicillins and it
is used to treat infections caused by bacteria. Flucloxacillin works by
interfering with the ability of bacteria to form cell walls, which are vital
for their survival. They keep unwanted substances from entering their
cells and stop the contents of their cells from leaking out. Flucloxacillin
impairs the bonds that hold the bacterial cell wall together. This allows
holes to appear in the cell walls and kills the bacteria. Flucloxacillin
differs from other penicillin antibiotics and is used primarily to treat
infections caused by bacteria that are resistant to other penicillin antibi-
otics. It is a useful fluorine compound because it can be easily dissolved
in water and used for MRI and MRS.
Interesting work has been done by Dzik-Jurasz et al. in 2004 [104] in
order to examine microenvironmental factors likely to influence the lon-
gitudinal relaxation time of MR visible drugs or compound in vivo at
1.5 T. In particular the influence of paramagnetic MR contrast agent
on the longitudinal relaxation time of flucloxacillin using 19F MRS was
assessed.
The chemical structure of flucloxacillin is showed in figure 8.2. It has
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to be said that the fluorine concentration in the drug is very low, es-
pecially compared to other compounds like perfluoro-compound FC-43
and PFOB (figures 8.2, 8.3 and 8.1 respectively) and this is the main
reason why flucloxacillin cannot be used in vivo with whole body scan-
ners.
3. Perfluorotributylamine, FC- 43
This fluorine compound has been used for in vitro tests because of its
high NMR signal. Since it is toxic, it can just be used for animal studies
or in humans if safely encapsulated. The molecular structure is given in
figure 8.3.
4. Perfluorononane
The use of perfluorononane as a contrast agent in vivo has been presented
from Schwarz et al. [105,106]. In their work 19F MR images of the
GI tract of mice and man have been acquired in combination with 1H
MR images, which provided anatomical information. Perfluorononane,
structurally similar to PFOB, was in one case ingested [106] and in the
other case [105]included in capsules for transit studies in man. In both
studies Perfluorononane with a nominal purity of 97% was purchased
from Aldrich Chemical Co. (Switzerland). Perfluorononane, C9F20 see
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Figure (8.3): Chemical structure of perfluorotributylamine FC-43
(C12F27N).
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Figure (8.4): Chemical structure of perfluorononane (C9F20).
figure 8.4, is a perfluorinated linear alkane with a molecular weight of
488 Da. It is a colorless, odorless liquid with low surface tension and
high specific density. It has a magnetic susceptibility approaching that
of biological tissues. Since perfluorononane is immiscible with water, no
dilution and accompanying signal loss occur even when the contrast agent
is in contact with the intraluminal contents of the GI tract. It is neither
resorbed nor metabolized and being nontoxic it can also be used for the
localization of pharmaceutical capsule disintegration to be evaluated in
situ. Furthermore, perfluorononane exhibits long Tl and T2 relaxation
times in vitro, which are comparable to those of water in biological tissue.
Since perfluorononane has a low viscosity and surface tension, it passes
through the gut faster than the contents: on one hand this is useful
to assess morphologic and pathologic details but this also limits its use
as a marker for the transit. This could be overcome controlling the
intestinal movements by means of anesthesia or lack of food input. Since
perfluorononane is neither resorbed nor metabolized, the only way it can
leave the body is by excretion thus making it an ideal marker for the
GI tract. The main concern about using it for biological application is
therefore the presence of toxic impurities.
5. Hexajluorobenzene
The main advantage of hexafl.uorobenzene (HFB) is that the fluorine
atoms are all magnetically equivalent and thus a single resonance is
observed providing optimal sensitivity and avoiding the need for selec-
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Figure (8.5): Chemical structure of hexafluorobenzene(C6F6).
tive excitation-observation regimens associated with 19F MRI of others
PFCs. Because it is highly volatile, it clears from the body rapidly, with
a complete clearance from the body within 24 hours. This has to be
considered if quantitative measurements are needed. Mason et al. [107]
used HFB as a sensitive 19F NMR indicator of tumor oxygenation based
on direct intratumor injection in animals. This approach was based on
the linear relationship existing between the 19F spin-lattice relaxation
rate (R1=1/T1) of perfluorocarbons and partial oxygen pressure (p02),
described by Parhami and Fung in 1983 [108]. The determination of a
tumor p02 by means of non invasive method is very important because
it is a fundamental parameter for the effectiveness of various therapies.
HFB proved to be considerably more sensitive to changes in p02 than
other molecules used and it also has the lowest sensitivity to changes in
temperature. The proton and the fluorine MR images were compared to
indicate the distribution of the fluorine compound in the tumor.
Although known to be toxic, HFB was used in sealed minicapsules for the
investigation in a rat model by Christmann et al. [109]. The simultaneous
visualization of HFB-Iabelled microcapsules and anatomical structures of
the GI tract in rats was investigated. In proton MRI, fluorine labelled
capsules are dark while the GI contents are bright. On the contrary,
on the fluorine MRI only the fluorine filled capsule is displayed. The
superimposition of the two images gives an explicit localization of the
oral dosage forms even in the distal parts of the GI tract.
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Figure (8.6): Chemical structure of Perfiuoro-15-crown-5-ether (15C5).
o
Figure (8.7): Chemical structure of 5-Fluorouracil (5FU).
6. Perftuoro-15-crown-5-ether (15e5)
Perfluoro-15-crown-5-ether (15C5), figure 8.6, is an excellent contrast
agent for MRI because its NMR spectrum has a single narrow resonance
and since it has a large number of equivalent fluorine atoms per molecule,
it has a very high sensitivity. 15C5 has been used by Ahrens et al. [110]to
track cells in vivo. The fluorine-labelled cells were injected intravenously
or into tissue in mice and then tracked using 19F-MRI.
Previously, encapsulated 15C5 has also been used for MRI to measure
the partial pressure of oxygen in tissue [111].
Unfortunately, despite the successful studies on animals, 15C5 cannot be
used in humans because of its high clearance rate from the body, which
is presumed to be through the liver, spleen and lungs.
7. 5-Fluorouracil (5FU)
5-Fluorouracil (5FU), figure 8.7, after several decades of use, is still one
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of the most widely used agents for the treatment of several cancers espe-
cially of the gastrointestinal tract, breast and ovary. The metabolism of
5FU has been extensively studied and monitored in in vivo studies with
MR [112].
Dzik-Jurasz et al. [113] investigated with 19F MRS the distribution of
hepatobiliary fluorine signals arising from the catabolism of 5-fluorouracil
(5FU) in nine patients.
More recently, McIntyre et al. [114]examined a total of 32 subjects with
colorectal cancer undergoing 5FU treatment in a 1.5 T MRI scanner.
They showed how MRS can distinguish the parent drug from its active
and inactive metabolites in vivo, with a good time resolution for the
analysis of the drug metabolism.
Table 8.1 summarizes the names and references for the potential compounds
to be used in vivo. In this work, in vitro tests have been performed with PFOB,
flucloxacillin and FC-43. However for the in vivo experiments PFOB has been
chosen because of its favorable properties, having a high density fluorine atoms
and possibly a single peak. In particular, PFOB will be encapsulated for GI
transit measurements.
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8.3 In vitro tests of fluorinated compounds
8.3.1 High resolution MRS
Preliminary in vitro tests of fluorinated compounds were carried out with
a Bruker AV(II) 600 NMR spectrometer operating at a fluorine detection fre-
quency of 564MHz. Different samples have been prepared with the compounds
presented in section 8.2.1:
• Flucloxacillin sodium
This compound has been purchased in powder for solution for injection so
it has been very easy to prepare a solution where the drug was completely
dissolved. In our case a test bottle was filled with 20 ml of distilled water
in which 20 mg of drug has been dissolved: about 570 j.tlof this solution
was put in a test tube suitable to be inserted in the spectrometer .
• Perftuorooctyl bromide (PFOB)
PFOB was purchased from Apollo Scientific and tested neat in an organic
solvent (CDCI3, deuterated chloroform) and in an aqueous emulsiorr' for
which 10 ml of PFOB were dispersed in 100 ml of deionized water. The
PFOB was tested as an emulsion in this first in vitro test because the
first aim was to try and verify if the PFOB could be diluted and used
for ingestion. In this case, PFOB would have provided an easy way of
measuring the transit of meals in the gastrointestinal tract. For this
reason, in order to stabilize the emulsion, 1 g of surfactant (Tween 20,
Sigma-Aldrich) has been added. An Ultraturrax emulsifier was used for
10 minutes in order to get a droplet size of 8 j.tm. The spectra of PFOB
2An emulsion is a mixture of two immiscible substances: one substance (the dispersed
phase) is dispersed in the other (the continuous phase). Whether an emulsion turns into
a water-in-oil emulsion or an oil-in-water emulsion depends on the volume fraction of both
phases and on the type of emulsifier. The emulsifier is a substance which stabilizes an
emulsion, frequently a surfactant.
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in CDCl3 and in aqueous emulsion are reported in figure 8.9 with the
assignments of the peaks according to Shukla et aL [117].
• FC-43
A 1ml test tube containing neat perfluoro-compound FC-43 (Acros Or-
ganics) was inserted in the spectrometer in order to acquire the spectrum
of the compound (the chemical structure is shown in figure 8.3).
High resolution spectra have been acquired for these fluorine compounds in
order to compare the relative chemical shifts and the signal amplitudes. Figure
8.8 shows the spectra obtained: the signal to noise ratio is very high because
of the use of the high resolution spectrometer. The spectrum obtained for flu-
cloxacillin sodium is from -100 and -120 ppm and it shows a very sharp single
line at about -110 ppm. This result in particular has been very interesting
because it states that the compound is very pure and the neat spectrum could
very useful for future possible applications even if the density of fluorine atoms
is very low, thus limiting its use in humans because the amount needed would
be unsafe. The spectra of the tri-fluoroacetic acid and of the sodium fluoride
have been added as a reference. Trifluoroacetate is often used as a chem-
ical shift reference, but 19F NMR doesn't have a single generally accepted
reference compound. For in vivo applications, the reference is inevitably an
external reference compound with the associated problems of magnetic sus-
ceptibility differences between sample and reference. This can lead to errors of
several ppm, making in vivo assignments of resonances difficult. Although the
total chemical shift range spans more than 300 ppm, spectral overlap is a sig-
nificant problem as many relevant compounds have almost identical chemical
environments (and almost the same chemical shift).
FluorineMltf of these compounds with a high resolution spectrometer has
been very useful to see the characteristics of each spectrum, hence helping
to choose the optimal compound to be used in vivo. Flucloxacillin proved to
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Figure (8.8): Illustration of range of 19F NMR chemical shifts obtained with
a Bruker spectrometer operating at a frequency of 564 MHz. The spectra are
showed together in order to compare the range of ppm they occupy, the ampli-
tudes are not referred to the y axis showed. The spectra of the Tri-fluoroacetic
acid and of the Sodium Fluoride have been added as a reference.
o
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Figure (8.9): Spectrum of the PFOB at acquired with a Bruker spectrometer
operating at a frequency of 564 MHz in an organic solvent, CDCl3 (top) and in
aqueous emulsion (bottom). Peaks have been assigned according to Shukla et
al. [117].
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be unable to provide enough signal on the Philips 3T scanner so the spectra
of PFOB and FC-43 were compared. These two fluorine compounds have a
very similar spectrum that provide a very good SNR in both cases. PFOB
has been chosen for our studies because it gives a very good signal as the
other compound but it also has been approved by the U.S. Food and Drug
Administration thanks to its bio-compatibility and its inertness, as explained
in section 8.2.2.
As Lee et al. reported in their work [86], PFOB exhibits a very complex
MR spectrum because of the nonequivalent chemical environments for the
individual fluorine atoms within the molecular configuration, so that PFOB
has multiple spectral peaks, as shown in figure 8.9. This complicated spectrum
has the obvious disadvantage of producing chemical shift artifacts that lead to
misregistration in MRI. In particular, because of this chemical shift dispersion,
replicated images of the PFOB distribution appear along the readout direction.
In order to avoid these effects, a chemically selective method to excite only the
o peak in figure 8.9 has been used because it gives the strongest resonance and
it is well separated from the others.
The acquisition bandwidth was chosen narrow enough to exclude the other
resonances (434 Hz). This approach only uses a fraction of the total signal
because it considers only three out of the 17 fluorine nuclei of the molecule,
thus reducing the SNR. However, since there is no endogenous fluorine sig-
nal, the CNR is relatively high thus making this choice a good compromise
between a measurable signal and an easy imaging protocol. Other approaches
could be considered to solve the chemical shift dispersion, such as the chemical
shift imaging (CSI), in which the localization is performed by phase encoding
only. In that case, the signal from the 17 nuclei can be collected without the
appearance of replicated images thus increasing the SNR but it would require
a longer acquisition time and the use of strong gradients to reduce the artifact
from the two resonant groups CF2 and CF2Br.
-=
20 10 o
Frequency (ppm)
-10 -20
Figure (8.10): Spectra of the PFOB at 3T for the calculation of T1. The triflu-
oromethyl CF3 group has been arbitrarily assigned at 0 ppm on spectrum. The
data were acquired by incrementing the TE value from 100 ms to 4850 ms in
250 ms steps for a total of 20 TIs.
8.3.2 t: and T2 of PFOB
The relaxation times of PFOB have been measured using two PRESS se-
quences, based on the largest peak of the spectrum i.e. with the trifluoromethyl
C F3 group assigned at 0 ppm. The measurements were performed at room
temperature (20°C), run overnight to acquire a great number of averages.
For the T', measurement of PFOB, the data were acquired by incrementing
the TI value from 100 ms to 4850 ms in 250 ms steps for a total of 20 TIs
(figure 8.10). The TR was set at 10000 ms and TE equal to 28 ms. The
number of averages was set at 128.
T2 was measured acquiring spectra with different TEs, with a starting value
of 50 ms and spacing 50 ms for a total of 10 spectra. The NSA was set at 512,
TR = 3000 ms and TE = 50 ms.
The analysis of the spectra was performed with jMRUI software: the areas
of the peaks were plotted versus the TIs and TEs respectively for the Tl and
the T2 calculation and the curves were fitted according to equations 2.14 and
2.16.
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The Tl for the PFOB was found to be 1278ms, confirming the value found
by Sotak et al [103]at 2 T. T2 of the PFOB resulted equal to 398 ms.
The relatively long Tl relaxation time results in long image acquisition time
and short T2 relaxation times results in MR signal attenuation, both of which
has to be considered when performing 19F MRI.
8.3.3 Susceptibility of PFOB
The evaluation of the susceptibility of the fluorine agent is fundamental
prior to the use of the compound in vivo. PFOB is considerably more dense
than water (1.93 g/rnl}, In particular, if PFOB has to be encapsulated for
transit studies in the GI tract it is important that its susceptibility is not too
different from water or it will cause large field gradients and the signal from
the agent may be dephased. In order to measure the susceptibility of PFOB,
the sample was placed in a medium-walled NMR tube of 20 mm diameter,
which was inserted in a collar on the top of a 500 ml spherical flask full of
water. This phantom was placed in the centre of the bore with the long axis
of the tube perpendicular to the main magnetic field. An FFE sequence was
used to acquire phase images in the coronal plane (TR=100 ms, rec. res. =
0.48 mm x 0.48 mm, 10 slices of 1 mm thickness), for TE =10, 25 and 50 ms
in order to calculate the field shift from the relation ¢="( ~B~T. A second
phase map was acquired after replacing the sample with water without moving
the phantom by using a cannula and a syringe to pull the PFOB out and then
pouring the water. The difference between the two phase maps is due to the
difference in susceptibility between PFOB and water, and susceptibility can
be calculated from:
(8.1)
where R is the radius of the tube, r is the distance from the centre of the
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tube, () is the angle around the coronal plane (defined relatively to Eo) and
.6.X is the susceptibility difference between the PFOB and the water.
Figure 8.11 shows the images used to calculate the susceptibility of the
PFOB which was found to be 7.0 ± 0.3 10-7, units relative to water. The
images of the phantom also show that for higher TEs, the artefacts near the
test tube worsens, due to the presence of the glass.
TE (ms) 10 25 50
PFOB
in water
Water
in water
Figure (8.11): Phase images for PFOB and water at different TEs
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8.4 19F coil characterisation
This section reports a series of tests performed on the 19F coil presented
in chapter 4 prior to its use in vivo. These tests include a heating test of the
coil, the compatibility of the 19F coil with the 1H body coil, maps for the B1
and the sensitivity of the coil and also a test to verify the loading of the coil
in in vivo conditions.
8.4.1 Methods
Different phantoms have been imaged on a 3T Philips Achieva scanner,
using the body coil and the 19F coil for the proton and the fluorine images
respectively. A standard FFE sequence (TR=1000 ms, 2.4 mm x 2.4 mm
voxel size, 1 slice of 50 mm thickness) was used to acquire images of the
PFOB. Figure 8.12 shows the 2 experimental setups for the tests: the phantom
8.12(a) has been used for the sensitivity map of 19F while the cylindrical water
phantom 8.12(b) has been used for the other tests.
+ Z
,
,
,
,
-.
X
(a) Schematic illustration of the grid used for
the sensitivity map. 2 ml balls have been filled
with PFOB.
(b) 20 em diameter water test object designed
for surface coils with curved surface.
Figure (8.12): Phantoms used for the 19F coil tests.
For the heating test a gradient echo sequence was repeated operating at
100% of the allowed body SAR for 5.5 minutes to test if any RF coupling
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between the body coil and the 19F coil would cause any heating. The spec-
ification is that surfaces that could be touched must not heat above 41°C,
however the aim should be to see minimal temperature rise, i.e. smaller than
5 degrees. An optical temperature sensor (courtesy os PulseTeq) was used to
measure the temperature change.
The spatial distribution of the Bl field has been tested for homogeneity.
Since large volumes of PFOB were not available, a 20 em NMR tube was
scanned in 3 different positions in the FOV. The FFE sequence was acquired
at multiple flip angles a (a= 40°, 70°, 90°, 110°, 130° and 150°) and the
images have been analyzed by a Matlab program which performs the fit of the
experimental data to the theoretical equation
8= 80(sina) (8.2)
where 8 is the signal obtained and a is the flip angle which, together with
80, is the parameter of the fitting.
The effect of loading the coil with a human being has also been investigated
by using a test tube filled with PFOB positioned between the legs of the
subject, inside the 3T scanner bore. The two surface coils were positioned one
at top and one below the legs and secured with straps.
8.4.2 Results
The gradient echo images shown in figure 8.13 show that the presence of the
19F coil doesn't affect the image quality: the image SNR and uniformity close
to the copper tracks of the 19F coil were not visibly changed by the presence
of the 19F coil, which was plugged in and in position during the proton scan
with the body coil.
The high SAR scans showed no detectable heating in the coil and a change
less than 2°C on the cable foam, which is acceptable.
Figure (8.13): Gradient echo images of a water phantom positioned between
the two 19F coils, acquired with the body coil. The 19F coil doesn't affect the
quality of the lH images.
z
x
y
Figure (8.14): Three-dimensional illustration of the grid used for the sensitivity
map. The size and the colour of the balls represent the sensitivity according to
the legend.
The results for the sensitivity test are shown in figure 8.14 which represents
the signal obtained from each sample in the corresponding position in the FOV
shown in figure 8.12(a). The size of the circle scales with the signal and the
colour corresponds to the intensity level. From the figure we can deduce that
with our coil we can get good signal from a depth of up to 12.5 em, which is
sufficient for most subjects considering that the two coils are positioned one
at the front of the body and the other on the back as shown in the figure 4.5.
Figure 8.15 shows the results for the B1 map in the three positions in the
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FOV. The B1 fields are homogeneous over the full volume of the sample even
if it has to be considered that a 20 em distance between the two coils is not
always in accordance with the in vivo conditions.
Figure (8.15): Spatial distribution of the B1 magnetic fieldgenerated by the RF
pulse on the transverse plane: A left lateral, B central and C right lateral.
The fluorine coil showed a good performance when loaded with a human
being. The fluorine image obtained has been superimposed on the proton one
and it is represented in figure 8.16, showing a very high SNR. This first in vivo
result has been very successful, thus laying the foundations for future studies
in the gut.
Figure (8.16): Overlay of the proton and the fluorine images in vivo: the 19F
intensity of the PFOB is displayed in green and the 1H images are shown in
gray scale.
Using markers to nreasure (;I transit 184
8.5 Capsules for GI transit studies
As previously mentioned, the measurement of transit time ofmarkers through
the gastrointestinal tract would be very useful for the diagnosis of functional
gastrointestinal diseases. For this reason the development of a safe noninvasive
technique to estimate the transit time in the gut has been investigated. In par-
ticular, fluorine compounds were initially thought to be ingested together with
meals to measure the transit of such meal in the gut. As previously shown,
PFOB is suitable for being used in aqueous emulsions, and this consisted in our
first approach for the gut transit measurement. However, during the course
of this thesis, the PFOB which was previously used in vivo [97,100] was no
longer available on the market. The only available source of PFOB consisted in
chemical industries as Apollo Scientific, which don't guarantee the use of com-
pounds for human use. For this reason, even if PFOB is FDA approved, the
encapsulation of the compound was considered. In particular, different types
of capsules have been tested for safety and effectiveness. The development of
the whole system for GI transit times measurement using labelled capsules is
described.
8.5.1 Methods
Different types of capsules have been prepared and tested for in vivo use.
In particular, gelatine capsules and plastic capsules were tested for stability in
acidic environment and for leakage.
Gelatine capsules
Some batches of 0 sized gelatine capsules were dip-coated in Eudragit S100,
a pH-sensitive coating polymer commonly used for delivery of drug molecules
to colon for the treatment of colon cancer. A 200 ml solution of Eudragit 8100
was made up from 26 g of Eudragit S100 (Degussa, Rohm Pharma Polymers)
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powder, provided by the Medical Physics Department, Queens Medical Cen-
tre, Nottingham, dissolved in 80 ml of Acetone and 120 ml of Isopropanol at
37° Celsius, according to the Medical Physics Department Clinical Procedures
Manual. Since Eudragit S100 is designed for delivery in the colon, i.e. it dis-
solves at pH=7.0, it has been necessary to perform multiple coatings, from 1
to 30 layers, in order to avoid dissolution in the whole GI tract.
Plastic capsules
Plastic capsules have been manufactured in our mechanical workshop with
the same shape as the 0 sized gelatine capsules. The material was Poly-
oxymethylene (commonly referred to as POM and also known as polyacetal
or polyformaldehyde), chosen because of its favorable properties: its chemical
stability and inertness towards biological material is comparable to Teflon but
it is far more rigid and thus easier to machine at high precision. It is commonly
known under DuPont's trade name Delrin.
The capsules were made from a plastic rod that was lathed and milled into
the shape of a conventional size 0 gelatine capsule, with a final length of 22
mm and a diameter of 8 mm. Detailed measures are given in table 8.2 and in
figure 8.17(b).
Material
Length
Width
Weight (empty)
Weight (full of PFOB)
Density (full)
Internal volume
Delrin
22mm
8mm
1.0 9
2.5 9
1.7 g/cm3
0.8 ml
Table (8.2): Characteristics of the capsules.
In analogy with the gelatine capsules, our capsules consisted of two half-
shells with a cuff that allowed the two pieces to be fitted together, see figure
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8.17. A little hole was drilled on top so that liquid compounds could be poured
in with a needle avoiding air bubbles. A little plastic screw was then inserted
and glued with superglue (Loctite) in the hole to prevent leakage from the hole.
The standard operating procedure (SOP) for manufacturing the capsules are
given in appendix A. The manufacture of these capsules aimed at their use
in vivo, for the tracking in the gastrointestinal tract in healthy and diseased
human subjects. Therefore the main effort in the production is the safety of
the capsules and the prevention of the leakage.
(a) This figure presents a picture of
the used custom manufactured Der-
lin capsule.
Js
f~:i:
u.z::': ,:
! i
e
(b) This figure
provide exact
geometric data of
the used capsules.
a=3 mm, b=8
mm, c=15.5 rnm,
d=1.5 mm, e=8
mm. s is the
screw.
Figure (8.17): Example of a custom manufactured capsule.
pH test
In order to check the chemical stability and the biological inertness of the
capsules, pH tests were performed with both types of capsules using three
buffer solutions to simulate in vivo behaviour. Simulated gastric fluid was
made up from 2 g of sodium chloride, NaCI, dissolved in 7 ml of concentrated
hydrochloric acid, HCI, diluted and made up to 1 litre with distilled water.
The final pH range estimated on the basis of an average of several batches was
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1.0-1.3. Buffer solutions of pH 4, 7 and 10 were also used so that the whole
range of pHs in the GI tract could be simulated. A pre-calibrated pH meter
Corning 240 was used to measure the pH of all solutions used. In order to
simulate the in vivo condition, the capsules were left in the simulated gastric
fluid up to 8 hours and they were examined hourly for integrity.
Leakage test with radiolabels
The plastic capsules were tested for leakage using radiolabels. 7 capsules
were filled with 0.5 ml of PFOB and 0.25 ml of Tc99m04- of activity 250
MBq and then individually immersed in 45 ml of tap water. The 6 test tubes
were subsequently shielded for radioactivity and immersed in a water bath at
37° Celsius, figure 8.18, where they have been maintained at constant body
temperature and in movement for up to 48 hours. 1 ml samples were taken
from the water every 4 hours.
A 3 inch well-type sodium iodide scintillation crystal detector, PerkinElmer
WALLAC Wizard 3", 1480 Automatic gamma counter was used to establish
the amount of activity released into the beaker. The gamma counter was used
to measure the activity of samples, withdrawn from the beaker at specified
time intervals.
It has to be underlined that the use of radioactives has implied extra care
and specific training in order to perform the tests safely. For example, the
filling of the capsule with 0.25 ml of Tc99m04- of activity 250MBq is extremely
dangerous for the very high activity of the compound. Also, the capsule with
the Tc99m04- was to be held with the hand while pouring the PFOB in and
this procedure is also very dangerous. The risk of spilling the radioactive
while closing the capsule is also quite high especially because the procedure
has to be undertaken as quickly as possible in order to avoid any unnecessary
exposition to the radioactive. Given the technical difficulties associated with
the use of radioactives, another testing method has been take into account and
(a) Illustration of the capsule filled (b) The 6 shielded test tubes are im-
with 0.5 ml of PFOB and 0.25 ml of mersed in a water bath at 37° Cel-
Tc99m04- of activity 250 MBq, indi- sius. The capsules have been main-
vidually immersed in 45 ml of tap wa- tained at constant body temperature
ter. On the left the shield used for each and in movementin the water bath for
test tube is presented. 48 hours. 1 ml sampleswere taken ev-
ery 4 hours during the day.
Figure (8.18): Equipment for the leakage test of the capsules with radioactive
materials.
it is explained below.
Leakage test with a VIS spectrophotometer
An alternative leakage test would use an optical marker, using a spec-
trophotometer in the range of the visible light. The preparation of the cap-
sules followed the standard procedure explained in appendix A, including the
use of superglue to seal the capsules and a glue approved for human use (Blue
Histoacryl® by Brown) for an additional coating layer. 10 capsules were filled
with 0.8 ml of blue food colour using a needle through the hole on top. The
screw was then inserted and glued. They were left to dry for a day and then
they were individually immersed in 45 ml of tap water in a water bath at 37°
Celsius. The capsules have been maintained at constant body temperature in
a water bath equipped with a motor system to keep the samples in motion with
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1 ml samples taken every 3 hours up to 48 hours (the set up of the experiment
is presented in figure 8.19).
Figure (8.19): Experimental setup for the leakage test: the capsules have been
filledwith blue dye and then glued. They have then been maintained at constant
body temperature and in movement in a water bath. 1 ml samples have been
taken every 3 hours up to 48 hours.
A UV/VIS Jenway Model 6105 spectrophotometer was used to establish
the presence of colour in the samples. After choosing the blue complimentary
colour, the precise analytical wavelength was selected by scanning in 5 nm steps
until a maximum absorbance value was reached, corresponding to a wavelength
value of 400 nm.
Blank and sample calibration of the instrument was carried out at the
beginning and at the end of every sample batch.
The linearity (i.e. concentration vs reading) of the methodology at the
selected wavelength A has been verified by preparing samples at different con-
centrations. The absorbance is defined as
10
Abs>. = [091O! (8.3)
where I is the intensity of light at the wavelength A that has passed through
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the sample and 10 is the incident light intensity.
8.5.2 Results
Gelatine capsules
The gelatine capsules which successfully stayed intact at pH 1 up to 8 hours
were the ones with more than 15 layers and these have been then inserted in
a solution with higher pH. 25 and 30 layers were found to be necessary to
guarantee the integrity of the capsules in basic solution up to 48 hours. It
might be concluded that 30 layers would be enough for guaranteeing the total
absence of leakage in the GI tract but it has to be said that at this stage
no mechanical strain has been applied to the capsules and they were kept
at room temperature, which is lower than the body temperature. Also, the
manufacture of the capsules with 30 coating layers is time consuming and not
effective.
Given these results the use of gelatine capsules was abandoned and the
leakage test was not performed.
Plastic capsules
The plastic capsules proved to be insoluble and stable in water, in 0.1 M
hydrochloric acid and in buffer solutions of pH 4.0, 7.0 and 10.0. Therefore
they were also tested for leakage as described below.
Leakage test with radiolabels
Gamma counter data is presented as a percentage loss of activity from
the capsule and a percentage increase in the activity of the solution. Decay
corrections were done over the time span of detection.
As can be seen in figure 8.20(a), the released activity appears to level off
at a value below 0.025 % for five out of seven capsules. These values were
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then constant for 24 hours, meaning that the leak is due to the initial closing
procedure, when it could be expected that some of the Tc99m04- may remain
attached superficially to the surface of the capsules. A much bigger release,
up to 5 %, has been found for two capsules, figure 8.20(b). These data suggest
that there is a possibility that Tc99m04- does in fact slowly diffuse out of
capsules. This might also be due to the initial procedure of closure of the
capsule and might be overcome by careful preparation. It is worth noting that
working with radioactives required quick handling of the beads thus providing
considerable opportunities for error in the closing procedure.
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(a) Five out of seven capsules showed a (b) Two out of seven capsules showed
small leakage equal to a released activ- a much bigger leakage reaching the 5%
ity of maximum 0.025%. in one case probably due to inaccuracy
during the preparation of the capsule.
Figure (8.20): Results from the leakage test of the 7 capsules with radioactives.
In addition, a leakage test using a radioactive must take account of the
time needed for the capsule to dry after being glued which would noticeably
increase the amount of radioactive needed, thus raising many further safety
Issues.
Leakage test with a VIS spectrophotometer
Figure 8.21 reports the values of the absorbance versus the concentration of
the blue colour in water: it shows the linear dependence of the concentration
with the absorbance. The resolution of the instrument for the absorbance is
0.001 thus meaning a resolution in concentration of less than 1 part in 10000.
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This technique has been adopted as standard procedure to test the leakage of
the capsules.
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Figure (8.21): Linearity tests showing the absorbance value versus the concen-
tration.
Figure 8.22 shows the mean values of the absorbance for the 10 capsules
tested for up to 48 hours. The values obtained are within the resolution of the
instrument, meaning that no leakage was found.
-20 o 20 40 60
Time (hours)
Figure (8.22): (Mean ± STD). Results for the leakage test with the VIS spec-
trophotometer: the mean values of absorbance for the 10 capsules used for the
test for up to 48 hours. The values obtained are considered not significant
because they lie within the instrument resolution, i.e. less than 1 part in 10000.
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8.5.3 Conclusion
The tests performed on the different capsules showed that the in house
manufactured plastic capsules are safe for in vivo use. The leakage test carried
out with the VIS spectrometer proved to be safe and easy to perform. It
also showed better results, i.e. no leakage from the capsules, as it allows a
more careful and efficient preparation of the capsules. The in vivo experiment
presented in the following sections have been performed on the basis of these
in vitro results, therefore preparing and testing the capsules according to the
procedure just described.
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8.6 GI transit in vivo study with the use of
fluorinated markers
8.6.1 Introduction
The purpose of this pilot study is to develop a protocol of measuring gut
transit times using capsules labelled with a fluorine compound as described
above. As discussed in section 8.2.2, PFOB proved to be a safe and effective
contrast agent to be encapsulated for gastrointestinal MR, so it has been used
to label the home made capsules described in section 8.5.1.
8.6.2 Method
This study was approved by the University of Nottingham Medical School
Ethics Committee and all volunteers gave written informed consent. For this
pilot study we recruited 2 healthy volunteers who attended the MRI centre
on 4 consecutive days having fasted overnight on the first occasion. All im-
ages were acquired with a 3T Philips Achieva system using a range of MRI
sequences for both proton and fluorine scans. The volunteers received a break-
fast meal comprising a standard rice pudding meal and pure orange juice from
concentrate used in previous studies [61]. Then they underwent a baseline
scan before consuming 4 capsules filled with 0.8 ml PFOB and prepared as
explained in section 8.5.1 with water ad libitum. PFOB with a nominal purity
of 99.0% was purchased from Apollo Scientific. However this has not been
testified as safe for human consumption and therefore the PFOB was encap-
sulated securely as described above. Subjects were then scanned immediately
after swallowing the capsules and then blocks of subsequent fluorine and pro-
ton MRI were routinely acquired every 30 min for 7 hours. The subjects were
imaged again the following days to acquire a single data point at 24, 48 and
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72 hours after dosing. Coronal images were acquired in order to use the same
geometrical orientation as other imaging techniques such as X-ray. A range of
MRI sequences were used to image the stomach, bowels and the colon:
• Proton images were acquired with a dual echo FFE sequence (TEl = 2.3,
TE2 = 4.6, rec. res = 1.56 mm x 1.56 mm). The data matrix consisted
of 2562pixels over a field of view of 400 x 400 cm2• 15 contiguous slices
with a slice thickness of 10 mm were acquired for a total scan time of 20
seconds, i.e. within a single breath hold.
• The fluorine images were acquired without moving the volunteer as the
fluorine coil was already in place when the proton images were acquired
with the whole body coil. An FFE sequence was used (TE=3.0 ms, acq.
res = 2.3 mm x 2.3 mm, TR 350 ms, FOV(AP, FH, RL)=300x230x300,
flip angle 70°, NAV 1) to acquire 3 slices 100 mm thick, for a total scan
duration of 22 seconds. A narrow acquisition bandwidth (434 Hz) was
used to overcome the chemical shifts artifacts as discussed in section 8.3.
In vivo proton and fluorine images of the abdominal region were superimposed
using a code written in Matlab to correctly locate the position of the capsules
within the GI tract (figure 8.23).
8.6.3 Results
The two volunteers tolerated the capsules and the study procedures well
although one of the volunteers found it difficult to swallow the capsules at first
because of their rigid structure. There were no adverse events in this study.
Images of the first volunteer showed all the capsules in the stomach up to
2 hours after ingestion. At 24 hours one of the capsules was visible in the
ascending colon and at 48 hours the fluorine images showed one capsule in
the rectum (see figure 8.24). Nothing was found at 72 hours; the volunteer
confirmed that the capsules had all been evacuated.
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Figure (8.23): Example of proton and fluorine images (left) and their super-
imposition (right), see section 8.6.2 for details. This image was taken for one
subject immediately after swallowing the capsules.
Similar results were obtained for the second volunteer (see figure 8.25): the
capsules were visualized in the stomach at 45 minutes and then in the small
bowel at 2 hours after ingestion. At 24 hours one capsule was detected in the
rectum. Nothing was found at 48 and 72 hours.
Figure (8.24): Superimposition of proton and fluorine images at different time
points for the first volunteer: at 2 hours the capsules are all in the stomach
(left), at 24 hours one capsule was found in the ascending colon (middle) and
at 48 hours one capsule was found in the rectum.
8.6.4 Discussion and conclusion
This first pilot study was successful. The method proved to be well toler-
ated by the volunteers and the capsules were visualized and correctly located
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Figure (8.25): Superimposition of proton and fluorine images at different time
points for the first volunteer: a capsule was visualised in the stomach at 45
minutes (left), and another one in the small bowel at 2 hours after ingestion
(middle). At 24 hours one capsule was detected in the rectum.
in the GI tract for the 2 volunteers. The capsules were all evacuated by 72
hours for both volunteers.
However, some issues have been raised; for example, the capsules are quite
large making them quite challenging for healthy volunteers to consume and
hence possibly not suitable for patients. However, it has to be pointed out
that the size of the capsules is similar to the Smart pill (© 2009 SmartPill
Corporation) capsules normally used for clinical practice [118-120].
The detection of the capsules with the fluorine coil proved to be very dif-
ficult most of the time because the sensitive volume of the coil was not big
enough to cover the entire GI tract. In order to overcome this problem, it
was often necessary to reposition the coil. This is of course a major issue be-
cause the method needs to be implemented and used with patients and needs
to be reproducible, quick and easy to use. In this regard double labelling of
the capsules with gadolinium based contrast agent and fluorine has been con-
sidered allowing an easy visualization of the capsules on T1-weighted proton
images, followed by a fluorine scan to allow the confirmation of the presence
of a capsule in the surrounding anatomical structures.
This has been implemented in a second study that is reported in the fol-
lowing section.
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8.7 GI transit time using double-labelled
markers
A chelated form of the rare earth element gadolinium (Gd) has been used as
a water phase marker together with the fluorine compound PFOB described in
the previous section. The contrast agent that we used is Gadoteridol (Gd-HP-
D03A, Prohance® ; Bracco-Altana, Konstanz, Germany) that is a non-ionic,
extracellular, water-soluble contrast material for MRI. It has paramagnetic
properties with Gd concentration of 0.5 M. Each millilitre of Prohance contains
279.3 mg of Gadoteridol [121]. Gadoteridol is usually applied intravenously:
the safety and benefit of intravenous Gadoteridol injection have been demon-
strated in various MRI studies [122,123]. However we enclosed this contrast
agent in the capsules to be administered orally. It has also been shown that the
Gd molecule does not dissociate in the acidic gastric environment [16,124,125].
The safety of the capsules, proven by means of the leakage tests described in
the previous sections, guarantees the safe use of Gadoteridol itself.
In order to find the optimal concentration of gadolinium and the minimum
amount of solution to be put in the capsules, some preliminary tests were
performed.
8.7.1 In vitro test: finding the optimal Gd concentra-
tion
As explained in section 2.2.9, the effect of the contrast agents on the relax-
ation times depends on their concentration (see equation 2.24). Therefore an
in vitro test has been performed using sequences optimised to be used in vivo,
acquired in one or two breath holds.
Eleven solutions of Gadoteridol in water at different concentration ranging
from 0.25 J.tM to 25 J.tM were prepared at room temperature.
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The test tubes were then imaged in a water phantom with the following
sequences:
• A T1-weighted TFE sequence (TR=4.6ms, TE=2.3ms, rec. res. 1.14 x
1.14 x 3 mm"). This has been used because the signal from the Gd is
very bright due to the Tl shortening of the contrast agent and it will be
helpful to locate the capsules for the in vivo study.
• A HASTE sequence (TSE) with parameters TR=1670ms, TE=65ms,
acq. res. 5 x 5 x 10 mm", This is a T2-weighted sequence and there-
fore the signal from the gadolinium is completely lost because of the T2
shortening. However, the images showing a signal drop corresponding to
the gadolinium presence can be useful in order to provide additional de-
tails when distinguishing the capsules from other anatomical structures
in vivo.
• T2-weighted FFE sequence (TR=100 ms, TE=25 ms and acq. res. of 1
x 1 x 1 mm3). This sequence is not optimised on the basis of the Gd
concentration but it provides good anatomical details, thus helping for
the exact localisation of the capsules in the gastrointestinal tract.
Figure 8.26 shows the results for the in vitro test.
In particular, figure 8.26A shows the Trweighted TFE sequence for the 11
samples, showing the change in signal according to the Gd concentration. The
signal obtained from this image has been plotted in logarithmic scale as a func-
tion of the concentration in order to find the optimal concentration to be used
for the capsules, see graph 8.27. It can be seen that there is a biphasic relation-
ship, due to the competing effects of Tl and T2, between the concentration of
Gd-HP-D03A and the MRI signal intensity which has a log-linear dependency
between 2 and 10 ILM. From the graph 8.27 it is possible to conclude that for
this sequence the concentration that maximises the signal is equal to 15 ILM.
This concentration will be used to prepare the capsules for the in vivo study.
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Figure (8.26): A shows how the signal changes according to the concentration
of gadolinium in the sample in the Tl weighted TFE image. B shows how
for a different sequence, the TSE, the MRI signal is completely lost because
of the presence of Gd. C shows a T2 weighted FFE sequence acquired just
for argument sake in order to demonstrate that the presence of Gd may create
susceptibility artifacts and signal loss if the concentration is not optimised.
Figure 8.26B shows the results for the HASTE sequence, confirming the sig-
nal loss due to the contrast agent, also dependent on the concentration value.
Figure 8.26C shows the results for the different concentrations acquired with
a T2-weighted FFE sequence: this has been acquired in order to demonstrate
that the presence of Gd may create susceptibility artifacts at high concentra-
tion. In conclusion, a concentration of 15 J.LM will be used together with a T,
weighted TFE sequence for the in vivo studies described below.
8.7.2 In vivo pilot study
Methods
This study was approved by the University of Nottingham Medical School
Ethics Committee and all volunteers gave written informed consent. In analogy
with the first study, we recruited 2 healthy volunteers that attended the MRI
centre on 4 consecutive days having fasted overnight on the first occasion.
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Figure (8.27): Signal intensity versus concentration of gadolinium in water,
calculated using a Tl-weighted TFE sequence (TR=4.6ms, TE=2.3ms). The
MRI signal response decreases ar both high and low concentrations, although
there is a log-linear relationship between 2 and 10 f,lM.
All images were acquired with a 3T Philips Achieva system using a range of
MRI sequences for both proton and fluorine scans. The volunteers received
a breakfast comprising a standard rice pudding and pure orange juice from
concentrate used in previous studies [61]. They underwent a baseline scan
before swallowing 4 capsules with water ad libitum, filled with 0.2 ml of Gd 15
JLM solution and 0.6 ml of PFOB and prepared as explained in section 8.5.1.
PFOB with a nominal purity of 99.0% was purchased from Apollo Scientific.
They were then scanned immediately after this and then blocks of subsequent
fluorine and proton MRI were routinely acquired every hour for 7 hours. The
subjects were imaged again the following days to acquire a single data point
at 24, 48 and 72 hours after dosing. A range of MRI sequences were used to
image the stomach, bowels and the colon. For the proton images three different
sequences have been used:
• A heavily T1-weighted TFE sequence (TR=4.6 ms, TE=2.3 ms, acq. res.
= 3.03 mm x 3.01 mm, rec. res. = 1.14 mm x 1.14 mm, thickness 3 mm)
The total number of slices is 40 with no gap and the total duration is 25
s, performed with 2 breath holds. This sequence has been optimised in
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vitro (details in the previous section) and it shows a very bright signal
from the Gd, providing a very efficient tool to find the capsules in the
gut. On the contrary, the PFOB produces a signal void.
• Haste sequence (TSE) with parameters TR=1667 ms, TE=65 ms, acq.
res. = 5.00 mm x 5.05 mm, rec. res. = 1.56 mm x 1.55mm and thickness
10 mm for a total number of 10 slices with no gap. This is a T2 weighted
sequence therefore the Gd is displayed very dark but it can be useful,
together with the other images, when distinguishing the capsules from
the other anatomical structures. Being a proton scan, the PFOB is also
displayed dark .
• Dual echo FFE sequence (TR/TE1/TE2 (ms) = 126/2.3/ 5.8, acq. res.
2.00 mm x 2.50 mm, rec. res. = 1.56 mm x 1.56 mm) to acquire proton
images with good anatomical images for the exact localisation of the
capsules in the gastrointestinal tract. The data matrix consisted of 2562
pixels that represented a field of view of 400 x 400 crn2• 30 contiguous
slices with a slice thickness of 5 mm were acquired for a total scan time
of 40 seconds, two breath holds.
The fluorine images were acquired without moving the volunteer as the fluorine
coil was already in place when the proton images were acquired with the whole
body coil. An FFE sequence was used (TR=350 ms, TE=3.0 ms, acquired
resolution = 2.34 mm x 2.34 mm, FOV (AP, FH, RL)=300x230x300, flip angle
70°, NAV 1) to acquire 3 slices 100 mm thick, for a total scan duration of 22
seconds. A low bandwidth was used to overcome the chemical shifts artifacts
exposed in section 8.3.
In vivo proton and fluorine images of the abdominal region were superim.-
posed to correctly locate the position of the capsules within the GI tract.
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Results
The two volunteers tolerated the capsules and the study procedures well
and there were no adverse events in this study. The capsules were detected
in the gut for both volunteers at all time points until evacuation. Figure 8.28
summarises the results for this study. At 2 hours, the 4 capsules were visible
in the stomach for both volunteers. From 2 to 5 hours the capsules were seen
in the small bowel for both subjects. At 24 hours, for subject 1 two capsules
were found in the transverse colon and 2 in the rectum, whilst for subject 2,
1 capsule was found in the descending colon and 2 in rectum. At 48 and 72
hours no capsules were found for both volunteers.
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.Sub2
Small bowel
Ascending
colon .xl
Transverse
colon
Descending
colon .xl
Rectum
.x2 NONE NONE
.x2 NONE NONE
L-t--+---+---+---+---t·················I················+·················1·······
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Figure (8.28): Position of the capsules for the 2 subjects over time. The capsules
were detected in the gut for both volunteers at all time points until evacuation.
Figure 8.29 and 8.30 show examples of the different images acquired for
this experiment. In particular, figure 8.29(a) shows the dual echo FFE and
figure 8.29(b) shows the haste sequence which display the gadolinium very
bright and very dark respectively. The presence of the capsules, together with
their position, is very easy to locate in both cases. Figure 8.30 shows the
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images (MIP) acquired with the Trweighted TFE sequence for volunteer 1 at
24 hours: 2 capsules are found in the transverse colon and 2 in the rectum.
The fluorine images confirm the presence of the capsules especially in those
cases where other bright anatomical structures such as vessels are evident.
However it has to be underlined that the slice thickness of the fluorine
images is much bigger (100 mm for the fluorine sequence compared with 3
mm of the proton T1-weighted TFE sequence), thus the fluorine slice covers a
region that is displayed in multiple slices in the proton images. An example is
given in figure 8.31.
(a) Coronal dual echo FFE sequence
showing the 4 capsules very bright in
the stomach.
(b) Haste sequence (TSE) showing the cap-
sules in the stomach: the Gd and PFOB are
both displayed dark.
Figure (8.29): Example from a volunteer's proton sequences soon after swallow-
ing the 4 capsules.
8.7.3 Discussion
The use of double-labelled markers has proved successful because all the
capsules were easily detected in the gut for both volunteers at all time points
until evacuation. By using the range of sequences available one can easily
differentiate the bright signal of the gadolinium in the capsules from the vessels
nearby and the fluorine image gives double confirmation of their position.
However, in most cases the fluorine coil had to be repositioned after the exact
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Figure (8.30): MIPs of the T1-weighted TFE sequence for volunteer 1 at 24
hours. Two capsules are easily visible in the transverse colon (left) and two are
in the rectum (right).
location of the capsules was established by the proton images because the
fluorine coil sensitivity doesn't cover the entire GI tract.
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(a) Proton T1-weighted TFE images for the second volunteer at 24 hours showing the pres-
ence of 3 capsules in the last part of the SB and one capsule in the AC.
(b) MIP of the Proton T1-weighted TFE images (left)
and fluorine FFE image (right). The fluorine image is
a single slice showing the 4 capsules all together be-
cause the slice thickness is much higher compared to
the proton images.
Figure (8.31): Proton and fluorine images for the second volunteer at 24 hours .
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8.8 Studying the GI transit time using double-
labelled markers: mode of action of Moviprep
8.8.1 Introduction
Moviprep is an osmotic laxative commonly used in the clinical practice for
the bowel preparation carried out before a colonoscopy. When fully made up as
1 litre of Moviprep, it provides 100 grams of polyethlene glycol, a nonnutrient
substance which is not absorbed and therefore rapidly leaves the stomach and
generates a substantial inflow of fluid in the upper small intestine. Water
flowsdown the osmotic gradient markedly increasing the small intestinal water
content compared with fasting. We have shown in section 6.2 that the arrival
of small bowel fluid induced by mannitol produces a radical change in the
heterogeneous structure of the ascending colon. The rate of recovery after
purgation with polyethylene glycol is said to be normally rapid but slower
in certain patient groups though data is still very limited [126]. It has been
reported that patients find an improvement in bowel function after colonic
lavage thus suggesting that the reconstituted microbiota may be different,
though this has not been scientifically proven.
In this study the colonic transit after purgation with polyethylene glycol is
investigated by means of the double-labelled markers developed. In particular,
two different cases will be compared: the intake of Moviprep in a single 2 litre
dose or in a split dose of 1 litre per day as it has been previously shown that
Moviprep is more effective and better tolerated in a split dose [127]. The
changes in colonic transit in these two arms of the study will be investigated.
Using merkers to meaSllre GI transit 208
8.8.2 Methods
This study was approved by the University of Nottingham Medical School
Ethics Committee and all volunteers gave written informed consent. For this
study 24 healthy volunteers (12 females) were recruited. They had normal
BMI and mean age of 25.7±9.9. The volunteers were split into two groups.
Group 1 received a split dose of Moviprep, i.e. 1 litre on Day 1 and 1 litre
on Day 2. Group 2 had the 2 litre dose of Moviprep in one day. In order to
prevent nutritional bias of colonic transit all volunteers were asked to follow a
dietary plan, avoiding alcohol for at least 24 hours before the study day.
The transit scans were carried out at 3 time points throughout the study:
7 days before dosing, 14 days after dosing and 28 days after dosing, to see the
extended effect of purging the bowel on the colon. For each of these occasions
volunteers swallowed 3 capsules, with as much water as they desired, 24 hours
before the scan under the supervision of one of the study investigators. On the
study day the volunteers attended the study centre having fasted overnight
and a 30 min scan was performed. A series of images, in analogy with the
pilot study described in section 8.7.2, were acquired to localize the position of
the capsules in the gut.
The transit was assessed by scoring the position of the capsules according
to the scores represented in figure 8.32. The geometric centre of the 3 capsules
was calculated to give a single final score.
8.8.3 Results
All volunteers attended every session and completed the study. The experi-
ment procedures were well tolerated and all the capsules were easily swallowed.
None of the capsules were found in the upper part of the GI tract, confirming
the time scales found in the pilot study. For the majority of the subjects the
detection of the capsules with the gadolinium sequences was straightforward
Using markers to mCdSllrt.' GI tDlllsit 209
..._--_.
8
1 Small Bowel
2 Lower AC
3 Upper AC
4 Right TC
5 Left TC
6 DC
7 Sigmoid and rectum
8 Excreted
Figure (8.32): Illustration of the scores associated with each region of the gut.
In order to give a comparable score for the transit of the capsules in the gut,
the bowels were divided in 8 sections, and the geometric centre was calculated
as a final score.
and quick, with a few cases having visible capsule in the survey scans (figure
8.33).
Figure (8.33): Examples to show the evidence of the position of the capsules
from the survey scans. These images correspond to different subjects at different
time points.
For the fluorine scans it was often necessary to reposition the coil after
the survey scan, in order to get a good coverage of the area to image and a
good signal from the PFOB. However, the scan time didn't normally exceed
20 minutes duration.
The fluorine images confirm the presence of the capsules especially in those
cases where other bright anatomical structures are evident. Some examples are
given in figures 8.34 and 8.35: in figure 8.34 the presence of a fourth capsule
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was denied by the fluorine images that only showed 3 of them; figure 8.35
shows how the signal from the capsules is sometimes similar to vessels.
Figure (8.34): Example of anatomical structure similar in shape to the capsules.
The fluorine images showed signal only from 1, 2 and 4, therefore number 3 is
not a capsule.
Figure (8.35): Example of capsules that can be confounded as vessels. In both
cases the fluorine images confirmed their presence.
Figure 8.36 shows two examples of the MIPs (maximum intensity pro-
jections) of the T1-weighted TFE sequence (left) and of the dual echo FFE
sequence (right) for the same volunteer. The capsules are easy to see in the
ascending and descending colon in both images.
A whole set of images acquired with the sequences optimised during the
pilot study is represented in figure 8.37, showing an example of 3 capsules in
the rectum for one of the subjects.
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Figure (8.36): Example of MIPs from a volunteer's proton images 24 hours after
swallowingthe 3 capsules: Tl-weighted TFE sequence (left) and dual echo FFE
sequence (right). Both images clearly show the position of the capsules within
the gut, in this case two in the ascending colon and 1 in the descending.
dual Echo FFE HASTE T1-weighted TFE 19F FFE
Figure (8.37): Example of MIPs from a volunteer's whole set of sequences 24
hours after swallowing the 3 capsules. The position of the 3 capsules in the
rectum is evident in all images.
The geometric centres did not show a significant trend of transit change
across the three scans for the two groups. Figure 8.38 reports the mean results
for all volunteers on the 3 days.
For Group 1 each visit has a mean centre around the value 6 corresponding
to the descending colon. The overall change in the three visit is n t statistically
different. The differences for the three visits in Group 2 are slightly more
significant, indicating a slowing down of transit at visit 2 and a faster transit
at visit 3 although this change is not statistically significant (p<O.25). The
data from single individuals show a great variability: transit increased in some
subjects whilst for others it stayed constant, with the largest changes in Group
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Figure (8.38): Graph showing the mean geometric centre of the capsules with
the standard error across the three visits for Group 1 and Group 2.
2. Figure 8.39 shows the gender differences for the transit. There are no
statistically significant differences.
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Figure (8.39): Gender differences for the mean geometric centre of the capsules
with the standard error across the three visits.
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8.8.4 Discussion and conclusion
Several techniques have been used to measure the colonic transit time
including radio-opaque markers, isotopes, colored dyes, beads, and contrast
agents [128-130]. However, there is no universally accepted or standardized
technique.
This study showed that the double-labelled markers are a very useful
method for the transit measurement in the gut, with the main advantage com-
pared to alternative techniques being the absence of ionising radiation. The
production of the capsules is also cheaper compared to other techniques such
as the Smartpill. In addition, for clinical purposes, it is preferable to use a
single test that provides comprehensive information regarding gastrointestinal
transit, and without radiation. Therefore MRI constitutes an invaluable tool
to investigate several aspects of the gut physiology in a single study day.
Regarding the MR imaging technique, MIPs of the abdomen were used
in order to analyse the transit time. The duration of this analysis takes less
than 5 minutes for each time point and it is therefore suitable for clinical
routine practice. This method has proved to be well tolerated by a large
number of subjects, who swallowed the three capsules easily. The detection
of the capsules at 24 hours was easy and relatively quick thanks to the use of
the gadolinium solution and the transit of the capsules was consistent among
individuals, with all the capsules being found in the lower GI tract. However
this technique showed several aspects that need further improvements. Firstly,
the number of capsules may be too limited to correctly determine the transit
in the gut and smaller capsules should be used to this aim. Also, because
of the size and the weight of the capsules, they might not travel at the same
rate as chyme along the gut, as shown in other studies [131]. It also has to be
mentioned at this point that the fluorine detection has to be improved because
the SNR is at the moment lower than the gadolinium. This would mean an
improvement in the hardware and specifically in the coil itself and eventually
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a further improvement of the sequences used in order to maximise the signal.
With these improvements, the double-labelled markers technique would be a
valid alternative compared to other techniques.
The present technique should be compared with other types of examina-
tions such as conventional colonic transit using radiopaque markers and scintig-
raphy. The validation study is currently under way. Figure 8.40 shows the
x-ray image of a phantom with the empty capsules behind.
Figure (8.40): X-rays images of a phantom with the empty capsules behind.
Courtesy of Dr Ching Lam.
We have found that the changes in transit scores after dosing with Moviprep
were not significant for both Group 1 and Group 2. One main reason could
be that the number of subjects per group was not sufficient as the effect of
purging the bowel on transit is very variable between individuals. However, it
was interesting to notice that the biggest changes in transit were in Group 2,
corresponding to the single 2 litre dose of Moviprep in the same day. One could
speculate that the considerable stretch of the colonic muscles may have a long-
term effect on motility but further measurements are needed. Alternatively one
could think that the colonic transit time is not effectively modified by a single
purging event, as diarrhoea lasts longer in patients with IBS-like symptoms.
Also, this measurement might not be sensitive enough as discussed above.
In addition, the transit scans have been performed only after 14 days from
the Moviprep dose. There may have been a period of increased transit imme-
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diately after the dosing days which was not investigated. This could be taken
into account for future experiments.
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8.9 Optimisation of the GI transit markers
8.9.1 Introduction
Following the studies described in the previous sections, further steps in
the optimisation of the GI transit marker were undertaken. Firstly the size of
the capsules was designed smaller so that their use could be easily extended
to patients, also allowing the ingestion of an increased number. Secondly,
the density of the capsules is to be considered. To this aim the filling of the
capsules, i.e. the ratio between gadolinium solution and fluorine compound,
is to be investigated. In order to address these points, a pilot study has been
performed.
8.9.2 Methods
Small capsules were designed and produced with the same method and
same shape as already described with final dimensions of 7 mm diameter and
20 mm length. They were filled with 0.2 ml of 15 J.tM Gadoteridol solution
in distilled water and 0.2 ml of PFOB. The total density of the capsules was
1.78. The capsules were filled and tested for leakage according to the SOP in
appendix A.
This study was approved by the University of Nottingham Medical School
Ethics Committee and all volunteers gave written informed consent. Two
healthy volunteers were recruited and imaged on 3 consecutive days at multiple
time points spread during the day. All images were acquired with a 3T Philips
Achieva system using a range of MRI sequences for both proton and fluorine
scans. The volunteers received a meal comprising a standard rice pudding at 8
pm on the first study day and they swallowed 5 capsules with water ad libitum.
They were then scanned immediately after this and then at 13, 19, 24 and 37
hours. The same MRI sequences as the studies previously described were used
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to image the stomach, bowels and the colon.
8.9.3 Results
The two volunteers swallowed the 5 capsules easily and there were no ad-
verse event in the study. The capsules were detected in the gut on the proton
images at all time points until evacuation. However, the fluorine images didn't
show enough signal, therefore the results are based on the gadolinium detection
only. Figure 8.41 summarises the results for the transit for both volunteers .
Stomach
• Subl
.Sub2
Small bowel
Ascending
colon .x2
Transverse
colon
Descending
colon
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Rectum
.x2
.x4
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Figure (8.41): Position of the capsules for the 2 subjects over time. The capsules
were detected in the gut for both volunteers at all time points until evacuation.
Figure 8.42A shows an example of the 'T, weighted TFE sequence from
subject 1. Figure 8.42B shows the same sequence on the same subject with
the addition of the saturation bands in order to help the differentiation between
capsules and other structures such as vessels.
Figure 8.43 shows the T1-weighted TFE sequence acquired for subject 1 at
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Figure (8.42): Tl-weighted TFE sequence from subject 1 at time t=24 hours.
Images shown in B are acquired as the ones shown in A but with the addition
of the saturation bands that suppress the signal from the vessels such those in
the liver.
time t=19 hours with the 3D scan mode. It was acquired with the body coil
as the fluorine coil was still in position. The images shows a very high SNR
and the position of the capsules is easily detectable.
8.9.4 Discussion and conclusion
This pilot study aimed at the optimisation of the double labelled capsules
for their application with patients. To this aim smaller capsules were designed.
However the internal volume of the capsules, equal to 0.4 ml, was found to be
not enough for the detection of fluorine signal. On the contrary, the amount
of gadolinium solution, equal to the previous studies, was enough for the easy
detection of the capsules in the different regions of the gut. Further improve-
ments of the proton sequences will consider the use of the saturation bands
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Figure (8.43): 3D acquisition for the T1-weighted TFE sequence for subject 1
showing an increased SNR.
and the use of 3D acquisitions. In this last case, the use of a SENSE coil
would be necessary in order to acquire the data in one or two breath holds
only. However, this would be feasible only if the fluorine coil is not used at the
same time. For these reasons it may be concluded that for gut transit mea-
surements the use of these plastic capsules filled with the gadolinium solution
only is effective. The numerous advantages of using fluorine based compounds
still apply for absorption studies, e.g. as a marker for liver absorption studies,
as the gadolinium wouldn't be as effective. The main concern about using the
fluorine compounds is still their safety. In case chemical industries will start
producing PFOB, or similar compounds, approved for human use as it was the
case for the Imagent GI (Alliance Pharmaceutical, San Diego, California) used
by Mattrey et al. in the past [100], the possible applications of fluorine in gut
imaging would be countless.
Chapter 9
Conelus ions
The work described in this thesis was directed towards developing and ap-
plying MRI techniques for the investigation of colon function under any con-
ditions non invasively and without any bowel preparation. It has been shown
that these methods can find their applications in medical research, pharma-
ceutical trials as well as in studies of the gut physiology.
Chapter 6 presented the first in vivo study of colonic response to an exper-
imental model of human diarrhoeal disease using MRI. This study was used to
understand the time course of the physiological response of the gut and it al-
lowed observation of the colon under physiological and pathological conditions.
Colon function was monitored using a multimodal MRI approach. The water
content was measured extending the method introduced by Road et al. [38]to
the colonic water contents. It was found that after a mannitol drink, which is
an unabsorbable osmotically active solution that causes secretion in the small
bowel, the amount of water in the ascending colon increased significantly, to-
gether with the geometrical volume, with a first peak at 90 minutes after the
drink and a successive peak soon after the solid meal. T, and T2 were also
measured in vitro to understand colonic content properties. In addition, a
texture analysis based method was developed for the objective assessment of
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colonic contents. It was found that texture features such as contrast and ho-
mogeneity are an effective and robust method to assess the heterogeneity and
the mesoscopic structure of the colon. A possible extension of this work is the
application of texture analysis to patients in order to have more information on
the colonic content structure under various conditions. Also, more data would
be desirable for the estimation of Tl and T2 in vitro. Another aspect that
would need further improvements is the study of the motility of the ascending
colon, with the optimization of MRI sequences to overcome the artifacts due
to breathing.
Chapter 7 used the techniques developed in chapter 6 to investigate the
colonic function under pharmacological interventions. The MRI protocol de-
veloped proved to be powerful and well tolerated for studying the gastrointesti-
nal tract response to anticonstipation and antidiarrhoeal agents. In particular
it was found that the antidiarrhoeal agent loperamide, administered alone or
combined with simethicone, increased the gastric emptying rate of the non-
nutrient mannitol meal, decreased the small bowel water content and the net
secretion in the gut over time, and delayed the arrival of f:l.uidsin the ascending
colon. Finally, the drugs also reduced significantly the contrast homogeneity
ratio calculated.
Chapter 8 described a novel methodology for directly monitoring transit
through the gut. This was achieved by using f:l.uorinatedcompounds encap-
sulated in ad hoc built plastic capsules safe for human use. The choice of
the best compound, the optimisation of MRI sequences and the development
of the best capsules for a safe use in vivo, were the main object of the last
chapter. This methodology, which is currently filed as a patent", has also been
applied in vivo for the investigation of an osmotic laxative commonly used
in the clinical practice for the bowel preparation. Future work on this topic
would involvethe use of other markers for a broader application of the method
1Application Title: Magnetic resonance imaging methods and apparatus for use in such
methods. Application Number:GBll09268.1 Application Date: 02/06/11.
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and the further optimisation of the sequences and the hardware available for
the improved detection of the fluorine signal. This would guarantee the suc-
cessful application of this method with better results compared to the use of
gadolinium only, which at the moment would be the easier and effective solu-
tion. A validation study for the double labelled markers is currently under way
comparing this technique with radiopaque markers and scintigraphy. Possible
collaborations with companies for the distribution of this methodology are also
being pursued.
In conclusion, the MRI methods presented here proved to constitute an
invaluable tool to investigate several aspects of the gut physiology and the
colon function in a single study day.
Appendix A
Standard operating procedure
for the capsules manufacture for
in vivo studies
A.1 Manufactureof the capsules
The manufacture of the capsule has been performed in the workshop of the
SPMMRC by Mr Ian Thexton. The raw material used is Polyoxymethylene
(commonly referred to as POM and also known as polyacetal or polyformalde-
hyde), supplied by DuPont's under their trade name Delrin. The plastic rod
is milled (figure A.I) and lathed (figure A.2), with hemispherical ends until it
has these dimensions: 8 mm in diameter, and 22 mm long with hemispherical
ends, with wall thickness of 1 mm and with a small hole drilled in one end 1
mm in diameter. The cuff with the hole is 3 mm thick; the other one is 1.5 mm
(see figure 8.17). The capsules are then kept in the workshop in a clean bowl
until the whole lot has been completed. Screws are also provided, purchased
from RS, standard M2 nylon capsules.
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Figure (A.l): CNC control milling machine.
Figure (A.2): Hardinge lathing machine
Figure (A.3): Illustration of the capsules left to dry on the sticks after sealing.
A.2 Preparation of the capsules for in vivo
studies
The preparation of the capsule for the in vivo experiments presented in
chapter 8 follows the procedure below and it has been held in the prep room
of the SPMMRC, University of Nottingham.
Day 1
Prepare the material: capsules, superglue, gloves, goggles, lab coat, tissues,
sticks and foam. Wear gloves, goggles and the lab coat. Clean the work area
before starting. Put a number of sticks in the foam equal to the total number
of capsules to fill. Leave a spare stick to help spreading the glue uniformly.
Glue the external part of the capsule that needs to be put in the other half,
trying to make it as uniform as possible with the spare stick. Promptly push
the matching half together to make a tight fit. Clean the capsule with a tissue
so that little glue is left on the exterior of the capsule. Put the capsule on the
stick via the hole on top (figure A.3). Repeat the same procedure for all the
capsules. Leave them to dry for a day in prep room and label them as "do not
touch". Clean up work area.
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Day 2
To prepare the 15 JLM Gd solution disperse 1 ml of Gadoteridol using a
new syringe and mix it with 33 ml of distilled water.
Prepare the materials required to fill the capsules: bottle of PFOB, gadolin-
ium solution, 2 syringes with needles, plastic screws, grid to hold the capsules,
tissues and blue dye for food. Wear gloves, goggles and the lab coat. Check
that the capsules are dry. Take randomly 20% of the capsules and leave them
apart for the leakage test.
Capsules for experiment
Put the remaining capsules in the grid provided, standing them in upright
position with the hole on top. Use a syringe to measure 0.6 ml of PFOB.
Inject it in the hole carefully and slowly. Leave the syringe on a tissue on the
table with the cap on. Take a new syringe and inject 0.2 ml of the gadolinium
solution slowly into the capsule. Take the screw and put a drop of superglue
on it and screw it in. Remove any residual glue from the capsule with a tissue.
Repeat the same procedure for the other capsules. Leave them to dry for a
day in prep room and label them as "do not touch". Clean up work area.
Capsules for leakage test
Put the capsules in the grid provided, making them stand in an upright
position with the hole on top. Using a new syringe inject 0.8 ml of blue dye
into the capsule via the hole in the top carefully and slowly. Leave the syringe
on a tissue on the table with the cap on. Take the screw and put a drop
of superglue on it and screw it in. Repeat the same procedure for the other
capsules. Leave them to dry for a day in prep room and label them as do not
touch. Clean up work area.
Day 3
Prepare the material: all capsules, cutter, file, glue approved for human use
(BLUE Histoacryl® by Brown). Wear gloves, goggles and the lab coat. Cut
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the top of the screw off the capsule so that the surface is nice and round. Use
a file, if necessary, to smooth the surface of the capsule. Clear the exterior of
the capsules of any unwanted material. Open the Histoacryl and pour a drop
on the top of the capsules where the screw has just been cut. Leave it to dry.
Repeat with all the capsules. Leave them to dry for a day in prep room and
label them as do not touch. Clean up work area.
Day 4
Check that the capsules are dry and clear the exterior of the capsules of
any unwanted material.
Capsules for experiment
Keep the capsule in a covered plastic dish, and label the dish with date and
contents of the capsules. 30 minutes before giving the capsules to the subject
prepare a plastic bowl with 2.5 I of tap water and dilute a half cupful of Milton
disinfectant in it and leave the capsules in the bowl for at least 20 minutes.
Be careful not to touch the capsules with dirty hands, rinse once and serve in
the reception room in a paper dish with some napkins. Subject are allowed to
drink as much water as they want to help them swallow the capsules but this
will have to be checked for each experiment.
Capsules for leakage test
Prepare the material: capsules, 50ml plastic test tubes with lid, water bath,
thermometer for the water bath, tube rack for the water bath, eppendorfs. Fill
the water bath with water and set the temperature to be 37°C. Leave it until
it reaches the desired temperature (check with the thermometer). Fill each
test tube with 45 ml tap water and put one capsule in. Close the test tube
and put it in the test rack in the water bath. Take a 1 ml sample from each
test tube and put it in different eppendorfs and label them. Repeat this step
every 3 hours up to 72 hours.
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A.3 Leakage test with the spectrophotometer
Prepare the material (after collecting all the sam plcs): UV-Vis spectrom-
eter (figure A.4), labelled eppendorfs, syringe, eppendorfs provided specific
for the spectrometer analysis, Turn the spectrometer on and leave it for 15
minutes to allow the lamp to warm up prior to use.
Calibration: Place a blank solution (1 ml distilled water) in the eppendorf
and insert it in the cell holder. Close the sample chamber lid and select the
required wavelength (400nm). Select Abs by use of the MODE keypad. Press
the CAL keypad. The display will update to zero. Select %T by use of the
MODE keypad. Press the CAL keypad. The display will update to 100.0. The
unit is now ready to measure.
Place the first sample in the cell holder, close the sample chamber lid
and write down the values for Abs and %T. Repeat for each sample without
changing the wavelength. At the end put the blank solution (distilled water)
in the cell holder and write down the values for Abs and %T to check for the
stability. The test is now complete, clean up work area.
Figure (A.4): UVjVIS spectrophotometer Jenway Model 6105 (courtesy of Not-
tingham Digestive Diseases Centre NIHR Biomedical Research Unit, University
of Nottingham) used to establish the presence of colour in the samples.
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